<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> ALCOBRA LTD. (Form: 20-F, Received: 03/04/2016 15:49:25) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_IDENTITY_OF_PERSONNEL **FIS_OFFER_STATISTICS **FIS_KEY_INFORMATION **FIS_COMPANY_INFORMATION **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_OPERATING_AND_FINANCIAL_REVIEW **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION_TABLE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_FINANCIAL_DATA **FIS_LEGAL_PROCEEDINGS **FIS_LISTING **FIS_ADDITIONAL_INFORMATION **FIS_MARKET_RISK **FIS_OTHER_SECURITIES **FIS_PART_II **FIS_DEFAULTS **FIS_MATERIAL_MODIFICATIONS **FIS_CONTROL_AND_PROCEDURES **FIS_AUDIT_COMMITTEE_EXPERT **FIS_CODE_OF_ETHICS **FIS_ACCOUNTANT_FEES **FIS_EXEMPTIONS_FROM_LISTING **FIS_PURCHASES_OF_EQUITY **FIS_CHANGE_IN_ACCOUNTANT **FIS_CORPORATE_GOVERNANCE **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_III **FIS_FINANCIAL_STATEMENTS **FIS_FINANCIAL_STATEMENTS_2 **FIS_EXHIBITS **FIS_EXHIBIT_INDEX **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_BALANCE_SHEET_2 **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT FIS_EXHIBIT_4 FIS_EXHIBIT_12 FIS_EXHIBIT_12_2 FIS_EXHIBIT_13 FIS_EXHIBIT_13_2 FIS_EXHIBIT_15 ">
<META NAME="DETECTED PAGES" CONTENT="129">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="V432397_20F_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	FORM 20-F
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	ANNUAL REPORT PURSUANT TO SECTION 13
	OR 15(d) OF THE SECURITIES
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	EXCHANGE ACT OF 1934
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	For the fiscal year ended December 31,
	2015
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Commission file number: 001-35932
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Alcobra Ltd.
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(Exact name of Registrant as specified
	in its charter)
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	State of Israel
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(Jurisdiction of incorporation or organization)
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Azrieli Triangle Building
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	132 Derech Menachem Begin, 39
<SUP>
	th&nbsp;
</SUP>
	Floor
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Tel Aviv 6701101 Israel
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(Address of principal executive offices)
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Dr. Yaron Daniely
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Azrieli Triangle Building
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	132 Derech Menachem Begin, 39
<SUP>
	th&nbsp;
</SUP>
	Floor
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Tel Aviv 6701101 Israel
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Tel: +972.72.220.4661
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(Name, Telephone and/or Facsimile number
	and Address of Company Contact Person)
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Securities registered or to be registered
	pursuant to Section 12(b) of the Act:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 51%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Title
	of each class
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Name
	of each exchange on which registered
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ordinary
	Shares, par value of NIS 0.01
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Nasdaq
	Global Market
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Securities registered or to be registered
	pursuant to Section 12(g) of the Act: None
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Securities for which there is a reporting
	obligation pursuant to Section 15(d) of the Act: None
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Indicate the number of outstanding
	shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	27,560,920 Ordinary
	Shares, par value NIS 0.01 per share
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Indicate by check mark whether the
	registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Yes
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	If this report is an annual or transition
	report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities
	Exchange Act of 1934.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Yes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Indicate by check mark whether the
	registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
	the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
	to such filing requirements for the past 90 days.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Yes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Indicate by check mark whether the registrant has submitted
	electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant
	to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
	the registrant was required to submit and post such files).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Yes
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Indicate by check mark whether the
	registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Act).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Large Accelerated Filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Accelerated
	Filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Non-Accelerated Filer
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Indicate by check mark which basis
	of accounting the registrant has used to prepare the financial statements included in this filing:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S.
	GAAP&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	International
	Financial Reporting Standards as issued by the International Accounting Standards Board&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;If &ldquo;Other&rdquo;
	has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has
	elected to follow.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item
	17
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item
	18
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	If this is an annual report, indicate
	by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&uml;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;Yes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;No
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<U>
	TABLE OF CONTENTS
</U>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	Number
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 73%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_029">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART ONE
</B>
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 1.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_001">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Identity of directors, senior management and advisers
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 2.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_002">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Offer statistics and expected timetable
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 3.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_003">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Key information
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 4.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V432397_20F_HTM_NOTE_004">
	Information on the company
</A>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	26
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 4A.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_005">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unresolved staff comments
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	42
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 5.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_006">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Operating and financial review and prospects
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	43
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 6.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_007">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Directors, senior management and employees
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	48
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 7.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V432397_20F_HTM_NOTE_008">
	Major shareholders and related party transactions
</A>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	59
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 8.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_009">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial Information
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	60
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 9.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_010">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The offer and listing
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	61
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 10.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_011">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Additional information
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	62
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 11.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_012">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Quantitative and qualitative disclosures about market risk
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	72
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 12.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_013">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Description of securities other than equity securities
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	72
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A HREF="#V432397_20F_HTM_NOTE_014">
	PART TWO
</A>
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 13.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_015">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Defaults, dividend arrearages and delinquencies
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	72
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 14.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_016">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Material modifications to the rights of security holders and use of proceeds
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	72
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 15.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_017">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Controls and procedures
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	72
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16A.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_018">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Audit committee financial expert
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16B.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_019">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Code of ethics
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16C.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_020">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Principal accountant fees and services
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16D.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_021">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exemptions from the listing standards for audit committees
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16E.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_022">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Purchases of equity securities by the issuer and affiliated purchasers
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16F.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_023">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Change in registrant's certifying accountant
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16G.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_024">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Corporate governance
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	73
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 16H.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<A HREF="#V432397_20F_HTM_NOTE_025">
	Mine safety disclosure
</A>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	76
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
<A HREF="#V432397_20F_HTM_NOTE_026">
	PART THREE
</A>
</U>
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 17.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_030">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial statements
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	76
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 18.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_027">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial statements
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	76
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item 19.
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_NOTE_028">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibits
</FONT>
</A>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
	76
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;&nbsp;&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	INTRODUCTION
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Unless otherwise indicated, all references to the &ldquo;Company,&rdquo;
	&ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;Alcobra&rdquo; refer to Alcobra Ltd. and its subsidiary, Alcobra Inc., a Delaware
	corporation. References to &ldquo;U.S. dollars&rdquo; and &ldquo;$&rdquo; are to currency of the United States of America, and
	references to &ldquo;NIS&rdquo; are to new Israeli shekels. References to &ldquo;Ordinary Shares&rdquo; are to our Ordinary Shares,
	par value of NIS 0.01 per share.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	We do not endorse or adopt any third-party research or forecast
	firms&rsquo; statements or reports referred to in this annual report and assume no responsibility for the contents or opinions
	represented in such statements or reports, nor for the updating of any information contained therein.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	SPECIAL NOTE REGARDING FORWARD-LOOKING
	STATEMENTS
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	This annual report contains express or implied &ldquo;forward-looking
	statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities
	laws.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	These forward-looking statements include, but are not limited
	to:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; WIDTH: 3%">
	&bull;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FDA approval
	of, or other regulatory action in the United States and elsewhere with respect to, our drug candidate, a proprietary formulation
	of metadoxine, or MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the commercial
	launch and future sales of MDX or any other future products or product candidates;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our ability
	to achieve favorable pricing for MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our ability
	to maintain orphan drug designation for MDX, and implications if such designation is lost;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our expectations
	regarding the commercial supply of our MDX drug candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	third-party
	payor reimbursement for MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our estimates
	regarding anticipated expenses, capital requirements, the sufficiency of our funds through 2017 and our needs for additional
	financing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the patient
	market size of Attention Deficit and Hyperactivity Disorder, or ADHD, and Fragile X Syndrome, or Fragile X, and market adoption
	of MDX by physicians and patients;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the timing,
	cost or other aspects of the commercial launch of MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the design
	of future clinical trials and our ability to better control placebo response and treatment response variability;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the timing,
	duration and cost of clinical trials for MDX or whether such trials will be conducted at all;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	completing,
	receiving favorable results, and announcing results of clinical trials for MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	issuance
	of patents to us by the United States Patent and Trademark Office, or U.S. PTO, and other governmental patent agencies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our ability
	to protect our proprietary technology and enforce our intellectual property rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our intention
	to file a joint NDA for the adult and pediatric sub-populations for ADHD;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	whether
	we will be able to maintain fast track designation for MDX for Fragile X; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our expectations
	regarding licensing, acquisitions and strategic operations.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	some cases, forward-looking statements are identified by terminology such as &quot;may,&quot; &quot;will,&quot; &quot;could,&quot;
	&quot;should,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;believes,&quot; &quot;intends,&quot;
	&quot;estimates,&quot; &quot;predicts,&quot; &quot;potential,&quot; or &quot;continue&quot; or the negative of these terms or
	other comparable terminology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors
	that may cause actual results or performance to differ materially from those projected. These statements are only current predictions
	and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&rsquo;s actual
	results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
	statements. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the
	conclusions of future research or trials would not suggest different conclusions or that historic results referred to herein would
	not be interpreted differently in light of additional research and clinical and preclinical trials results.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Also,
	while the FDA has indicated to us that positive efficacy results from certain clinical studies may be sufficient to demonstrate
	efficacy for approval of MDX, the FDA is not bound by these communications and accordingly may change its position in the future.
	The forward-looking statements contained in this annual report are subject to risks and uncertainties, including those discussed
	under Item 3.D. Risk Factors and in our other filings with the Securities and Exchange Commission, or the SEC. Readers are cautioned
	not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Although we believe that
	the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
	performance, or achievements. Except as required by law, we are under no duty to (and expressly disclaim any such obligation to)
	update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after
	the date of this annual report.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
<U>
<A NAME="V432397_20F_HTM_NOTE_029">
</A>
	PART ONE
</U>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<EFX_IDENTITY_OF_PERSONNEL>
<A NAME="FIS_IDENTITY_OF_PERSONNEL"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -1IN">
<B>
<A NAME="V432397_20F_HTM_NOTE_001">
</A>
	ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IDENTITY
	OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	Not applicable.
</P>
</EFX_IDENTITY_OF_PERSONNEL>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_OFFER_STATISTICS>
<A NAME="FIS_OFFER_STATISTICS"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -1IN">
<B>
<A NAME="V432397_20F_HTM_NOTE_002">
</A>
	ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OFFER
	STATISTICS AND EXPECTED TIMETABLE
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	Not applicable.
</P>
</EFX_OFFER_STATISTICS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<EFX_KEY_INFORMATION>
<A NAME="FIS_KEY_INFORMATION"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -1IN">
<B>
<A NAME="V432397_20F_HTM_NOTE_003">
</A>
	ITEM 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KEY
	INFORMATION
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	3.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selected
	financial data
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Our historical consolidated financial
	statements are prepared in accordance with generally accepted accounting principles in the United States and are presented in
	U.S. dollars. The selected historical consolidated financial information as of December 31, 2014 and 2015 and for the years ended
	December 31, 2013, 2014 and 2015 have been derived from, and should be read in conjunction with, the consolidated financial statements
	of Alcobra Ltd. and notes thereto appearing elsewhere in this annual report. The selected financial data as of December 31, 2011,
	2012 and 2013 and for the years ended December 31, 2011 and December 31, 2012 have been derived from the audited financial statements
	of Alcobra Ltd. not included in this annual report.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The information presented below is
	qualified by the more detailed historical consolidated financial statements set forth in this annual report, and should be read
	in conjunction with those consolidated financial statements, the notes thereto and the discussion under Item 5 &ndash; &ldquo;Operating
	and Financial Review and Prospects&rdquo; - included elsewhere in this annual report.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Consolidated Statement of Operations
	Data &ndash; Years Ended December 31
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	(in thousands of U.S. dollars, except
	share and per share data)
</I>
<B>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2012
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2011
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	13,461
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	25,105
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	7,066
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	818
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,822
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Pre-commercialization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,245
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,992
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,839
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	683
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,084
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,698
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,290
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,501
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,906
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial expenses (income), net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	197
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss before taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,398
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,851
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,487
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,579
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,929
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Taxes on income (tax benefit)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Deemed dividend
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	180
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,449
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,834
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,548
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,579
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Basic and diluted net loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Shares used in computing basic and diluted&nbsp;&nbsp;net&nbsp;&nbsp;loss per share
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,638,207
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,674,818
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,177,786
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,791,932
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,843,388
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Consolidated Balance Sheet Data &ndash;
	as of December 31
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<I>
	(in thousands of U.S. dollars, except
	for share data)
</I>
<B>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2012
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	2011
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Working capital
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	49,994
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	19,751
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	48,582
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(588
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	448
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71,683
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22,318
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,324
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	201
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,204
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Shareholders' equity
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,943
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48,688
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(567
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	985
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Number of shares outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,560,920
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,702,772
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13,636,709
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,794,256
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,096,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	3.B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Capitalization
	and indebtedness
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	3.C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Reasons
	for the offer and use of proceeds
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	3.D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risk
	factors
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In conducting our business, we face
	many risks that may interfere with our business objectives. Some of these risks could materially and adversely affect our business,
	financial condition and results of operations. In particular, we are subject to various risks resulting from changing economic,
	political, industry, regulatory, business and financial conditions. The risks and uncertainties described below are not the only
	ones we face.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	You should carefully consider the following
	factors and other information in this annual report before you decide to invest in our Ordinary Shares. If any of the negative
	events referred to below occur, our business, financial condition and results of operations could suffer. In any such case, the
	trading price of our Ordinary Shares could decline, and you may lose all or part of your investment.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Product Development,
	Regulatory Approval and Commercialization
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We depend entirely on the success of our only current
	clinical-stage product candidate, MDX, and we may not obtain regulatory approval of MDX for the treatment of ADHD or other cognitive
	dysfunctions such as Fragile X, or we may be unable to successfully commercialize it.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We have invested almost all of our
	efforts and financial resources in the research and development of MDX, which is currently our only clinical-stage product candidate.
	As a result, our business is entirely dependent on our ability to complete the development of, obtain regulatory approval for,
	and successfully commercialize, MDX in a timely manner. The process to develop, obtain regulatory approval for, and commercialize
	MDX is long, complex, costly and uncertain of outcome.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The research, testing, manufacturing,
	labeling, approval, sale, marketing and distribution of drugs are subject to extensive regulation by the Food and Drug Administration,
	or FDA, in the United States and other regulatory agencies in other countries. These regulations differ from country to country.
	We are not permitted to market MDX or any other product candidate in the United States until we receive approval of a New Drug
	Application, or NDA, from the FDA, or in any foreign countries until we receive the requisite approval from regulatory agencies
	in such countries. We are required to conduct multiple additional pre-clinical and clinical trials to be able to submit an NDA
	to the FDA or comparable applications to other regulatory authorities in other countries. The results of additional pre-clinical
	and clinical trials may be unsatisfactory, and even if we believe those trials to be successful, there are many reasons why the
	FDA may not approve our NDA should we be in a position to file one.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Approval procedures vary among countries
	and can involve additional product testing and additional administrative review periods. The time required to obtain approval
	in other countries might differ from that required to obtain FDA approval. The marketing approval process in other countries may
	include all of the risks detailed above regarding FDA approval in the United States as well as other risks. In particular, in
	many countries outside the United States, it is required that a product receive pricing and reimbursement approval before the
	product can be commercialized. This can result in substantial delays in such countries. In other countries, product approval depends
	on showing superiority to an approved alternative therapy. This can result in significant expense for conducting complex clinical
	trials. Finally, we do not have any products approved for sale in any jurisdiction, including international markets, and we do
	not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements
	in international markets or to obtain and maintain required approvals or if regulatory approvals in international markets are
	delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Marketing approval in one country does
	not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative
	effect on the regulatory process in others. Failure to obtain marketing approval in other countries or any delay or setback in
	obtaining such approval would impair our ability to develop foreign markets for MDX. This would reduce our target market and limit
	the full commercial potential of MDX.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The commencement and completion of clinical trials
	can be delayed or prevented for a number of reasons.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We may not be able to commence or complete
	the clinical trials that would support our submission of an NDA to the FDA. Drug development is a long, expensive and uncertain
	process, and delay or failure can occur at any stage of any of our clinical trials. Clinical trials can be delayed or prevented
	for a number of reasons, including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	difficulties
	obtaining regulatory approval to commence or complete a clinical trial, or complying with conditions imposed by a regulatory
	authority regarding the scope or term of a clinical trial;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	delays
	in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, contract
	manufacturing organizations, or CMOs, and trial sites, the terms of which can be subject to extensive negotiation and may
	vary significantly among different CROs and trial sites;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	failure
	of our third-party contractors, such as CROs and CMOs, or our investigators to comply with regulatory requirements or otherwise
	meet their contractual obligations in a timely manner;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	insufficient
	or inadequate supply or quality of a product candidate or other materials necessary to conduct our clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	difficulties
	obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	requiring alterations to any of our study designs, our pre-clinical strategy or our manufacturing plans;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	challenges
	recruiting and enrolling subjects to participate in clinical trials for a variety of reasons, including size and nature of
	subject population, proximity of subjects to clinical sites, eligibility criteria for the trial, nature of trial protocol,
	the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs
	for similar indications;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	difficulties
	in maintaining contact with subjects after treatment, which results in incomplete data;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	receipt
	by a competitor of marketing approval for a product targeting an indication that our product targets, such that we are not
	&ldquo;first to market&rdquo; with our product candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	governmental
	or regulatory delays and changes in regulatory requirements, policy and guidelines; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	varying
	interpretations of data by the FDA and similar foreign regulatory agencies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Clinical trials may also be delayed
	or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
	by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board overseeing the
	clinical trial at issue, or other regulatory authorities due to a number of factors, including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	failure
	to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	inspection
	of the clinical trial operations or trial sites by the FDA or other regulatory authorities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	unforeseen
	safety issues, including serious adverse events associated with a product candidate, or lack of effectiveness; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	lack of
	adequate funding to continue the clinical trial.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Positive results in previous
	pre-clinical and clinical trials of MDX may not be replicated in future clinical trials of MDX, which could result in development
	delays or a failure to obtain marketing approval.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Positive results in previous pre-clinical
	and clinical studies of MDX may not be predictive of similar results in future clinical trials. Also, interim results during a
	clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries
	have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development.
	Accordingly, the results from the completed pre-clinical studies and clinical trials for MDX may not be predictive of the results
	we may obtain in later stage trials. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators
	may require us, to conduct additional clinical trials. Moreover, clinical data are often susceptible to varying interpretations
	and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies
	and clinical trials have nonetheless failed to obtain FDA approval for their products.
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Obtaining approval of an NDA even after clinical trials
	that are believed to be successful is an uncertain process.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	Even if we complete our planned clinical
	trials and believe the results to be successful, all of which are uncertain, obtaining approval of an NDA is an extensive, lengthy,
	expensive and uncertain process, and the FDA (and other regulatory agencies) may delay, limit or deny approval of MDX for many
	reasons, including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we may
	not be able to demonstrate to the satisfaction of the FDA that MDX is safe and effective for any indication;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the results
	of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA for approval;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may disagree with the number, design, size, conduct or implementation of our clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate that MDX&rsquo;s clinical and
	other benefits outweigh its safety risks;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may disagree with our interpretation of data from pre-clinical studies or clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may not accept data generated at our clinical trial sites;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the data
	collected from pre-clinical studies and clinical trials of MDX may not be sufficient to support the submission of an NDA;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may have difficulties scheduling an advisory committee meeting in a timely manner, or the advisory committee may recommend
	against approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical
	studies or clinical trials, limitations on approved labeling, or distribution and use restrictions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may require development of a risk evaluation and mitigation strategy as a condition of approval;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may identify deficiencies in the manufacturing processes or facilities of third party manufacturers with which we enter into
	agreements for clinical and commercial supplies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may change its approval policies or adopt new regulations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the FDA
	may require that an NDA application for ADHD includes the pediatric sub-population, delaying an approval for the adult sub-population;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we may
	have successful clinical trial results for adults but not children and adolescents.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Before we can submit an NDA to the FDA, we may be required to conduct multiple registration studies, which are trials intended
	to support FDA product registration. Registration studies frequently produce unsatisfactory results even if prior clinical
	trials were successful. Therefore, the results of the additional trials that we conduct may or may not be successful. The
	FDA may suspend all clinical trials or require that we conduct additional clinical, nonclinical, manufacturing validation
	or drug product quality studies and submit those data before it will consider or reconsider the NDA. Depending on the extent
	of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require
	us to expend more resources than we have available. It is also possible that additional studies, if performed and completed,
	may not be considered sufficient by the FDA to approve the NDA. If any of these outcomes occur, we would not receive approval
	for MDX and may be forced to cease operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Even if we obtain FDA approval for
	MDX for the treatment of ADHD, or other cognitive dysfunctions, the approval might contain significant limitations related to
	use restrictions for certain age groups, warnings, precautions or contraindications, or may be subject to significant post-marketing
	studies or risk mitigation requirements. If we are unable to successfully commercialize MDX, we may be forced to cease operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Even if MDX receives marketing approval, there could
	be adverse effects not discovered during development.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	Even if MDX receives marketing approval,
	we or others may later identify undesirable side effects caused by the product or problems with our third-party manufacturers
	or manufacturing processes, and in either event a number of potentially significant negative consequences could result, including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	regulatory
	authorities may suspend or withdraw their approval of the product;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	regulatory
	authorities may require the addition of labeling statements, such as warnings or contraindications or distribution and use
	restrictions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	regulatory
	authorities may require us to issue specific communications to healthcare professionals, such as &ldquo;Dear Doctor&rdquo;
	letters;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	regulatory
	authorities may issue negative publicity regarding the affected product, including safety communications;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we may
	be required to change the way the product is administered, conduct additional pre-clinical studies or clinical trials or restrict
	the distribution or use of the product;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we could
	be sued and held liable for harm caused to patients; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our reputation
	may suffer.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Any of these events could prevent us from achieving or maintaining
	market acceptance of the affected product candidate and could substantially increase commercialization costs or even force us
	to cease operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Obtaining regulatory approval for clinical trials
	of MDX in children will be more difficult than obtaining such approvals for adult clinical trials since the requirements for regulatory
	approval to conduct pediatric clinical trials are more stringent.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Pediatric drug development requires
	additional non-clinical work (such as animal studies in juvenile animals and additional reproductive toxicity work), as well as
	staged clinical work in determining safe dosing and monitoring. These additional tasks involve investment of significant additional
	resources beyond those needed for development of the drug for adults. Development of our drug for children may be significantly
	delayed due to these additional requirements.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Changes in regulatory requirements and guidance or
	unanticipated events during our clinical trials may occur, which may result in necessary changes to clinical trial protocols,
	which could result in increased costs to us, delay our development timeline or reduce the likelihood of successful completion
	of our clinical trials.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Changes in regulatory requirements
	and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need to amend clinical
	trial protocols. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may
	impact the cost, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate,
	any of our clinical trials, the commercial prospects for MDX would be harmed and our ability to generate product revenue would
	be delayed, possibly materially.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may not be able to maintain FDA &ldquo;Orphan Drug&rdquo;
	designation for metadoxine, the active ingredient in MDX to treat Fragile X.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The regulatory authorities in some
	jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan
	drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease
	or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Generally, if a product with an orphan
	drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the
	product is entitled to a period of marketing exclusivity, which precludes the FDA or the European Medicines Agency, or EMA, from
	approving another marketing application for the same drug for that time period. The applicable period is seven years in the United
	States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria
	for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan
	drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the
	manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Although we have obtained orphan drug
	designation for MDX to treat Fragile X in the United States, we may not be the first to obtain marketing approval for any particular
	orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan
	drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs
	with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently
	approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is
	shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the
	development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have obtained fast track designation from the FDA
	for MDX for the treatment of Fragile X. However, fast track designation may not lead to a faster development or regulatory review
	or approval process, and it does not increase the likelihood that our product candidate will receive marketing approval.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-SIZE: 10PT">
	If
	a product is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the
	potential to address unmet needs for this condition, the sponsor may apply for FDA fast track designation. If the fast track designation
	is obtained, the FDA may initiate review of sections of an NDA, before the application is complete. This &ldquo;rolling review&rdquo;
	is available if the applicant provides, and the FDA approves, a schedule for submission of the individual sections of the application.
	In addition, such a product could be eligible for priority review if supported by clinical data at the time of NDA (if the product
	is indicated for a serious condition and demonstrates the &ldquo;Potential To Be a Significant Improvement in Safety or Effectiveness&rdquo;).
	A priority review designation means the FDA&rsquo;s goal is to take action on the marketing application within six months of receipt
	(compared with 10 months under standard review), and the sponsor may apply for a priority review designation when the NDA is submitted
	to the FDA. In September 2015, the FDA notified us that we had obtained fast track designation for MDX for the treatment of Fragile
	X. Fast track designation does not ensure that we will experience a faster development, regulatory review or approval process
	compared to conventional FDA procedures or that we will ultimately obtain regulatory approval of MDX. Additionally, the FDA may
	withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development
	program.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Current and future legislation may increase the difficulty
	and cost for us to obtain marketing approval of and commercialize MDX or any other product candidate that we develop and affect
	the prices we may obtain.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	In the United States and some foreign
	jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
	that could prevent or delay marketing approval for MDX or any other product candidate that we develop, restrict or regulate post-approval
	activities and affect our ability to profitably sell MDX or any other product candidate for which we obtain marketing approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Legislative and regulatory proposals
	have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.
	We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations
	will be changed, or what the impact of such changes on the marketing approvals of MDX, if any, may be. In addition, increased
	scrutiny by the U.S. Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well
	as subject us to more stringent product labeling and post-marketing testing and other requirements.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	In the United States, the Medicare
	Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical
	products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology
	based on average sales prices for drugs. In addition, this legislation authorized Medicare Part D prescription drug plans to limit
	the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal
	coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction
	initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products
	and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors
	often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement
	that results from the MMA may result in a similar reduction in payments from private payors.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of
	2010, or collectively PPACA, was enacted. The PPACA is a sweeping law intended to broaden access to health insurance, reduce or
	constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare
	and the health insurance industry, impose new taxes and fees on the healthcare industry and impose additional health policy reforms.
	This law revises the definition of &ldquo;average manufacturer price&rdquo; for reporting purposes, which could increase the amount
	of Medicaid drug rebates to states once the provision is effective. Further, the new law imposes a significant annual fee on companies
	that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance have also been
	enacted, which may require us to modify our business practices with healthcare practitioners.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	While
	the U.S. Supreme Court upheld the constitutionality of most elements of the PPACA in June&nbsp;2012, other legal challenges are
	still pending final adjudication in several jurisdictions.&nbsp;&nbsp;In addition, Congress has also proposed a number of legislative
	initiatives, including possible repeal of the PPACA.&nbsp;&nbsp;At this time, it remains unclear whether there will be any changes
	made to the PPACA, whether to certain provisions or its entirety.&nbsp;&nbsp;We can provide no assurance that the PPACA, as currently
	enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future
	federal or state legislative or administrative changes relating to healthcare reform will affect our business.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Even if MDX or any other product candidate that we
	develop receives marketing approval, we will continue to face extensive regulatory requirements and the product may still face
	future development and regulatory difficulties.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	Even if marketing approval is obtained,
	a regulatory authority may still impose significant restrictions on a product&rsquo;s indications, conditions for use, distribution
	or marketing or impose ongoing requirements for potentially costly post-market surveillance, post-approval studies or clinical
	trials. For example, any labeling ultimately approved by the FDA for MDX, if it is approved for marketing, may include restrictions
	on use, such as limitations on how ADHD is defined and diagnosed or limiting MDX to second-line or concomitant therapy. In addition,
	the labeling may include significant restrictions on use. MDX will also be subject to ongoing FDA requirements governing the labeling,
	packaging, storage, advertising, distribution, promotion, recordkeeping and submission of safety and other post-market information,
	including adverse events, and any changes to the approved product, product labeling, or manufacturing process. The FDA has significant
	post-market authority, including, for example, the authority to require labeling changes based on new safety information and to
	require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug. These risks include
	adverse drug interactions and concomitant therapy with other medications. In addition, manufacturers of drug products and their
	facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance
	with current Good Manufacturing Practice, or cGMP, and other regulations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	If we, our drug products or the manufacturing
	facilities for our drug products fail to comply with applicable regulatory requirements, a regulatory agency may:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	issue
	warning letters or untitled letters;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	seek an
	injunction or impose civil or criminal penalties or monetary fines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	suspend
	or withdraw marketing approval;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	suspend
	any ongoing clinical trials;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	refuse
	to approve pending applications or supplements to applications;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	suspend
	or impose restrictions on operations, including costly new manufacturing requirements;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	seize
	or detain products, refuse to permit the import or export of products or request that we initiate a product recall; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	refuse
	to allow us to enter into supply contracts, including government contracts.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	We cannot predict the likelihood, nature
	or extent of government regulation that may arise from future legislation or administrative action, either in the United States
	or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
	or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may
	not achieve or sustain profitability, which would adversely affect our business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If we obtain approval to commercialize MDX outside
	of the United States, a variety of risks associated with international operations could materially adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	If MDX is approved for commercialization
	outside the United States, we will likely enter into agreements with third parties to market MDX outside the United States. We
	expect that we will be subject to additional risks related to entering into or maintaining international business relationships,
	including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	different
	regulatory requirements for drug approvals in foreign countries;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	differing
	United States and foreign drug import and export rules;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	reduced
	protection for intellectual property rights in foreign countries;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	unexpected
	changes in tariffs, trade barriers and regulatory requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	different
	reimbursement systems;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	economic
	weakness, including inflation, or political instability in particular foreign economies and markets;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	compliance
	with tax, employment, immigration and labor laws for employees living or traveling abroad;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	foreign
	taxes, including withholding of payroll taxes;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	foreign
	currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident
	to doing business in another country;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	workforce
	uncertainty in countries where labor unrest is more common than in the United States;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	production
	shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	potential
	liability resulting from development work conducted by these distributors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	business
	interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Any government investigation of alleged
	violations of law could require us to expend significant time and resources in response, and could generate negative publicity.
	Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize
	and generate revenues from MDX. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company
	and our operating results will be adversely affected.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If we receive marketing approval for MDX, sales will
	be limited unless the product achieves broad market acceptance.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	The commercial success of MDX and
	any other product candidate for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon
	the acceptance of the product by the medical community, including physicians, patients and healthcare payors. The degree of market
	acceptance of any approved product will depend on a number of factors, including:
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	demonstration
	of clinical safety and efficacy compared to other products;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the relative
	convenience and ease of administration;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the prevalence
	and severity of any adverse side effects;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	limitations
	or warnings contained in the product&rsquo;s approved labeling;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	distribution
	and use restrictions imposed by the FDA or agreed to by us as part of a mandatory or voluntary risk management plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	availability
	of alternative treatments, including, in the case of MDX, a number of competitive products already approved for the treatment
	of ADHD (or Fragile X, or other cognitive dysfunctions, as the case may be) or expected to be commercially launched in the
	near future;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	pricing
	and cost effectiveness;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the effectiveness
	of our or any future collaborators&rsquo; sales and marketing strategies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our ability
	to obtain sufficient third-party coverage or reimbursement; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the willingness
	of patients to pay for drugs out of pocket in the absence of third-party coverage.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	If MDX is approved but does not achieve
	an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from the
	product, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party
	payors on the benefits of the product may require significant resources and may never be successful.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The FDA and other regulatory agencies actively enforce
	the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses,
	we may become subject to significant liability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The FDA and other regulatory agencies
	strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted
	for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&rsquo;s approved labeling.
	In particular, any labeling approved by the FDA for MDX may include restrictions on use, such as limitations on how ADHD is defined
	and diagnosed, limiting the use of MDX to a specific population, such as a defined age group, or limiting MDX to second-line or
	concomitant therapy. The FDA may impose further requirements or restrictions on the distribution or use of MDX as part of a mandatory
	plan, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting
	treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. If we receive
	marketing approval for MDX, physicians may nevertheless prescribe MDX to their patients in a manner that is inconsistent with
	the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The
	federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined
	several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or
	permanent injunctions under which specified promotional conduct is changed or curtailed.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	It will be difficult for us to profitably sell MDX
	if reimbursement for the product is limited.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Market acceptance and sales of MDX
	will depend on reimbursement policies and may be affected by healthcare reform measures. Government authorities and third-party
	payors, such as private health insurers and health maintenance organizations (HMOs), decide which medications they will pay for
	and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government
	authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement
	for particular medications. We cannot be sure that reimbursement will be available for MDX and, if reimbursement is available,
	the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing
	approval. In addition, third-party payors are likely to impose strict requirements for reimbursement in order to limit off label
	use of a higher priced drug. Reimbursement by a third-party payor may depend upon a number of factors including the third-party
	payor&rsquo;s determination that use of a product candidate is:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a covered
	benefit under its health plan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	safe,
	effective and medically necessary;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	appropriate
	for the specific patient;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	cost effective;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	neither
	experimental nor investigational.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Obtaining coverage and reimbursement
	approval for a product candidate from a government or other third-party payor is a time-consuming and costly process that could
	require us to provide supporting scientific, clinical, and cost effectiveness data for the use of our product candidates to the
	payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot
	be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that
	reimbursement amounts will not reduce the demand for, or the price of, our product candidate. If reimbursement is not available
	or is available only to limited levels, we may not be able to commercialize certain of our product candidates profitably, or at
	all, even if approved.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If third-party manufacturers fail to comply with manufacturing
	regulations, our financial results and financial condition will be adversely affected.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Before they can begin commercial manufacture
	of MDX, contract manufacturers must obtain regulatory approval of their manufacturing facilities, processes and quality systems.
	In addition, pharmaceutical manufacturing facilities are continuously subject to inspection by the FDA and foreign regulatory
	authorities before and after product approval. Due to the complexity of the processes used to manufacture pharmaceutical products
	and product candidates, any potential third-party manufacturer may be unable to continue to pass or initially pass federal, state
	or international regulatory inspections in a cost effective manner.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	If a third-party manufacturer with
	whom we contract is unable to comply with manufacturing regulations, we may be subject to fines, unanticipated compliance expenses,
	recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions,
	and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We currently have no manufacturing, sales or distribution
	capabilities to market and sell MDX. If we do not establish these capabilities we will rely primarily on third parties to market
	and sell MDX.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	While we have begun to implement pre-commercialization
	activities, we currently have no manufacturing, sales or distribution capabilities. To the extent we rely on third parties to
	commercialize MDX, if marketing approval is obtained, we may receive less revenue than if we commercialized MDX ourselves. In
	addition, we would have less control over the sales efforts of any third parties involved in our commercialization efforts. In
	the event we are unable to collaborate with a third-party marketing and sales organization to commercialize MDX, particularly
	for broader patient populations, our ability to generate revenue will be limited.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our market is subject to intense competition. If we
	are unable to compete effectively, MDX or any other product candidate that we develop may be rendered noncompetitive or obsolete.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	There are a number of existing treatments
	for ADHD currently on the market, all of which are marketed by pharmaceutical companies that are far larger and more experienced
	than we are. The FDA has not approved any drugs specifically for the treatment of Fragile X or its symptoms, although there are
	several pharmaceutical companies with compounds to treat Fragile X in late stage clinical development. Patients and doctors are
	often unwilling to change medications, and this factor will make it difficult for MDX to penetrate the market. Further, our industry
	is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical
	and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and
	research institutions. All of these competitors currently engage in, have engaged in or may engage in the future in the development,
	manufacturing, marketing and commercialization of new pharmaceuticals, some of which may compete with MDX or other product candidates
	we may have in the future. Smaller or early stage companies may also prove to be significant competitors, particularly through
	collaborative arrangements with large, established companies. These companies may have products in development that are superior
	to MDX. Key competitive factors affecting the commercial success of MDX and any other product candidates that we may develop in
	the future are likely to be efficacy, time of onset, safety and tolerability profile, reliability, convenience of dosing, price
	and reimbursement.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;Many of our potential competitors
	have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery
	and development of drug candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those
	products. Established competitors may invest heavily to quickly discover and develop novel compounds that could make MDX or other
	product candidates we may develop obsolete. Accordingly, our competitors may be more successful than we may be in obtaining FDA
	and other marketing approvals for drugs and achieving widespread market acceptance. Our competitors&rsquo; drugs may be more effective,
	or more effectively marketed and sold, than any drug we may commercialize and may render MDX or any other product candidate that
	we develop obsolete or non-competitive before we can recover the expenses of developing and commercializing the product. We anticipate
	that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.
	Finally, the development of new treatment methods for the diseases we are targeting could render MDX or any other product candidate
	that we develop non-competitive or obsolete.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We face potential product liability exposure, and,
	if claims are brought against us, we may incur substantial liability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	The use of MDX or other drugs exposes
	us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers
	or others selling or otherwise coming into contact with our products. If we cannot successfully defend ourselves against product
	liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability
	claims may result in:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	decreased
	demand for MDX or any other product candidate for which we obtain marketing approval;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	impairment
	of our business reputation and exposure to adverse publicity;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	increased
	warnings on product labels;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	withdrawal
	of clinical trial participants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	costs
	of related litigation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	distraction
	of management&rsquo;s attention from our primary business;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	substantial
	monetary awards to patients or other claimants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	loss of
	revenue; and&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the inability
	to successfully commercialize MDX or any other product candidate for which we obtain marketing approval.&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If product liability lawsuits are successfully brought
	against us, our insurance may be inadequate.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We obtained clinical trial insurance
	coverage for our Phase 3 clinical trial in adult ADHD with a $5.0 million aggregate coverage limit in the United States and Israel
	and we expect that we will obtain additional insurance as we conduct additional clinical trials. However, our insurance coverage
	may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, the insurance market experiences significant
	changes from year to year due to various factors including the international claims record and general reinsurance terms. Therefore,
	coverage may become more expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost
	or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for MDX or any
	other product candidate, we intend to expand our insurance coverage to include the sale of commercial products; however, we may
	be unable to obtain this product liability insurance on commercially reasonable terms. On occasion, large judgments have been
	awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation
	or other proceedings, even if resolved in our favor, could be substantial. A successful product liability claim or series of claims
	brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our
	cash and adversely affect our business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The product liability insurance we
	will need to obtain in connection with the commercial sales of our product candidates if and when they receive regulatory approval
	may be unavailable in meaningful amounts or at a reasonable cost. If we are the subject of a successful product liability claim
	that exceeds the limits of any insurance coverage we obtain, we would incur substantial charges that would adversely affect our
	earnings and require the commitment of capital resources that might otherwise be available for the development and commercial
	launch of our product programs.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Financial Position
	and Need for Additional Capital
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have a limited operating history and we have incurred
	significant operating losses since our inception, and anticipate that we will incur continued losses for the foreseeable future.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We are an emerging biopharmaceutical company
	with a limited operating history. We are in the development stage. To date, we have focused almost exclusively on developing our
	lead compound, MDX. We have funded our operations to date primarily through proceeds from the private placement and public offering
	of ordinary shares and convertible notes. We have only a limited operating history upon which you can evaluate our business and
	prospects. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the
	risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical
	industry. We have not generated any revenue from product sales to date. We have incurred losses in each year since our inception
	in February 2008. Our loss attributable to holders of our ordinary shares for the year ended December 31, 2014 and 2015 was approximately
	$32.8&nbsp;million, and $19.5 million, respectively. As of December 31, 2015, we had an accumulated deficit of $71 million. Substantially
	all of our operating losses resulted from costs incurred in connection with our development program and from general and administrative
	costs associated with our operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our research and development expenses
	may increase in connection with our clinical development plan. In addition, if we obtain marketing approval for MDX, we will likely
	incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development expenses.
	Furthermore, we incur and will continue to incur additional costs associated with operating as a public company, which are at
	least several hundred thousand dollars annually. As a result, we expect to continue to incur significant and increasing operating
	losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products,
	we are unable to predict the extent of any future losses or when we will become profitable, if at all
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have not generated any revenue from MDX or any
	other product candidate and may never be profitable.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our ability to become profitable depends
	upon our ability to generate revenue. To date, we have not generated any revenue from our development stage product candidate,
	MDX, and we do not know when, or if, we will generate any revenue. We do not expect to generate significant revenue from sales
	of our product candidate unless or until we obtain marketing approval of, and commercialize, MDX. Our ability to generate revenue
	depends on a number of factors, including our ability to:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	obtain
	favorable results from and progress the clinical development of MDX;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	develop
	and obtain regulatory approval for registration studies protocols for MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	subject
	to successful completion of registration, clinical trials and perhaps additional clinical trials of MDX, apply for and obtain
	marketing approval;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	contract
	for the manufacture of commercial quantities of MDX at acceptable cost levels if marketing approval is received; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	establish
	sales and marketing capabilities, both internal and external, to effectively market and sell MDX in the United States and
	other countries.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Even if MDX is approved for commercial
	sale for the treatment of ADHD or Fragile X, it may not gain market acceptance or achieve commercial success. In addition, we
	anticipate incurring significant costs associated with commercialization. We may not achieve profitability soon after generating
	product revenue, if ever. If we are unable to generate product revenue, we will not become profitable and would be unable to continue
	operations without continued funding.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may need substantial additional capital in the
	future. If additional capital is not available, we will have to delay, reduce or cease operations.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We may need to raise substantial additional
	capital to fund our operations and to develop and commercialize MDX. Our future capital requirements may be substantial and will
	depend on many factors including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our clinical
	trials results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the scope,
	progress, results and costs of researching and developing MDX;&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the cost,
	timing and outcomes of seeking marketing approval of MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the cost
	of filing and prosecuting patent applications and the cost of defending our issued patents and future patents, if issued;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the cost
	of prosecuting infringement actions against third parties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	exploration
	and possible label expansion of MDX for the treatment of other conditions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the costs
	associated with commercializing MDX if we receive marketing approval, including the cost and timing of establishing sales,
	marketing and distribution capabilities to market and sell MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the cost
	of manufacturing MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the timing,
	receipt and amount of sales of, or royalties on, sales of MDX, if any;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	subject
	to receipt of marketing approval, revenue received from sales of approved products, if any, in the future;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any product
	liability or other lawsuits related to our products; &nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	costs
	associated with the expansion of our product pipeline;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the expenses
	needed to attract and retain skilled personnel; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the costs
	associated with being a public company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Based on our current operating plan,
	we anticipate that our existing resources will be sufficient to enable us to maintain our currently planned operations, including
	our continued product development, through 2017. We believe these funds will enable us, among other things, to complete our ongoing
	second Phase 3 clinical trial in adult ADHD and our planned clinical trials in pediatric ADHD and Fragile X.. Our operating plan
	may significantly change as a result of new clinical data or other considerations related to our clinical development plan.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We will require significant additional
	funds to initiate and complete the FDA approval process. Changing circumstances may cause us to consume capital significantly
	faster than we currently anticipate. We have no committed external sources of funds. Additional financing may not be available
	when we need it or may not be available on terms that are favorable to us. If adequate funds are not available to us on a timely
	basis, or at all, we may be required to:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	delay,
	limit, reduce, or terminate clinical trials or other development activities for MDX; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	delay,
	limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary
	to commercialize MDX, if we obtain marketing approval.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	In addition, we may seek additional
	capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current
	or future operating plans.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Raising additional capital would cause dilution to
	our existing shareholders, and may restrict our operations or require us to relinquish rights.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We have in the past and may continue
	to seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and
	strategic and licensing arrangements. Including our initial public offering in 2013, we have completed four underwritten public
	offerings to date. To the extent that we raise additional capital through the sale of equity or convertible notes securities,
	your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your
	rights as a shareholder. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements
	that include covenants limiting or restricting our ability to take specific actions such as incurring debt, making capital expenditures
	or declaring dividends. If we raise additional funds through collaboration, strategic alliance and licensing arrangements with
	third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or
	grant licenses on terms that are not favorable to us.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Reliance on
	Third Parties
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have no manufacturing capacity and may choose to
	rely on third-party manufacturers for our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We do not currently operate manufacturing
	facilities for clinical production of MDX. We do not intend to develop facilities for the manufacture of products for clinical
	trials or commercial purposes in the foreseeable future. We will rely on third-party manufacturers to produce bulk drug products
	required for our clinical trials on a timely basis. We plan to continue to rely upon CMOs and, potentially, collaboration partners
	to manufacture commercial quantities of our drug product candidates if and when approved for marketing by the applicable regulatory
	authorities. If the third-party manufacturing sources we rely on cease to be available to us on commercially reasonable terms
	or on a timely basis, we may not be able to complete development, production and marketing of MDX.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Reliance on third-party manufacturers
	entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third
	party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party
	because of factors beyond our control (including a failure to synthesize and manufacture our product candidates in accordance
	with our product specifications) and the possibility of termination or nonrenewal of the agreement by the third party, based on
	its own business priorities, at a time that is costly or damaging to us. We will be dependent on the ability of these third-party
	manufacturers to produce supplies of drug product adequate to support our clinical development programs and future commercialization
	of our MDX. In addition, the FDA and other regulatory authorities require that MDX be manufactured according to cGMP and similar
	foreign standards. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes,
	including any failure to deliver sufficient quantities of MDX in a timely manner, could lead to a delay in, or failure to obtain,
	regulatory approval for trial initiation or marketing of MDX. In addition, such failure could be the basis for action by the FDA
	to withdraw approvals for product candidates previously granted to us and for other regulatory action, including recall or seizure,
	fines, imposition of operating restrictions, total or partial suspension of production or injunctions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We have limited staffing and rely on
	our manufacturers to purchase from third-party suppliers the materials necessary to produce MDX for our clinical studies. There
	are a small number of suppliers for certain capital equipment and materials that we use to manufacture our drugs. Such suppliers
	may not sell these materials to our manufacturers at the times we need them or on commercially reasonable terms. We do not have
	any control over the process or timing of the acquisition of these materials by our manufacturers. Moreover, we currently do not
	have any agreements for the commercial production of these materials. Although we generally do not begin a clinical trial unless
	we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply
	of a product candidate or the material components thereof for an ongoing clinical trial due to the need to replace a third-party
	manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval. If
	our manufacturers or we are unable to purchase these materials after regulatory approval has been obtained for MDX, its commercial
	launch would be delayed or there would be a shortage in supply, either of which would impair our ability to generate revenues
	from the sale of MDX.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our contract manufacturers have not
	completed process validation for the drug substance manufacturing process. If our contract manufacturers are not approved by the
	FDA, our commercial supply of drug substance will be significantly delayed and may result in significant additional costs. We
	purchase finished MDX drug product from a third party under a clinical supply agreement. We do not have an agreement in place
	for, and we have not identified, a secondary fill/finish supplier. If we need to identify an additional fill/finish manufacturer,
	we would not be able to do so without significant delay and likely significant additional cost.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our contract manufacturer&rsquo;s failure
	to achieve and maintain high manufacturing standards, in accordance with applicable regulatory requirements, or the incidence
	of manufacturing errors, could result in patient injury or death, product shortages, product recalls or withdrawals, delays or
	failures in product testing or delivery, cost overruns or other problems that could seriously harm our business. Contract manufacturers
	often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified
	personnel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our existing manufacturers and any
	future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business. In the event
	of a natural disaster, business failure, strike or other difficulty, we may be unable to replace a third-party manufacturer in
	a timely manner and the production of MDX would be interrupted, resulting in delays and additional costs.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	In addition, because some of our contract
	manufacturers of the bulk drug substance are located outside of the United States, we may face difficulties in importing our drug
	substances into the United States as a result of, among other things, FDA import inspections, incomplete or inaccurate import
	documentation or defective packaging.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Any collaboration arrangements that we may enter into
	in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential
	future product candidates.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We may seek collaboration arrangements
	with pharmaceutical or biotechnology companies for the development or commercialization of our current and potential future product
	candidates. We may enter into these arrangements on a selective basis depending on the merits of retaining commercialization rights
	for ourselves as compared to entering into selective collaboration arrangements with other pharmaceutical or biotechnology companies
	for each product candidate, both in the United States and internationally. We will face, to the extent that we decide to enter
	into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements
	are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish and
	implement collaborations or other alternative arrangements should we so choose to enter into such arrangements. The terms of any
	collaborations or other arrangements that we may establish may not be favorable to us.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Any future collaborations that we enter
	into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of
	our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will
	apply to these collaborations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Disagreements between parties to a
	collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process
	or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements
	can be difficult to resolve if neither of the parties has final decision making authority.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Even with respect to certain other
	programs that we intend to commercialize ourselves, we may enter into agreements with collaborators to share in the burden of
	conducting clinical trials, manufacturing and marketing our product candidates or products. In addition, our ability to apply
	our proprietary technologies to develop proprietary compounds will depend on our ability to establish and maintain licensing arrangements
	or other collaborative arrangements with the holders of proprietary rights to such compounds. We may not be able to establish
	such arrangements on acceptable terms or at all.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Collaborations with pharmaceutical
	or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination
	or expiration would adversely affect us financially and could harm our business reputation.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We currently depend on third parties to conduct our
	clinical trials.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We rely on third parties, such as CROs,
	medical institutions, clinical investigators and contract laboratories to oversee some of the operations of our clinical trials
	and to perform data collection and analysis. If we are unable to maintain or enter into agreements with these third parties on
	acceptable terms, or if any such agreement is terminated, we may be unable to enroll patients on a timely basis or otherwise conduct
	our trials in the manner we anticipate. Even if we are able to maintain or enter into such agreements, we may face additional
	delays outside of our control if these parties do not perform their obligations in a timely fashion or in accordance with regulatory
	requirements. If these third parties do not successfully carry out their contractual duties or obligations and meet expected deadlines,
	if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
	to adhere to our clinical protocols or for other reasons, our financial results and the commercial prospects for MDX or any other
	potential product candidates could be harmed, our costs could increase and our ability to obtain regulatory approval and commence
	product sales could be delayed.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Risks Related to Our Intellectual Property
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We have filed multiple patent applications and have
	three issued patents by the U.S. PTO, and 11 issued patents in other jurisdictions. There can be no assurance that any of our
	other patent applications will result in issued patents. As a result, we may have limited protection of our proprietary technology
	in the marketplace.
</I>
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We have filed patent applications in
	many countries worldwide. These applications cover a range of areas including: different formulations of metadoxine, uses of metadoxine
	for cognitive impairments, new molecular derivatives of metadoxine, and methods for determining responsiveness to metadoxine treatment.
	As of December 31, 2015, we have three issued U.S. patents, covering the composition of the sustained release form of MDX, the
	use of metadoxine for ADHD, and new molecular derivatives of metadoxine. We also have six issued patents in Australia, Japan,
	India, Mexico, Russia and Europe that cover the composition of the sustained release form of MDX. The European patent includes
	the following territories: Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain,
	Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Latvia, Luxembourg, Monaco, Malta,
	Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey. Additionally, we have five issued patents
	in Australia, China, Japan, Mexico and New Zealand that cover the use of metadoxine for ADHD. Unless and until other pending applications
	issue, their additional protective scope is impossible to determine. It is impossible to predict whether or how many of these
	additional applications will result in issued patents. Even if pending applications issue, they may issue with claims significantly
	narrower than those we currently seek. The patent position of biotechnology and pharmaceutical companies is generally uncertain
	because it involves complex legal and factual considerations. The standards applied by the U.S. PTO and foreign patent offices
	in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding
	patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. Consequently, patents
	may not issue from our pending patent applications. As such, we do not know the degree of future protection that we will have
	on our proprietary products and technology.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The patent positions of pharmaceutical products are
	complex and uncertain and therefore we cannot predict the scope and extent of patent protection for MDX with respect to our issued
	patents, or any patents we may be issued in the future.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The patents we were issued as well
	as any additional patents that may in the future issue to us will not ensure the protection of our intellectual property for a
	number of reasons, including without limitation the following:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any issued
	patents may not be broad or strong enough to prevent competition from other products including identical or similar products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	if we
	are not issued additional patents or if issued patents expire, there would be no protections against competitors making generic
	equivalents;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	there
	may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	there
	may be other patents existing in the patent landscape for MDX that will affect our freedom to operate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	if our
	issued patents or future patents, if issued, are challenged, a court could determine that they are not valid or enforceable;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a court
	could determine that a competitor&rsquo;s technology or product does not infringe our issued patents or future patents, if
	issued;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our competitors
	might conduct research and development activities in countries where we do not have patent rights and then use the information
	learned from such activities to develop competitive products for sale in our major commercial markets;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our issued
	patents and future patents, if issued, could irretrievably lapse due to failure to pay fees or otherwise comply with regulations,
	or could be subject to compulsory licensing; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	if we
	encounter delays in our development or clinical trials, the period of time during which we could market our products under
	patent protection would be reduced.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may not be able to enforce our intellectual property
	rights throughout the world. This risk is exacerbated for us because metadoxine is manufactured and used in a number of foreign
	countries in other applications.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The laws of some foreign countries
	do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered
	significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This risk is exacerbated
	for us because metadoxine is manufactured and used in a number of foreign countries in other applications and is generally available.
	The manufacture of metadoxine and its use in other indications will not infringe our intellectual property rights, and will make
	it more difficult to monitor and enforce any patent rights that may be issued to us.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The legal systems of some countries,
	particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially
	those relating to life sciences. This could make it difficult for us to stop the infringement of any in-licensed patents we may
	acquire or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory
	licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability
	of patents against third parties, including government agencies or government contractors. In these countries, patents may provide
	limited or no benefit.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Proceedings to enforce our patent rights
	in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.
	Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes
	in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate
	protection for our technology and the enforcement of intellectual property.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may infringe the intellectual property rights of
	others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing
	our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our commercial success depends significantly
	on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example,
	there could be issued patents of which we are not aware that our products infringe. There also could be patents that we believe
	we do not infringe, but that we may ultimately be found to infringe. Moreover, patent applications are in some cases maintained
	in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially
	later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can take
	many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents
	that our products infringe. For example, pending applications may exist that provide support or can be amended to provide support
	for a claim that results in an issued patent that our product infringes.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Third parties may assert that we are
	employing their proprietary technology without authorization. If a court held that any third-party patents are valid, enforceable
	and cover our products or their use, the holders of any of these patents may be able to block our ability to commercialize our
	products unless we obtained a license under the applicable patents, or until the patents expire. We may not be able to enter into
	licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses
	or alternative technology could result in delays in the introduction of our products or lead to prohibition of the manufacture
	or sale of products by us. Even if we or any future strategic partners were able to obtain a license, the rights may be nonexclusive,
	which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from
	commercializing one or more of our products or be forced to cease some aspect of our business operations if, as a result of actual
	or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. This could harm our business
	significantly.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may be unable to adequately prevent disclosure
	of trade secrets and other proprietary information.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We rely on trade secrets to protect
	our proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable.
	However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants,
	outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary
	information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate
	remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our
	trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the
	scope of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary
	information to develop products that compete with our products or cause additional, material adverse effects upon our competitive
	business position.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Under applicable employment laws, we may not be able
	to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise
	of some of our former employees.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	We generally enter into non-competition
	agreements with our employees and certain key consultants. These agreements prohibit our employees and certain key consultants,
	if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period of
	time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may
	be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed
	while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former
	employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests
	of the employer which have been recognized by the courts, such as the secrecy of a company's confidential commercial information
	or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable
	to prevent our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain
	competitive may be diminished.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Any lawsuits relating to infringement
	of intellectual property rights necessary to defend ourselves or enforce our rights will be costly and time consuming.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our ability to defend our intellectual
	property may require us to initiate litigation to enforce our rights or defend our activities in response to alleged infringement
	of a third party. In addition, we may be sued by others who hold intellectual property rights who claim that their issued patents
	are infringed by MDX or any future products or product candidates. These lawsuits can be very time consuming and costly. There
	is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
	industries generally.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	In addition, our patents and patent
	applications, or those of our licensors, could face other challenges, such as interference proceedings, opposition proceedings,
	and re-examination proceedings.&nbsp;Any of these challenges, if successful, could result in the invalidation of, or in a narrowing
	of the scope of, any of our patent and patent applications subject to challenge.&nbsp;Any of these challenges, regardless of their
	success, would likely be time consuming and expensive to defend and resolve and would divert our management&rsquo;s time and attention.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Changes in U.S.&nbsp;patent law could diminish the
	value of our issued patents, or future patents, if issued, in general, thereby impairing our ability to protect our products.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	As is the case with other pharmaceutical
	companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in
	the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical
	patents is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently
	implementing wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years,
	either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
	certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination
	of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S.&nbsp;Congress,
	the federal courts, and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would
	weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Obtaining and maintaining our patent protection depends
	on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
	agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The U.S.&nbsp;PTO and various foreign
	governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during
	the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application,
	resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able
	to enter the market earlier than would otherwise have been the case.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Intellectual property litigation may lead to unfavorable
	publicity that harms our reputation and causes the market price of our ordinary shares to decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	During the course of any patent litigation,
	there could be public announcements of the results of hearings, rulings on motions and other interim proceedings in the litigation.
	If securities analysts or investors regard these announcements as negative, the perceived value of our products, programs or intellectual
	property could be diminished. Accordingly, the market price of our ordinary shares may decline.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Business Operations
	and Industry
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We are a clinical-stage company with no approved products,
	which makes it difficult to assess our future viability.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We are a clinical-stage biopharmaceutical
	company with a limited operating history. We have not yet demonstrated an ability to successfully overcome many of the risks and
	uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area.
	For example, to execute our business plan, we will need to successfully:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	execute
	product candidate development activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	obtain
	required regulatory approvals for the development and commercialization of our product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	maintain,
	leverage and expand our intellectual property portfolio;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	build
	and maintain robust sales, distribution and marketing capabilities, either on our own or in collaboration with strategic partners;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	gain market
	acceptance for our products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	develop
	and maintain any strategic relationships we elect to enter into; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	manage
	our spending as costs and expenses increase due to drug discovery, pre-clinical development, clinical trials, regulatory approvals
	and commercialization.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	If we are unsuccessful in accomplishing these objectives,
	we may not be able to develop product candidates, raise capital, expand our business or continue our operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We manage our business through a small number of employees
	and key consultants. We depend on them even more than similarly-situated companies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Our key employees include our Chief
	Executive Officer, Dr. Yaron Daniely, who has been with us since 2010, our Chief Financial Officer and Chief Operating Officer,
	Dr. Tomer Berkovitz, who has been with us since 2014, our Chief Medical Officer, Dr. Jonathan Rubin, who has been with us since
	2013, our Chief Commercial Officer, Mr. David Baker, who has been with us since 2014, our Senior Vice President CMC (chemistry,
	manufacturing and controls), Ms. Hanna Ron, who has been with us since 2011, our Senior Vice President Regulatory Affairs, Dr.
	Hagit Marchaim, who has been with us since 2014, our Vice President Finance, Ms. Irena Katsman, who has been with us since 2015,
	our Senior Vice President of Preclinical Development, Dr. Johanna Schumann, who has been with us since 2013, and our Director
	of Quality Assurance, Mr. Shlomi Ianovitz, who has been with us since 2015. Our future growth and success depend on our ability
	to recruit, retain, manage and motivate our employees and key consultants. The loss of the services of our chief executive officer,
	our chief financial officer or any of our key employees or the inability to hire or retain experienced management personnel could
	adversely affect our ability to execute our business plan and harm our operating results. Although we have employment agreements
	in place with management, these agreements are terminable at will with minimal notice.
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Because of the specialized scientific
	and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific and technical
	consultants. In particular, the loss of one or more of our senior executive officers or key consultants could be detrimental to
	us if we cannot recruit suitable replacements in a timely manner. We do not currently carry &ldquo;key person&rdquo; insurance
	on the lives of members of senior management. The competition for qualified personnel in the pharmaceutical field is intense.
	Due to this intense competition, we may be unable to attract and retain qualified personnel necessary for the development of our
	business or to recruit suitable replacement personnel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If we fail to maintain an effective system of internal
	control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result,
	our shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading
	price of our ordinary shares.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Effective internal control over financial
	reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures,
	are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
	implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection
	with Section 404 of the Sarbanes-Oxley Act may reveal deficiencies in our internal controls over financial reporting that are
	deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify
	other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in
	our reported financial information, which could have a negative effect on the trading price of our ordinary shares.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We are required to disclose changes
	made in our internal controls and procedures on an annual basis and our management is required to assess the effectiveness of
	these internal controls annually. However, for as long as we are an &ldquo;emerging growth company&rdquo; under the JOBS Act,
	our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control
	over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. We could be an emerging growth company for up to five
	years from our initial public offering in 2013. An independent assessment of the effectiveness of our internal controls could
	detect problems that our management's assessment might not. Undetected material weaknesses in our internal controls could lead
	to financial statement restatements and require us to incur the expense of remediation.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may need to significantly increase the size of
	our organization, and we may experience difficulties in managing growth.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We currently have 19 employees, and
	in order to commercialize our products, we may need to substantially increase our operations, including expanding our employee
	base of managerial, operational and financial personnel. Any future growth will impose significant added responsibilities on members
	of management, including the need to identify, recruit, maintain and integrate additional employees. To that end, we must be able
	to:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	manage
	our clinical trials and the regulatory process effectively;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	hire and
	train additional qualified personnel; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	integrate
	current and additional management, administrative, financial and sales and marketing personnel.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our relationships with customers and third-party payors
	in the United States and elsewhere will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and
	regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
	profits and future earnings.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Healthcare providers, physicians and
	third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of any product
	candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us
	to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements
	and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions
	under applicable federal, state and foreign healthcare laws and regulations include the following:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the Medicare-Medicaid
	Anti-Fraud and Abuse Act, as amended, or the Anti-Kickback Statute, prohibits, among other things, persons from knowingly
	and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce
	or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which
	payment may be made under federal and state healthcare programs such as Medicare and Medicaid;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-INDENT: -8.4PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the federal
	False Claims Act imposes criminal and civil penalties, against individuals or entities for knowingly presenting, or causing
	to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to
	avoid, decrease or conceal an obligation to pay money to the federal government and also includes provisions allowing for
	private, civil whistleblower or &ldquo;qui tam&rdquo; actions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-INDENT: -8.4PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the federal
	Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for
	Economic and Clinical Health Act, or HITECH, imposes criminal and civil liability for executing a scheme to defraud any healthcare
	benefit program. HIPAA and HITECH also regulate the use and disclosure of identifiable health information by health care providers,
	health plans and health care clearinghouses, and impose obligations, including mandatory contractual terms, with respect to
	safeguarding the privacy, security and transmission of identifiable health information as well as requiring notification of
	regulatory breaches. HIPAA and HITECH violations may prompt civil and criminal enforcement actions as well as enforcement
	by state attorneys general;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-INDENT: -8.4PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the federal
	false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making
	any materially false statement in connection with delivery of or payment for healthcare benefits, items or services;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-INDENT: -8.4PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the federal
	transparency requirements under the Health Care Reform Law requires manufacturers of drugs, devices, biologics and medical
	supplies to report to the U.S. Department of Health and Human Services information related to physician payments and other
	transfers of value and physician ownership and investment interests;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-INDENT: -8.4PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	analogous
	state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
	and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers,
	and some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines
	and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to
	report information related to payments to physicians and other health care providers or marketing expenditures; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 31.5PT; TEXT-INDENT: -8.4PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	analogous
	anti-kickback, fraud and abuse and healthcare laws and regulations in foreign countries may also apply.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Efforts to ensure that our business
	arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It
	is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes,
	regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found
	to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
	civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare
	and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities
	with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil
	or administrative sanctions, including exclusions from government funded healthcare programs.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If our employees commit fraud or other misconduct,
	including noncompliance with regulatory standards and requirements and insider trading, our business may experience serious adverse
	consequences.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We are exposed to the risk of employee
	fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide
	accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state
	healthcare fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized
	activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
	laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations
	may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs
	and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course
	of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business
	Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect
	and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
	investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any
	such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions
	could have a significant impact on our business, including the imposition of significant fines or other sanctions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	In addition, during the course of our
	operations, our directors, executives and employees may have access to material, nonpublic information regarding our business,
	our results of operations or potential transactions we are considering. Despite the adoption of an Insider Trading Policy, we
	may not be able to prevent a director, executive or employee from trading in our ordinary shares on the basis of, or while having
	access to, material, nonpublic information. If a director, executive or employee was to be investigated, or an action was to be
	brought against a director, executive or employee for insider trading, it could have a negative impact on our reputation and our
	stock price. Such a claim, with or without merit, could also result in substantial expenditures of time and money, and divert
	attention of our management team from other tasks important to the success of our business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our business may be affected by macroeconomic conditions.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	A deterioration in global economic
	conditions and uncertainties may have an adverse effect on our business. Interest rates and the ability to access credit markets
	could adversely affect the ability of patients and distributors to purchase, pay for and effectively distribute our products.
	Similarly, these macroeconomic factors could affect the ability of our CMOs, sole-source or single-source suppliers to remain
	in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability
	to manufacture products.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Risks Related to Our Ordinary Shares
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We do not know whether a market for our ordinary shares
	will be sustained or what the market price of our ordinary shares will be and as a result it may be difficult for you to sell
	your shares.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Although our ordinary shares are quoted
	on the NASDAQ Global Market, an active trading market for our shares may not be sustained. It may be difficult for you to sell
	your shares at all or without depressing the market price for the shares. As a result of these and other factors, you may not
	be able to sell your ordinary shares at or above the price you paid for such shares or at all. In addition, the trading price
	of our ordinary shares has been and is likely to continue to be volatile. The following factors, in addition to other risk factors
	described in this section, may have a significant impact on the market price of our ordinary shares:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	inability
	to obtain the approvals necessary to commence further clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	unsatisfactory
	results of clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	announcements
	of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes
	or delays in the regulatory review process;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	announcements
	of therapeutic innovations or new products by us or our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	adverse
	actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing
	activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	changes
	or developments in laws or regulations applicable to MDX;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any adverse
	changes to our relationship with manufacturers or suppliers;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any intellectual
	property infringement actions in which we may become involved;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	announcements
	concerning our competitors or the pharmaceutical industry in general;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	achievement
	of expected product sales and profitability or our failure to meet expectations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our commencement
	of, or involvement in, litigation;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any major
	changes in our Board of Directors or management;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	legislation
	in the United States relating to the sale or pricing of pharmaceuticals; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	future
	substantial sales of our ordinary shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	In addition, the stock market in general,
	and NASDAQ Stock Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or
	disproportionate to the operating performance of small companies. Broad market and industry factors may negatively affect the
	market price of our ordinary shares, regardless of our actual operating performance. Further, a systemic decline in the financial
	markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We may be subject to any number of legal proceedings.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	On December 16, 2014, a class action
	lawsuit was filed against us and certain of our current and former officers and directors in the United States District Court
	for the Southern District of New York. The complaint, brought by a putative class of investors, alleges, among other things, that
	our officers and directors made false or misleading statements relating to the results of our Phase 3 study for our MDX drug candidate.
	On May 20, 2015, we moved to dismiss the complaint. The motion to dismiss has been fully briefed, and oral argument occurred on
	September 22, 2015, and the court&rsquo;s decision remains pending. Such legal proceedings, regardless of their outcome, could
	be costly, divert management attention, or damage our reputation and demand for our products. Litigation, particularly in the
	United States, is inherently unpredictable and unexpectedly high awards of damages can result if we receive an adverse verdict.
	In many cases, particularly in the United States, the practice of the plaintiffs&rsquo; bar is to claim damages (compensatory,
	punitive and statutory) in extremely high amounts. Accordingly, it is difficult to quantify the potential exposure to claims in
	many proceedings of the type mentioned above. Unfavorable resolution of current and similar future proceedings could have a material
	adverse effect on our financial condition and results of operations. We may become subject to monetary and/or non-monetary sanctions
	and/or may be required to make significant provisions in our accounts related to legal proceedings, which could have a material
	adverse effect on our financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
<B>
<I>
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Sales of a substantial number of our ordinary shares
	in the public market by our existing shareholders could cause our share price to fall.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	Sales of a substantial number of our
	ordinary shares in the public market or the perception that these sales might occur, could depress the market price of our ordinary
	shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict
	the effect that sales may have on the prevailing market price of our ordinary shares.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If we were to be characterized as a &ldquo;passive
	foreign investment company&rdquo; for U.S. tax purposes, U.S. holders of our ordinary shares could have adverse U.S. income tax
	consequences.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	If we were to be characterized as a
	passive foreign investment company, or PFIC, under the U.S. Internal Revenue Code of 1986, as amended, or the Code, in any taxable
	year during which a U.S. taxpayer owns ordinary shares, such U.S. holder could be liable for additional taxes and interest charges
	upon certain distributions by us and any gain recognized on a sale, exchange or other disposition, including a pledge, of the
	ordinary shares, whether or not we continue to be a PFIC. Based on the nature of our business, the projected composition of our
	income and the projected composition and estimated fair market values of our assets, we believe that we may be deemed a PFIC.
	In particular, in light of the complexity of PFIC rules, we cannot assure you that we have not been a PFIC in prior years or are
	not a PFIC or will avoid becoming a PFIC in the future. Were we to be classified as a PFIC, a U.S. investor may be able to mitigate
	some of the adverse U.S. federal income tax consequences with respect to owning the ordinary shares for our taxable year ending
	December 31, 2015, provided that such U.S. investor is eligible to make, and successfully makes, a &ldquo;mark-to-market&rdquo;
	election. U.S. investors could also mitigate some of the adverse U.S. federal income tax consequences of us being classified as
	a PFIC by making a &ldquo;qualified electing fund&rdquo; election, provided that we provide the information necessary for a U.S.
	investor to make such an election. We intend to make available to U.S. investors upon request the information necessary for U.S.
	holders to make qualified electing fund elections. U.S. Holders are strongly urged to consult their tax advisors about the PFIC
	rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market
	election with respect to our Ordinary Shares in the event we that qualify as a PFIC. For more information see Item 10E. Taxation
	&ldquo;U.S. Federal Income Tax Consequences.&rdquo;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	If securities or industry analysts do not publish
	or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
	or publish negative reports regarding our business or our shares, our share price and trading volume could decline.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	The trading market for our ordinary
	shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business,
	our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts
	will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding
	our shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If
	any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility
	in the financial markets, which in turn could cause our share price or trading volume to decline.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Because we do not intend to declare cash dividends
	on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of our ordinary shares for
	any return on their investment.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We have never declared or paid cash
	dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation and
	expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. Moreover, the
	Israeli Companies Law imposes certain restrictions on our ability to declare and pay dividends. See Item 10.B. Articles of Association
	&ldquo;Dividend and Liquidation Rights&rdquo; for additional information.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The requirements associated with being a public company
	require significant company resources and management attention.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	We are subject to the reporting requirements
	of the Exchange Act the Sarbanes-Oxley Act, listing requirements and other applicable securities rules and regulations. The Exchange
	Act requires that we file periodic reports with respect to our business and financial condition and maintain effective disclosure
	controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented by the SEC and
	the NASDAQ Stock Market may also impose various additional requirements on public companies. As a result, we incur additional
	legal, accounting and other expenses that we did not incur as a nonpublic company. These expenses are at least several hundred
	thousand dollars annually.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	The JOBS Act will allow us to postpone the date by
	which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information
	we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the
	market price of our ordinary shares.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	For so long as we remain an &ldquo;emerging
	growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements
	that are applicable to public companies that are not &ldquo;emerging growth companies&rdquo; including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the provisions
	of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on
	the effectiveness of our internal control over financial reporting;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our ability
	not to comply with new accounting principles that do not apply to public companies until such accounting principles become
	applicable to private companies;&nbsp;and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any rules
	that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement
	to the auditor&rsquo;s report on the financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We intend to take advantage of these
	exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an emerging growth company until the
	earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of our initial
	public offering in 2013, (b)&nbsp;in which we have total annual gross revenue of at least $1.0&nbsp;billion, or (c)&nbsp;in which
	we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that is held by non-affiliates
	exceeds $700&nbsp;million as of the prior June&nbsp;30
<SUP>
	th
</SUP>
	, and (2)&nbsp;the date on which we have issued more than
	$1.0&nbsp;billion in non-convertible debt during the prior three-year period.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We cannot predict if investors will
	find our ordinary shares less attractive because we may rely on these exemptions. If some investors find our ordinary shares less
	attractive as a result, there may be a less active trading market for our ordinary shares, and our share price may be more volatile
	and may decline.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	As a foreign private issuer, we are permitted and
	intend to follow certain home country corporate governance practices instead of otherwise applicable SEC and NASDAQ requirements,
	which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	As a foreign private issuer, we are
	permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required under
	the Listing Rules of the NASDAQ Stock Market for domestic U.S. issuers. For instance, we intend to follow home country practice
	in Israel with regard to, among other things, director nomination procedures and approval of compensation of officers. In addition,
	we may follow our home country law instead of the Listing Rules of the NASDAQ Stock Market that require that we obtain shareholder
	approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance
	that will result in a change of control of the company, certain transactions other than a public offering involving issuances
	of a 20% or greater interest in the company, and certain acquisitions of the stock or assets of another company. Following our
	home country governance practices as opposed to the requirements that would otherwise apply to a United States company listed
	on NASDAQ may provide less protection to you than what is accorded to investors under the Listing Rules of the NASDAQ Stock Market
	applicable to domestic U.S. issuers.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	In addition, as a foreign private issuer,
	we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements,
	and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions
	contained in Section&nbsp;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
	and current reports and financial statements with the SEC as frequently or as promptly as domestic U.S. issuers whose securities
	are registered under the Exchange Act. Also, although a recent amendment to the Israeli Companies Law will require us to disclose
	the annual compensation of our five most highly compensated senior officers on an individual basis (rather than on an aggregate
	basis, as was permitted under the Israeli Companies Law for Israeli public companies listed overseas, such as in the United States,
	prior to such amendment), this disclosure will not be as extensive as that required of a U.S. domestic issuer. For example, it
	currently appears as if the disclosure required under Israeli law would be limited to compensation paid in the immediately preceding
	year without any requirement to disclose option exercises and vested stock options, pension benefits or potential payments upon
	termination or change of control. These exemptions and leniencies will reduce the frequency and scope of information and protections
	to which you are entitled as an investor.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
<B>
	&nbsp;
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<B>
	Risks Related
	to Israeli Law and Our Operations in Israel
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our headquarters and other significant operations
	are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in
	Israel.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our executive offices are located in
	Tel Aviv, Israel. In addition, the majority of our officers and directors are residents of Israel. Accordingly, political, economic
	and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a
	number of armed conflicts have taken place between Israel and its neighboring countries. Any hostilities involving Israel or the
	interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results
	of operations. During November 2012 and July 2014, Israel was engaged in an armed conflict with a militia group and political
	party which controls the Gaza Strip. In addition, recent political uprisings and conflicts in various countries in the Middle
	East, including Egypt and Syria, are affecting the political stability of those countries. It is not clear how this instability
	will develop and how it will affect the political and security situation in the Middle East. This instability has raised concerns
	regarding security in the region and the potential for armed conflict.&nbsp;In addition, it is widely believed that Iran, which
	has previously threatened to attack Israel, has been stepping up its efforts to achieve nuclear capability. Iran is also believed
	to have a strong influence among extremist groups in the region, such as Hamas in Gaza and Hezbollah in Lebanon. Additionally,
	the Islamic State of Iraq and Levant (ISIL), a violent jihadist group, is involved in hostilities in Iraq and Syria and has been
	growing in influence. Although ISIL&rsquo;s activities have not directly affected the political and economic conditions in Israel,
	ISIL&rsquo;s stated purpose is to take control of the Middle East, including Israel. The tension between Israel and Iran and/or
	these groups may escalate in the future and turn violent, which could affect the Israeli economy in general and us in particular.&nbsp;Any
	armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could
	harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may
	sometimes decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements
	when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel
	may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform
	their commitments under those agreements pursuant to force majeure provisions in such agreements.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our commercial insurance does not cover
	losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli
	government has in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of
	war, we cannot assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate
	us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business. Any
	armed conflicts or political instability in the region would likely negatively affect business conditions generally and could
	harm our results of operations.
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Further, in the past, the State of
	Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State
	of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results,
	financial conditions or the expansion of our business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Exchange rate fluctuations between the U.S. dollar
	and the New Israeli Shekel currencies may increase our expenses.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	The vast majority of our expenses are
	in U.S. dollars and New Israeli Shekels, or NIS. Our functional currency is the U.S. dollar and substantially all of our financial
	resources are denominated by U.S. dollars. As a result, we are exposed to the risks that the NIS may appreciate relative to the
	U.S. dollar, or if the NIS instead devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate
	of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the U.S.
	dollar cost of our operations in Israel would increase and our U.S. dollar-denominated results of operations would be adversely
	affected. For instance, in 2015, approximately 20% of our expenses were denominated in New Israeli Shekels. Changes of 5% and
	10% in the U.S. dollar - NIS exchange rate would have increased/decreased the operation expenses by 0.95% and 1.81%, respectively.
	The exchange rate as of December 31, 2015 was $1.00 = NIS 3.902. We cannot predict any future trends in the rate of inflation
	in Israel or the rate of devaluation (if any) of the NIS against the U.S. dollar.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	In the past, we received Israeli government grants
	for certain of our research and development activities. The terms of those grants may require us, in addition to payment of royalties,
	to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. We may be required
	to pay penalties in addition to repayment of the grants.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our research and development efforts,
	during the period between May 1, 2009 and April 30, 2010, were financed in part through royalty-bearing grants, in an amount of
	$106,494 that we received from Israel's Office of the Chief Scientist of the Ministry of Industry, Trade and Labor, or OCS. With
	respect to such grants we are committed to pay royalties at a rate of 3% to 5% on sales proceeds from MDX, according to the OCS
	approval, the company is required to pay royalties from any income generated in connection with delayed release metadoxine tablets
	up to the total amount of grants received, linked to the U.S. dollar and bearing interest at an annual rate of LIBOR applicable
	to dollar deposits. Regardless of any royalty payment, we are further required to comply with the requirements of the Israeli
	Encouragement of Industrial Research and Development Law, 5744-1984, and related regulations, or the Research Law, with respect
	to those past grants. When a company develops know-how, technology or products using OCS grants, the terms of these grants and
	the Research Law restrict the transfer of such know-how, and the transfer of manufacturing or manufacturing rights of such products,
	technologies or know-how outside of Israel, without the prior approval of the OCS. Therefore, if aspects of our technologies are
	deemed to have been developed with OCS funding, the discretionary approval of an OCS committee would be required for any transfer
	to third parties outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies,
	and may result in payment of increased royalties (both increased royalty rates and increased royalties ceilings) and/or payment
	of additional amounts to the OCS. We may not receive those approvals. Furthermore, the OCS may impose certain conditions on any
	arrangement under which it permits us to transfer technology or development out of Israel (including for the purpose of manufacturing).
	Currently, under the Research Law, there is no mechanism for the approval of licensing transactions of OCS-supported technologies,
	however, licensing OCS supported technologies may under certain circumstances be considered a transfer of know-how and therefore
	requires approval as aforementioned.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	The transfer of OCS-supported technology
	or know-how outside of Israel may involve the payment of additional amounts depending upon the value of the transferred technology
	or know-how, the amount of OCS support, the time of completion of the OCS-supported research project and other factors up to a
	maximum of six times the amount of grants received. These restrictions and requirements for payment may impair our ability to
	sell our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect
	to any product or technology outside of Israel (particularly since currently there is no mechanism for the approval of licensing
	transactions of OCS supported technologies). Furthermore, the consideration available to our shareholders in a transaction involving
	the transfer outside of Israel of technology or know-how developed with OCS funding (such as a merger or similar transaction)
	may be reduced by any amounts that we are required to pay to the OCS.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our obligations and limitations pursuant
	to the Research Law are not limited in time and may not be terminated by us at will. As of the date hereof, we have not been required
	to pay any royalties with respect to the OCS grants. As of the date hereof, production of bulk drug substance and drug products
	required for our clinical trials does not involve manufacture of OCS supported products, technologies or know-how, and/or transfer
	of OCS supported technologies or know-how, and therefore no OCS committee approval has been sought after or required in connection
	with such production by our third-party manufacturers.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Provisions of Israeli law and our amended and restated
	articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent
	a change of control, even when the terms of such a transaction are favorable to us and our shareholders.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Israeli corporate law regulates mergers,
	requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
	directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions.
	For example, a merger may not be consummated unless at least 50&nbsp;days have passed from the date on which a merger proposal
	is filed by each merging company with the Israel Registrar of Companies and at least 30&nbsp;days have passed from the date on
	which the shareholders of both merging companies have approved the merger. In addition, a majority of each class of securities
	of the target company must approve a merger. Moreover, a tender offer for all of a company's issued and outstanding shares can
	only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion
	of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer,
	unless, following consummation of the tender offer, the acquirer would hold at least 98% of the Company's outstanding shares.
	Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six
	months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition,
	unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Furthermore, Israeli tax considerations
	may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty
	with Israel exempting such shareholders from Israeli tax. See Item 10.E. Taxation &ldquo;Israeli Taxation Considerations&rdquo;
	for additional information.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our amended and restated articles of
	association also contain provisions that could delay or prevent changes in control or changes in our management without the consent
	of our Board of Directors. These provisions include the following:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	no
	cumulative voting in the election of directors, which limits the ability of minority shareholders to elect director candidates;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	right of our Board of Directors to elect a director to fill a vacancy created by the expansion of the Board of Directors or
	the resignation, death or removal of a director, which may prevent shareholders from being able to fill vacancies on our Board
	of Directors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	It may be difficult to enforce a judgment of a United
	States court against us and our officers and directors and the Israeli experts named herein in Israel or the United States, to
	assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We were incorporated in Israel. Most
	of our executive officers and directors reside outside of the United States, and all of our assets and most of the assets of these
	persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including
	a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States
	and may not necessarily be enforced by an Israeli court. It also may be difficult for you to effect service of process on these
	persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it
	may be difficult for an investor, or any other person or entity, to initiate an action with respect to United States securities
	laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of United States securities laws reasoning
	that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to
	hear a claim, it may determine that Israeli law and not United States law is applicable to the claim. If United States law is
	found to be applicable, the content of applicable United States law must be proven as a fact by expert witnesses, which can be
	a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding
	case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment
	against us in Israel, you may not be able to collect any damages awarded by either a United States or foreign court.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Your rights and responsibilities as a shareholder
	will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders
	of U.S. companies.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	The rights and
	responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of association and by
	Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders
	in typical U.S.-based corporations. In particular, a shareholder of an Israeli company has certain duties to act in good faith
	and fairness towards the Company and other shareholders, and to refrain from abusing its power in the Company. See Item 7. Major
	Shareholders and Related Party Transactions for additional information. There is limited case law available to assist us in understanding
	the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations
	and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	We are subject to anti-takeover provisions that could
	delay or prevent our acquisition by another entity.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Provisions of Israeli corporate and
	tax law and of our articles of association may have the effect of delaying, preventing or making more difficult any merger or
	acquisition of us. In addition, any merger or acquisition of us will require the prior consent of the office of the chief scientist,
	or the Chief Scientist, if intellectual property is removed from Israel, as well as the Investment Center of the Israeli Ministry
	of Industry, Trade and Employment, or the Investment Center. Israeli law regulates mergers, votes required to approve a merger,
	acquisition of shares through tender offers and transactions involving significant shareholders. Any of these provisions may make
	it more difficult to acquire us. Accordingly, our acquisition by another entity could be delayed or prevented even if it would
	be beneficial to our shareholders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Our operations may be disrupted as a result of the
	obligation of management or key personnel or consultants to perform military service.
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our male employees and consultants
	in Israel, including members of our senior management, may be obligated to perform one month, and in some cases longer periods,
	of annual military reserve duty until they reach the age of 40 (or older, for citizens who hold certain positions in the Israeli
	armed forces reserves). In this connection, we note that our Chief Financial Officer and Chief Operating Officer, Dr. Tomer Berkovitz,
	is 36 years old. In the event of a military conflict, they and other of our key personnel or consultants may be called to active
	duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists.
	It is possible that there will be similar large-scale military reserve duty call-ups in the future. Our operations could be disrupted
	by the absence of a significant number of our officers, directors, employees and consultants. Such disruption could materially
	adversely affect our business and operations.
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_KEY_INFORMATION>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<EFX_COMPANY_INFORMATION>
<A NAME="FIS_COMPANY_INFORMATION"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
<A NAME="V432397_20F_HTM_NOTE_004">
</A>
	ITEM 4.
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INFORMATION ON THE COMPANY
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	4.A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;History
	and development
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	We are an Israeli corporation based
	in Tel Aviv and were incorporated in 2008. Our principal executive offices are located at Azrieli Triangle Building, 132 Derech
	Menachem Begin, 39
<SUP>
	th&nbsp;
</SUP>
	Floor, Tel Aviv 6701101 Israel, and our telephone number is +972 72 220 4661. Our website
	address is www.alcobra-pharma.com. The information contained on, or that can be accessed through, our website is not part of this
	form. We have included our website address herein solely as an inactive textual reference.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	We are an &ldquo;emerging growth company,&rdquo;
	as defined in Section&nbsp;2(a) of the Securities Act of 1933, or the Securities Act, as modified by the JOBS Act. As such, we
	are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public
	companies that are not &ldquo;emerging growth companies&rdquo; such as not being required to comply with the auditor attestation
	requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. We could remain an &ldquo;emerging growth company&rdquo; for
	up to five years from our initial public offering in 2013, or until the earliest of (a)&nbsp;the last day of the first fiscal
	year in which our annual gross revenue exceeds $1&nbsp;billion, (b)&nbsp;the date that we become a &ldquo;large accelerated filer&rdquo;
	as defined in Rule&nbsp;12b-2 under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur
	if the market value of our ordinary shares that is held by non-affiliates exceeds $700&nbsp;million as of the last business day
	of our most recently completed second fiscal quarter, or (c)&nbsp;the date on which we have issued more than $1&nbsp;billion in
	nonconvertible debt during the preceding three-year period. Our wholly owned U.S. subsidiary, Alcobra, Inc., has been appointed
	our agent in the United States and is located at 600 West Germantown Pike, Suite 400, Plymouth Meeting, PA, 19462.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	We did not have any significant capital
	expenditures in 2013, 2014 and 2015. We have financed our capital expenditures with cash generated from proceeds from sales of
	our equity securities. We do not anticipate any significant capital expenditures in fiscal year 2016.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	4.B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business
	overview
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Who We Are
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 26PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	We are an emerging biopharmaceutical
	company primarily focused on the development and commercialization of our proprietary oral drug candidate, MDX, to treat ADHD
	and other cognitive dysfunctions including Fragile X. The most common currently available treatments for ADHD are stimulants that
	increase the brain chemicals dopamine and norepinephrine. Stimulants have significant side effects, and are classified as controlled
	substances, which have significant potential for misuse, abuse and addiction. MDX is not a stimulant, and works with a different
	mechanism of action. MDX is a proprietary, combined rapid onset/extended release formulation of the chemical pyridoxine pyroglutamate,
	which is more broadly known as metadoxine. Metadoxine is designed to be a monoamine-independent modulator of gamma-aminobutyric
	acid transmission. Metadoxine has been available since the 1980s only in immediate release forms for the acute treatment of alcohol
	intoxication and the chronic treatment of alcoholic liver disease in Italy, Portugal, Hungary, Russia, India, China, Mexico and
	Thailand.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
<I>
	MDX for the Treatment of ADHD
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	ADHD is one of the most common behavioral
	disorders in the world. It is estimated that between 8% and 10% of children worldwide are affected by this condition. Once believed
	to only affect children, ADHD is now known to persist into adolescence and adulthood in a large number of cases, with approximately
	50% of all children with ADHD continuing to have symptoms of the disorder as adults. Over 90% of adults with ADHD experience impaired
	attention and executive function symptoms, of which approximately 35% also experience hyperactivity-impulsivity symptoms.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	ADHD is a treatable condition. The
	most commonly used therapeutic drugs are stimulants (Schedule II, Controlled Substances), such as Ritalin, Adderall, Vyvanse and
	Concerta, which are all dopaminergic (related to dopamine) and noradrenergic (related to norepinephrine) compounds with significant
	abuse and misuse potential, as their use may lead to severe psychological or physical dependence. In addition, stimulants have
	numerous side effects, such as uncomfortable mental states, interference with sleep and appetite, development of nervous tics
	and potential cardiovascular effects resulting from increased blood pressure and heart rate. There are limited effective treatments
	for these side effects for patients taking the drugs. The prevalence of such side effects has also led to dramatically limited
	medication adherence rates. Up to 30% to 50% of those who are prescribed stimulants for ADHD either do not respond or cannot tolerate
	these treatments, and only about 20% of those who are prescribed stimulants are still taking them 12 months later. There also
	is a non-stimulant drug approved for children and adults with ADHD called Strattera (atomoxetine), approved in 2002. This drug
	also has significant potential side effects, such as fatigue, gastrointestinal upset, sexual problems, palpitations, increased
	heart rate and high blood pressure and also has regulatory warning labels relating to suicidal thoughts and liver damage. Moreover,
	Strattera may take six to eight weeks to achieve full clinical effectiveness. More recently, two additional non-stimulant medications
	were approved for use only in children and adolescents with ADHD, Intuniv (guanfacine) and Kapvay (clonidine). These two drugs
	have not been approved for use in adults with ADHD and have not had significant commercial success. All approved ADHD drugs need
	to be carefully monitored by the treating physician to optimize the dose, starting with a low dose and slowly escalating to the
	most effective and tolerable dose.
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In contrast to the most common available
	treatments, which involve the use of stimulants, MDX is not a stimulant and employs a different mechanism of action that is neither
	dopaminergic (related to dopamine) nor noradrenergic (related to norepinephrine). Our clinical trials to date have suggested a
	pro-cognitive effect and favorable tolerability and safety. We therefore believe MDX potentially represents an effective treatment
	and a safer alternative to currently marketed treatments.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In September 2011, we completed a 120
	subject double-blind placebo-controlled Phase 2 study in adult ADHD subjects in two academic sites in Israel. The study showed
	statistically significant improvement in clinical ADHD symptoms, and also showed favorable tolerability with no significant side
	effects over a placebo. The trial met all primary and secondary clinical endpoints showing statistically significant improvement
	over the placebo-treated control group.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In December 2013, we completed an additional
	36 subject double-blind placebo-controlled Phase 2 study in adult ADHD subjects, which confirmed our previous findings, highlighted
	the rapid onset of MDX, and demonstrated efficacy over placebo from the first day of dosing, using a computerized assessment tool.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In October 2014, we announced the results
	of a 300 subject double-blind placebo-controlled Phase 3 study in adult ADHD in 20 sites (18 in the United States and two in Israel).
	The study&rsquo;s primary efficacy endpoint did not reach statistical significance. A non-significant favorable trend was observed
	on the primary endpoint. Other secondary measures showed strong or statistically significant trends. Similar to previous studies,
	MDX showed a favorable safety profile.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In March 2015, we reported that our
	Phase 2 safety and tolerability study of a single administration of MDX in adolescent patients with ADHD achieved its primary
	endpoint. In the study, MDX showed good tolerability and no safety concerns were identified.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In the first quarter of 2015, we met
	with the FDA to discuss the results of our first Phase 3 study in adults with ADHD, the proposed protocol for our second Phase
	3 study in adults, the requirements for clinical development of MDX for pediatric ADHD, as well as the requirements for an NDA
	submission. The FDA confirmed that a single additional study showing efficacy in adult ADHD may provide a sufficient basis of
	efficacy for approval of MDX in this sub-population. The FDA also confirmed that a single Phase 2 study, followed by a single
	Phase 3 study, in a pediatric ADHD population can provide a sufficient basis of efficacy for approval of MDX in this population.
	We currently plan to file a joint NDA for the adult and pediatric sub-populations. We expect to launch the first of two adequate,
	well-controlled, short-term efficacy studies in children with ADHD in 2016. The study will be a multi-center, placebo-controlled,
	short-term efficacy study.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In the second quarter of 2015, we launched
	the MEASURE study (MDX Evaluation in Adults &mdash; StUdy of Response and Efficacy). The MEASURE study is our second Phase 3 study
	of MDX in adults with ADHD. The study includes design and operational elements to potentially mitigate placebo response and reduce
	treatment response variability, and we expect to report data by year end 2016.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	If the data from these and future pre-clinical
	and clinical trials demonstrate the safety and efficacy of MDX in the pediatric and adult sub-populations, we will seek to obtain
	marketing approval from the FDA for MDX for use in ADHD. We have similar plans to seek marketing approval in other territories.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
	MDX for
	the Treatment of Fragile X
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	We are also studying MDX for the treatment
	of Fragile X, a rare neurogenetic disorder related to autism marked by severe intellectual disability. In June 2015, we reported
	that our Phase 2 exploratory clinical study of MDX in adolescent and adult patients with Fragile X did not achieve statistical
	significance on the primary endpoint, yet demonstrated statistically significant improvements in certain clinically meaningful
	behavioral and cognitive endpoints, including the Vineland II Daily Living Skills Assessment. The FDA has granted fast track designation
	and Orphan Drug status to MDX for the treatment of Fragile X.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	In October 2015, we met with the FDA
	to discuss the results of our Phase 2 study in Fragile X and the requirements for NDA submission of MDX in this therapeutic indication.
	The FDA concurred that results from a single short-term, adequate and well-controlled efficacy study in adolescents and adult
	patients with Fragile X may be sufficient to support a claim of efficacy for approval of MDX in this indication (in line with
	the FDA's Guidance for Industry &mdash; Providing Evidence of Effectiveness for Human Drug and Biological Products, May 1998).
	We plan to submit a separate application for pediatric patients (ages 4-11) following FDA approval via a supplemental NDA. The
	FDA confirmed that the Vineland II Daily Living Skills Assessment could serve as the primary endpoint in the adolescents and adults
	Fragile X pivotal study.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 10PT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	To date, we have not generated revenue
	from the sale of any product, and we do not expect to generate significant revenue unless and until we obtain marketing approval
	of, and commercialize, MDX. As of December 31, 2015, we had an accumulated deficit of $71 million.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Our Strategic Plan
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 26PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Our objective is to develop and commercialize
	proprietary pharmaceutical products for treatment of central nervous system disorders, and cognitive dysfunctions in particular.
	To this effect, we intend to seek approval to conduct additional clinical trials for our most advanced product (MDX) and, if those
	trials are successful, seek marketing approvals from the FDA and other worldwide regulatory bodies for MDX for the treatment of
	ADHD in adults and children. We also plan to advance clinical studies and commercialization plans for MDX in Fragile X. To achieve
	these objectives, we plan to:
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.15IN">
	&bull;
</TD>
<TD>
	seek the necessary regulatory approvals to complete the
	clinical development of MDX for the treatment of ADHD in adults and children, and, if
	successful, file for marketing approval in the United States and other territories;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.65IN; TEXT-INDENT: -0.15IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.15IN">
	&bull;
</TD>
<TD>
	seek the necessary regulatory approvals to complete the
	clinical development of MDX for the treatment of Fragile X in adults and children, and,
	if successful, file for marketing approval in the United States and other territories;
	and
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.65IN; TEXT-INDENT: -0.15IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.15IN">
	&bull;
</TD>
<TD>
	prepare to commercialize MDX for the treatment of
	patients with ADHD and Fragile X by establishing independent distribution capabilities
	or in conjunction with other pharmaceutical companies in the United States and other
	key markets.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	About ADHD
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
	The ADHD Market
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The United States market size for ADHD
	treatment is estimated to be approximately $9 billion annually, which accounted for approximately 90% of the global ADHD market.
	The difference in market sizes between the U.S. and other countries is driven by different rates of diagnosis and treatment, different
	pricing, and the number of available brand name medications (non-U.S. markets are dominated by generic drugs). Global prevalence
	rates of the disease are estimated to be approximately 8-10% of school-aged children and approximately 4-5% of the adult population.
	Adult diagnosis and treatment is forecast to grow in the near future due to increased disease awareness and less sociological
	stigmatization towards the condition. In the United States, the rate of treatment with prescription medications is approximately
	70% in children and 45% in adults. In 2015, close to 67 million prescriptions were filled in the United States for approved ADHD
	medications versus less than 44 million in 2009. The U.S. market is projected to continue to grow in mid-single digits, driven
	by an increased prescription rate for adult ADHD, which has grown at approximately 10% annually over the last few years. The international
	ADHD market is projected to grow at a faster rate than the U.S. market in part because higher disease recognition and acceptance
	is expected in Japan and Europe. The estimated growth for the non-U.S. markets is also higher due to the recent launches for major
	ADHD drugs that have already been marketed in the United States, such as Vyvanse and Intuniv. Despite upcoming patent expiration
	dates and the entry of several generic compounds, the market size is expected to grow further as new drugs enter the market and
	compensate for the generic erosion.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
<B>
	Development
	of ADHD Symptoms
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;Once perceived to only affect
	children, ADHD is now known to persist into adolescence and adulthood in a sizeable number of cases. The following table illustrates
	how the nature of ADHD symptoms changes with age:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Children
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Adolescents
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 31%; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Adults
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Hyperactive
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Aggressive
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Low frustration tolerance
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Impulsive
</B>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Easily distracted
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Inattentive
</B>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Shifts activities
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Easily bored
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Impatient
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Restless
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Approximately 50% of adults who suffered
	from ADHD as children continue to have symptoms of the disorder as adults, with over 90% experiencing attention deficit symptoms
	and about 35% of them experiencing hyperactivity-impulsivity symptoms. As the majority of sufferers of ADHD age, their symptoms
	tend toward impatience, restlessness, boredom and low concentration levels from the more aggressive hyperactivity and impulsive
	behavior evident in children.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Although the definitive causes of ADHD
	are still unclear, current research suggests that ADHD is caused by an interaction between environmental factors and genetic predispositions.
	Biologic factors that reportedly increase the risk of having ADHD include maternal smoking, drug or alcohol abuse during pregnancy,
	brain injury and exposure to toxins. Furthermore, diet may play a role in ADHD.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
	Impact of Untreated
	and Undertreated ADHD
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	ADHD is believed to be one of the most
	under-diagnosed and under-treated mental health conditions facing children and adults. ADHD increases health risks, adverse social
	externalities and economic costs as illustrated in the following table. Despite the disorder being highly treatable, most adults
	with ADHD remain undiagnosed and untreated.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The following table illustrates the
	effects on society when ADHD remains untreated:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 34%">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Healthcare
	System
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&ntilde;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	50% in bicycle accidents
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&ntilde;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	33% in ER visits
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	2-4x more car accidents
</P>
</TD>
<TD STYLE="WIDTH: 3%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
<B>
	Patient
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&ntilde;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	criminal activity
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&ntilde;
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	incarceration
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Family
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	3-5x more divorce/separation
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	2-4x more sibling fights
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 34%">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
<B>
	School
	and Occupation
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	46% expelled
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	35% drop out
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	Lower occupational
	status
</P>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
<B>
	Society
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	Substance use disorders:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	2x risk and earlier
	onset
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	Less likely to quit
	in adulthood
</P>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
<B>
	Employer
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 5.4PT; TEXT-ALIGN: CENTER">
	Increased parental
	absenteeism and lower productivity
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
	Diagnosis of
	ADHD
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The diagnosis of ADHD is obtained by
	a psychiatric assessment which is intended to eliminate other potential causes. A formal diagnosis is completed by a qualified
	physician and is based on a number of set criteria. The Diagnostic and Statistical Manual of Mental Disorders, fourth edition,
	or DSM-V, diagnostic criteria are most widely used to diagnose ADHD.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 94%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	DSM-V
	criteria
</I>
	. The American Psychiatric Association provides a set of standardized criteria for classifying mental disorders
	known as the Diagnostic and Statistical Manual of Mental Disorders, or DSM. These criteria are based on the premise that attention
	deficits are distinct and differentiated conditions that are abnormalities resulting from biological origins that can be reliably
	and objectively measured. The diagnostic criteria include:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Inattention
	&ndash; the patient makes careless mistakes in activities and is easily distracted
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Hyperactivity
	&ndash; the patients fidgets, squirms, talks excessively or displays restless behavior
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Impulsiveness
	&ndash; the patient interrupts others and cannot wait for a turn
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	There
	must be clear evidence of significant impairment in social, school, or work functioning
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Signs
	of impairment present before twelve years of age and present in two or more settings (school/work and home)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 15%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 82%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Signs
	are not better accounted for by another mental disorder
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The DSM-V criteria are becoming more
	prevalent as the diagnostic measure for ADHD in Europe and Japan. If the DSM-V criteria are used, rather than an alternative measure
	in declining use, a diagnosis of ADHD is three to four times more likely. Consequently, the size of the market in Europe and Japan
	is set to grow with improved diagnosis rates driven by adoption of the DSM-V criteria.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Key Products &ndash; ADHD
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The four drugs to treat ADHD that to
	our knowledge had the most sales in 2014 on a worldwide basis are shown in the following table, together with the drug brand name,
	owner, and historic or expected peak sales. Out of the drugs listed below, Vyvanse, Concerta and Adderall XR are stimulants and
	Strattera is a non-stimulant drug.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Brand
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(launch)
</B>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Generic
	Name
</B>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Owner
</B>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD COLSPAN="2">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Global Sales
	in 2014
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	U.S. Dollars in Millions
</B>
</P>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Peak Global Sales
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	U.S. Dollars in Millions
</B>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 17%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Vyvanse
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2007)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 18%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lisdexamfetamine
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 12%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Shire
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 26%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,449
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 20%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&gt;
	2,000 (est. 2018)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Concerta
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2000)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OROS
	Methylphenidate
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	J&amp;J
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	599
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,326
	(2009)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Strattera
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2002)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Atomoxetine
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Eli
	Lilly
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	739
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&gt;800
	(est. 2016)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Adderall
	XR
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2001)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mixed
	Amphetamine Salts
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Shire
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	383
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,102
	(2008)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Limitations of Current Treatment Options for ADHD
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;Because of the significant side
	effects and abuse potential associated with current stimulant treatment options for ADHD which are classified in the same controlled
	substance category as narcotics, there is a significant need to develop safe and effective treatment alternatives.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Historically, the first line treatment
	for ADHD was stimulants, such as methylphenidate and amphetamine. These are classified as Schedule II controlled substances that
	can cause dependence and abuse. The danger of prescription drug abuse is one of the main causes of low treatment rates, particularly
	by primary care physicians (PCPs) who are the largest group of prescribers. All but one of the current drugs on the market to
	treat adult ADHD are stimulants. Strattera is the only drug currently on the market for adults with ADHD that is a non-stimulant.
	Strattera has been effective, but it also has serious side effects, such as fatigue, GI upset, sexual problems, palpitations,
	increased heart rate, blood pressure, and regulatory warning labels on suicidal thoughts and liver damage. Moreover, Strattera
	also takes six to eight weeks to achieve full clinical effects. MDX has low potential to be an abused drug, has shown efficacy
	after a single dose and improved safety profile, and we believe that, if approved, its market entry should increase treatment
	rates and drive market growth.
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	While stimulants have been shown to
	be effective for the treatment of ADHD, up to 30% to 50% of those who are prescribed stimulants for ADHD either do not respond
	or cannot tolerate these treatments. Consequently, medication adherence rate for these ADHD therapies is poor, with less than
	20% of patients continuing on therapy 12 months after they are first prescribed medication. Therefore, there is a significant
	need to develop safe and effective treatment alternatives, particularly ones devoid of abuse potential and significant side effects.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Clinical Data in ADHD
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
<B>
	Symptom and
	Clinical Efficacy Measurement
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	There are various methodologies for
	evaluating and measuring changes in the symptoms of ADHD patients, including behavior rating scales conducted by an observer or
	the patient themselves, and computer-based cognitive performance tests. Examples of commonly used methodologies to test the clinical
	efficacy of ADHD pharmacotherapies include:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Conners&rsquo;
	Adult ADHD Rating Scales, or CAARS.
</I>
	CAARS measures the presence, frequency and severity of ADHD symptoms. The scales quantitatively
	measure ADHD symptoms using 18 items. The scale has been used extensively in clinical trials including pivotal adult Phase
	3 studies of approved pharmacotherapies for ADHD. Behavioral rating scales, similar to the CAARS measure, but with age-appropriate
	questions, are used for the assessment of ADHD symptoms in children.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Test
	of Variables of Attention, or TOVA.
</I>
	TOVA is a computerized test that assists in the screening, diagnosis, and treatment
	monitoring of attention disorders such as ADHD. The test provides an objective, quantitative measure of attention. The test
	consists of a 20-minute activity that measures responses to either visual or auditory stimuli. These measurements are then
	compared to the measurements of a group of people without attention disorders who complete the same test. The test provides
	information about a subject&rsquo;s response style, such as the tendency to make impulsive errors or errors due to inattention,
	distraction or reaction time.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
	Clinical Studies
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&#9;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We have conducted
	several Phase 2 clinical trials in adults and adolescents with ADHD and one Phase 3 clinical trial in adult ADHD subjects, in
	the United States and Israel, testing the safety and efficacy of our novel non-stimulant drug candidate, MDX. These trials included:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a Phase
	2a open label proof of concept study of 40 adult ADHD subjects, followed by two extension studies to determine duration of
	effect and efficacy of various dosages;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a Phase
	2b, six-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center&nbsp;&nbsp;study of 120 adult ADHD
	subjects, in which ADHD subjects were randomly assigned in a 1:1 ratio to one of two treatment groups: a 1,400mg dose of MDX
	and a matching placebo;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a Phase
	2b randomized, double-blind, placebo-controlled, cross-over single center&nbsp;&nbsp;study conducted in 36 adult subjects
	with predominantly inattentive ADHD (PI-ADHD) with 1400 mg MDX, 700 mg MDX and matching placebo;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a Phase
	2b randomized, double-blind, placebo-controlled, parallel-group, multi-center study conducted in 83 adolescents with PI-ADHD;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a Phase
	3, six-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center&nbsp;study of 300 adult ADHD subjects,
	in which ADHD subjects were randomly assigned in a 1:1 ratio to one of two treatment groups: a 1,400mg dose of MDX and a matching
	placebo.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	In addition, we
	have an ongoing Phase 3, ten-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of 750 adult
	ADHD subjects, in which ADHD subjects are randomly assigned in a 1:1 ratio to one of two treatment groups: a 1,400mg dose of MDX
	and a matching placebo.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
<B>
<I>
	Summary of Phase 2a Clinical
	Studies in Adults
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	The Phase 2a study was designed to
	evaluate the effect of a single oral administration of MDX on cognitive function in subjects ranging from ages 18-45 who had been
	diagnosed as having ADHD. The study was performed at the ADHD unit of the Geha Mental Health Hospital (Israel). The primary outcome
	measures in the trial were the one-hour post-medication TOVA ADHD Score, and various TOVA subscores, Secondary outcome measures
	were subtests from the Wechsler Adult Intelligence Scale-Revised (WAIS-R test). The WAIS is a battery of tests designed to measure
	intelligence in adolescents and adults.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	Results of this clinical study showed
	clinically and statistically significant improvement (P-value &lt; 0.05) in all the TOVA parameters that were abnormal at baseline.
	&ldquo;P-value&rdquo; is a statistical measure for the probability of an error. In clinical investigations, p&lt;0.05 (meaning
	that the probability of an error in the outcome is small and less than 5%) is considered a statistically significant finding.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Furthermore, results
	of the Wechsler subtests confirmed the ability of MDX to improve cognitive functions in adults with ADHD, with clinical and statistically
	significant improvement seen in both working memory and spatial memory tests. A significant correlation was found between the
	drug response measured by the TOVA and the response measured by the WAIS-R subtests.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	In an extension study to evaluate the
	duration of drug benefits, 10 subjects were evaluated using TOVA immediately before, and 90 minutes, 4 hours and 7 hours after,
	taking a single 1400mg dose of MDX. Results demonstrated an extended effect of the drug on cognitive functions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	In another extension study designed
	to evaluate the relative efficacy of various MDX doses, 10 subjects were evaluated using TOVA 90 minutes after blindly taking
	either 700mg, 1400mg or 2100mg doses of MDX on separate occasions and in a random visit order. TOVA results following these treatments
	were compared to the baseline data obtained before any treatment in these subjects. Results confirmed the likely effective dose
	range for MDX to be 700-1400mg, demonstrating that the 1400 mg dose had the greatest magnitude of effect.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Summary of First Phase 2b Clinical
	Study in Adults
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We completed a six-week randomized,
	double-blind, placebo-controlled, parallel-group, multi-center Phase 2b study in 120 adult subjects with ADHD that was performed
	in two centers in Israel: the ADHD unit at Geha Mental Health Hospital and the Cognitive Neurology unit at Rambam Healthcare Campus.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	ADHD subjects were randomly assigned
	in a 1:1 ratio to one of two treatment groups: 1400mg MDX or matching placebo. The primary efficacy measure was CAARS questionnaire,
	and the secondary efficacy measures were the TOVA test and the Adult ADHD Quality of Life (AAQoL) questionnaire.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Significant improvements in CAARS scores
	(p&lt;0.02), TOVA ADHD scores (p&lt;0.02) and AAQoL scores (p&lt;0.01) were observed in the MDX treated group versus the placebo
	group. Improvements in CAARS and TOVA scores were statistically significant over the placebo after as little as two weeks of treatment.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Physical examination, laboratory parameters,
	vital signs, and electrocardiograms showed no consistent differences between treatment groups or cumulative changes over time.
	The most commonly reported adverse events were nausea, fatigue and headache. Nausea was the only adverse event to occur exclusively
	in the MDX group and should be considered an anticipated event in future MDX research; fatigue occurred in similar numbers in
	both groups, and headache occurred notably less frequently in the MDX group.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Summary of Second Phase 2b Clinical
	Study in Adults
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We completed an additional Phase 2b,
	randomized, double-blind, placebo-controlled, crossover comparison, single-center study in 36 adult subjects with Predominantly
	Inattentive ADHD (PI-ADHD). The study was designed to compare the efficacy, safety and tolerability of two doses of MDX, 1400
	mg and 700 mg, and placebo&lrm; for the treatment of symptoms in adults diagnosed with PI-ADHD. The primary efficacy endpoint
	of the study was met, as demonstrated by a significant difference between the change in TOVA ADHD score following single-dose
	administration of 1400 mg MDX versus Placebo&lrm; (mean change 6.5 vs. 4.4 points, p=0.0084). The difference between the change
	in ADHD score following administration of 700 mg MDX and Placebo was not statistically significant. A significant difference was
	observed between the change in TOVA ADHD score between the 700 mg MDX and 1400 mg MDX. Both doses of MDX were associated with
	a favorable safety profile, particularly in comparison to no treatment (Pre-dose) and Placebo&lrm;, per adverse event, laboratory
	(hematology, biochemistry, urinalysis), vital sign, electrocardiography, and physical and neurological evaluations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Summary of Phase 2 Clinical Study
	in Adolescents
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We completed a Phase 2 multi-center,
	randomized, double-blind, fixed dose study in 83 adolescents (aged 13-17) with PI-ADHD. The study was conducted in six sites in
	Israel. The study achieved its primary endpoint and demonstrated good tolerability and no safety concerns. The most common side
	effects were headache (8% in MDX, 12% in placebo), nausea (3% in MDX, 5% in placebo) and fatigue (3% in MDX, 5% in placebo). No
	clinically significant safety findings in laboratory values, vital sign measurements, ECG parameters, cardiovascular parameters
	or findings during clinical examination were observed. Analyses of secondary cognitive measures, after a single administration
	of MDX compared to placebo, did not produce statistically significant findings, yet resulted in an efficacy signal on the TOVA
	assessments Response Time and Errors of Omission.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Summary of First Phase 3 Clinical
	Study in Adults
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We completed a Phase 3, 6-week, multicenter,
	randomized, double-blind, parallel-group, fixed-dose study of MDX 1400 mg once daily compared with placebo in 300 adults with
	ADHD. The study was conducted at 18 sites in the United States and 2 sites in Israel. The study was designed to evaluate the efficacy
	of MDX 1400 mg daily compared with placebo in the treatment of ADHD in adults as measured by the CAARS questionnaire. The primary
	endpoint of change from Baseline in CAARS over Weeks one through six using the MMRM analysis did not reach statistical significance
	with MG01CI 1400 mg versus placebo for the Intend To Treat (ITT) Population (n=297; p=0.1358).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Several
	statistical analyses, some defined before the trial was completed (pre-specified), and some designed after trial completion (post-hoc)
	identified the placebo response in this trial to be of an unusual and extreme magnitude and variability as compared to past adult
	ADHD trials with MDX or other approved ADHD drugs. In one such pre-specified analysis, a pre-defined criteria for identifying
	extreme and unexpected clinical response was applied to all trial subjects (regardless of whether treated by placebo or MDX).
	This analysis identified two patients who reported such extreme responses, both of whom were assigned to placebo. When data from
	these two patients were excluded, in accordance with the pre-specified Statistical Analysis Plan (SAP), the analysis of the primary
	outcome showed a near-significant trend in favor of MDX, but still did not reach statistical significance (n=295; p=.0606). The
	change to a near significant level demonstrates the unusual impact of only two extreme patient responses on the overall placebo
	response. Analysis of other assessments used in the trial such as the Clinical Global Impression-Severity (CGI-S) scores, Clinical
	Global Impression &ndash; Improvement (CGI-I) scores, and others showed similar near-significant or significant outcomes.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Treatment with MDX was well tolerated.
	The most common adverse events were headache (15.1% in MDX, 12.3% in placebo), nausea (8.6% in MDX, 6.2% in placebo), and fatigue
	(7.2% in MDX, 8.2% in placebo). No drug-related serious adverse events were reported. No clinically significant abnormalities
	in any laboratory measurements, vital sign measurements, ECG parameters, suicidality questionnaires, or findings during clinical
	examination, including neurological examination, were observed.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 22.5PT; COLOR: #4472C4">
<FONT STYLE="FONT-SIZE: 12PT; COLOR: BLACK">
	Primary
	Efficacy Analysis Results
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 22.5PT; COLOR: #4472C4">
<FONT STYLE="FONT-SIZE: 12PT; COLOR: BLACK">
	CAARS
	Score: ITT (N=297)&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/04/0001144204-16-086094_TPG36.JPG" ALT="">
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
<B>
<I>
	Summary
	of Clinical Data in ADHD and Key Conclusions
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We have conducted
	three clinical efficacy studies in adults with ADHD and one clinical efficacy study in adolescents with PI-ADHD using MDX. Doses
	of MDX tested in the studies ranged from 700 mg to 2100 mg MDX, and safety and efficacy have been examined after both single and
	repeated administrations. After a single dose of 1400 mg MDX, an immediate response and clinically meaningful improvement in performance
	(as reflected by TOVA and WAIS-R scores) was seen, with improvements in response time and response time variability scores up
	to 7 hours post-dose. Administration of a single 1400 mg dose of MDX resulted in similar changes in the TOVA. A comparison of
	the effect of single doses of 700 mg, 1400 mg, and 2100 mg MDX indicated the possible superiority of the 1400 mg dose. When this
	dose of MDX was administered over a six-week period in adults with ADHD, there was a significant improvement in ADHD symptoms
	and subjects&rsquo; quality of life responses compared with placebo.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	In our first Phase 3 efficacy study
	of MDX in adults with ADHD, only a non-statistically significant trend favoring MDX was observed. Rigorous statistical analyses
	demonstrated an unusually high placebo response and variability in this trial, mostly due to two patients who were assigned to
	placebo and reported unusually and unreasonably high clinical responses. Multiple analyses of the primary and secondary endpoints
	provided supportive evidence of a signal of efficacy of MDX over placebo. Appropriate measures to better control placebo response
	in future trials of MDX are being evaluated.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	In all studies,
	MDX was well tolerated. The most commonly reported adverse events in the various clinical studies were nausea, fatigue and headache.
	In the first Phase 2b study described above, transient moderate nausea, lasting from one to two days, was the only adverse event
	to occur exclusively in the MDX group, with an incidence of approximately 17%; fatigue was largely the same in the control groups
	(27%) and the MDX groups (31%), and headache occurred notably less frequently in the MDX group, in about 29% of the subjects,
	as compared with 38% of the subjects in the placebo group. In the second phase 2b study described above, the most common adverse
	events reported during the treatment period were fatigue and headache. There were no serious or severe adverse events in these
	three clinical trials, and no clinically significant treatment-related abnormalities in vital signs, electrocardiograms (ECG),
	physical examination, and clinical labs (hematology, chemistry, and urinalysis). In the Phase 3 study, the most common adverse
	events were headache (15.1% in MDX, 12.3% in placebo), nausea (8.6% in MDX, 6.2% in placebo), and fatigue (7.2% in MDX, 8.2% in
	placebo). No drug-related serious adverse events were reported. No clinically significant abnormalities in laboratory values,
	vital sign measurements, ECG parameters, suicidality questionnaires, or findings during clinical examination, including neurological
	examination, were observed. In the phase 2 study of adolescents with PI-ADHD, the most common side effects were headache (8% in
	MDX, 12% in placebo), nausea (3% in MDX, 5% in placebo) and fatigue (3% in MDX, 5% in placebo). No clinically significant safety
	findings in laboratory values, vital sign measurements, ECG parameters, cardiovascular parameters or findings during clinical
	examination were observed.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	In addition, products
	containing metadoxine outside the United States cite infrequent diarrhea and moderate skin rash.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
<B>
<I>
	Ongoing
	and Planned Clinical Studies in ADHD
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	We have initiated
	a second Phase 3 clinical trial in the United States for the use of MDX to treat ADHD in adults. The design of this trial incorporates
	lessons learned from the first Phase 3 study, such as improved powering assumptions, duration of treatment, frequency and duration
	of trial visits, and site and patient selection and enrichment methods. Many of these design elements are targeted at achieving
	a more acceptable group placebo response and specifically excluding patients with extreme and unreasonable clinical response to
	placebo treatment.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	We plan to initiate
	in 2016 the first of two registration studies in the United States for the use of MDX to treat ADHD in pediatrics. The trial will
	include similar design and monitoring elements to our ongoing Phase 3 trial in adult ADHD to potentially mitigate the placebo
	effect and reduce variability.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	About Fragile X
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
	Description
	of Fragile X
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	Fragile X is a
	genetic disorder that is characterized by a high number (&gt;200) of repeated DNA base sequences (called CGG repeats) in the X
	chromosome. Fragile X is diagnosed by a blood test that measures the amount of CGG repeats. These repeated sequences are associated
	with a change in the amount of Fragile X Mental retardation protein, or FMRP, produced by the cell. A greater reduction in FMRP
	is associated with more severe physical symptoms and intellectual disability. Through the regulation of protein levels in nerve
	cells in the brain, FMRP is thought to be involved with brain pathways that undergo change to facilitate learning and memory.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	Fragile X is the
	most common single gene cause of intellectual disability and autism and an unmet medical need exists with no approved drugs for
	the treatment of Fragile X. Fragile X is named for the broken microscopic appearance of the X chromosome, one of the sex-linked
	chromosomes, that is observed in people with the syndrome. Fragile X affects all ethnic groups worldwide, with the full mutation
	expansions in
<I>
	FMR1
</I>
	(&ge;200 CGG repeats) occurring at an estimated frequency of 1:3600 males and 1:4000 to 6000 females.
	Fragile X is a rare disease, as defined by the Orphan Drug Act.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
<B>
	Fragile X Symptoms
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	Not every individual
	with the Fragile X mutation will show signs or symptoms of Fragile X, and disabilities will range from mild to severe. In males,
	Fragile X is associated with moderate to severe intellectual disability. About 25% of females with Fragile X will have intellectual
	disability, and most females with Fragile X will have a learning disability. Since females with Fragile X have one normal X chromosome
	and one chromosome with Fragile X, and either of the two X chromosomes is active in a given cell, females tend to have milder
	symptoms than males. Both males and females with Fragile X may show delay in acquiring language skills early in their life.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	Individuals with
	Fragile X often have a number of behavioral symptoms, including inattention, hyperactivity, impulsivity, autistic symptoms, shyness,
	aggression, social anxiety, hand flapping, hand biting, and high sensitivity to being touched. Autism spectrum disorder (ASD)
	is seen in approximately 30% of males and 20% of females with Fragile X, and an additional 30% of Fragile X individuals display
	autistic symptoms without having the ASD diagnosis. ADHD is commonly diagnosed in Fragile X, and has been reported to occur in
	approximately 60-75% of males with Fragile X.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Limitations of Treatment Options
	for Fragile X
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 21.3PT">
	The FDA has not
	approved any drugs specifically for the treatment of Fragile X or its symptoms. Individuals with Fragile X are treated based upon
	their symptoms. If the individual has ADHD or ADHD symptoms, the individual might be treated with ADHD medications, such as stimulants,
	atomoxetine and alpha-2 agonists (guanfacine or clonidine). If there are symptoms of aggression or irritability, the individual
	might be treated with antipsychotic medications. Anxiety symptoms might be treated with anti-anxiety drugs such as selective serotonin
	reuptake inhibitors (SSRIs). If there are seizures, the individual might be treated with anti-convulsant drugs.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Data from Pre-clinical Studies of
	metadoxine in Fragile X
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	We have reported
	a series of positive findings from pre-clinical studies with a mouse model of Fragile X (
<I>
	Fmr1
</I>
	knock-out mice). The
<I>
	Fmr1
</I>
	KO mouse model is a validated model of Fragile X, as mice with a missing Fragile X gene demonstrate hyperactivity, susceptibility
	to seizures, enlarged testicles, learning and memory and social interaction impairments and abnormal brain connections, similar
	findings to those of individuals with Fragile X.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	Metadoxine treatment
	rescued behavioral impairments of learning, memory, and social interaction in both adult (six-month-old) and juvenile (two-month-old)
<I>
	Fmr1
</I>
	KO mice, indicating that behavioral effects of metadoxine are independent of age. These behavioral findings are consistent
	with results of clinical trials of MDX in human adults with ADHD that demonstrated statistically significant improvements in several
	neuropsychological measures of selective and sustained attention after MDX treatment. Metadoxine-treated
<I>
	Fmr1
</I>
	KO mice (two-month-old
	and six-month-old) showed significant improvements in behavioral outcomes, including contextual fear conditioning (a test used
	to examine learning and working memory), social recognition and social memory and T-maze learning task (assessing spatial working
	memory skills), compared with vehicle-treated
<I>
	Fmr1
</I>
	KO mice.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
<B>
	Phase 2 Clinical
	Trial
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	We completed an exploratory,
	Phase 2, six-week, randomized, multicenter, placebo-controlled, double-blind, parallel group study of MDX once daily in 61 adolescents
	and adults with Fragile X. The study was conducted at 11 clinical sites in the United States and one clinical site in Israel.
	The primary endpoint was to show a reduction in the symptom score on the ADHD Rating Scale &ndash; Four (RS-IV) Inattentive subscale.
	The difference between the MDX-treated group and placebo was not statistically significant (p=0.21), favoring placebo. Related
	secondary endpoints such as the total ADHD Rating Scale (ADHD RS) score and CGI were similarly non-significant. The detection
	of a signal on this scale may have been obscured in this exploratory trial by the concomitant use of approved ADHD and other psychotropic
	medications by a majority of patients during the study and the imbalanced randomization of these patients, the limitations of
	the ADHD RS assessment in a population with highly variable and mostly abnormal intellectual capacity and developmental age, and
	the potential challenge in discerning changes in inattentive symptoms in this complex neurobehavioral disorder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Four measures,
	including the Vineland-II Adaptive Behavior Scale (Daily Living Skills and Socialization domains), the Aberrant Behavior Checklist
	(ABC), the Test of Attentional Performance for Children (KiTAP), and the Repeatable Battery for the Assessment of Neuropsychological
	Status List Learning test (RBANS-LL) were pre-specified as secondary outcomes in this trial. MDX showed a statistically significant
	benefit over placebo, in the intent to treat population, on the Vineland-II Daily Living Skills Domain (p=0.044) and on the computerized
	KiTAP Go/No Go (number of false responses) (p=0.043). These statistically significant findings also showed meaningful clinical
	effect sizes of 0.56 and 0.49, respectively (Cohen's d; standardized difference between two means). The Vineland-II Daily Living
	Skills assessment is a validated measure of adaptive behavior often used in FXS studies; it includes three subdomains which are
	assessed through a clinical interview with a caregiver: the personal subdomain; assessing basic functional skills such as eating,
	drinking, dressing or undressing, and maintaining personal hygiene, the domestic subdomain; assessing primarily household chores
	the individual can perform such as cooking, cleaning, putting things in place, and keeping themselves safe
</FONT>
<FONT STYLE="FONT-SIZE: 12PT">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	at&nbsp;home, and the community subdomain; assessing the subjects understanding and proper
	management of time, money, phone use, TV or computer use, travel, work skills and outdoor functions. The computerized KiTAP Go/No
	Go subtest directly examines the patient&rsquo;s ability to inhibit a reaction to a non-target stimulus. The remaining secondary
	measures did not yield statistically significant findings in the intent to treat population, although directional benefits were
	noted on the RBANS-LL, a short-term verbal memory task, and the KiTAP Distractibility (response time) test, a computerized continuous
	performance test of attention assessing the ability to maintain attention in the presence of distractors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	During the trial, MDX
	was generally well tolerated and no safety concerns were identified. The profile of adverse events in the MDX-treated group was
	similar to the placebo comparator group. The most common side effects were upper respiratory tract infection (6.7% in MDX, 15.6%
	in placebo), irritability (10.0% in MDX, 9.4% in placebo), and headache (10.0% in MDX, 3.1% in placebo). A single Serious Adverse
	Event of Bell's Palsy was recorded in the trial, and occurred in a placebo-treated patient.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
<B>
<I>
	Planned Clinical Studies in Fragile X
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	In October 2015, we met
	with the FDA to discuss the results of our Phase 2 study in Fragile X and the requirements for NDA submission of MDX in this therapeutic
	indication. The FDA concurred that results from a single short-term, adequate and well-controlled efficacy study in adolescents
	and adult patients with Fragile X may be sufficient to support a claim of efficacy for approval of MDX in this indication (in
	line with the FDA's Guidance for Industry &mdash; Providing Evidence of Effectiveness for Human Drug and Biological Products,
	May 1998). We plan to submit a separate application for pediatric patients (ages 4-11) following FDA approval via a supplemental
	NDA. The FDA confirmed that the Vineland II Daily Living Skills Assessment could serve as the primary endpoint in the adolescents
	and adults Fragile X pivotal study. Following the meeting with the FDA, we are completing analyses and plans for a Phase 3 clinical
	study in adolescents and adult patients with Fragile X.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	MDX Overview and Mechanism of Action
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	MDX is a proprietary,
	combined rapid onset/extended release formulation of the chemical Pyridoxine Pyroglutamate, which is more commonly known as metadoxine.
	MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release
	metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the
	human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	Metadoxine has
	been available since the 1980s in immediate release forms for the acute treatment of alcohol intoxication and the chronic treatment
	of alcoholic liver disease. Metadoxine was approved for these indications in Italy, Portugal, Hungary, Russia, India, China, Mexico
	and Thailand. A literature survey covering over 20 years of post-marketing surveillance identifies only a few cases of minor adverse
	events. To our knowledge, no drug-related serious adverse events have ever been reported. We have multiple claims in our issued
	patents and pending patent applications that may prevent the use of metadoxine by others to treat ADHD, Fragile X and other cognitive
	disorders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	Normally, the levels
	of neurotransmitters in the brain, such as dopamine, norepinephrine and serotonin, are fully regulated in order to ensure proper
	neurological function and neuron-to-neuron communication. Communication between neurons is achieved by the controlled release
	of neurotransmitters from one neuron, their transport by a dedicated transporter across the synapse (the gap between two neurons)
	to another neuron, and their binding and internalization into the target neuron using a unique, designated receptor. One of the
	purported causes of the symptoms of ADHD is low levels in the brain of these neurotransmitters causing the lack of regulation
	of neuronal networks.&nbsp; In the design of pharmacological treatments for ADHD, low neurotransmitter levels can be modulated
	and reversed through enhancing the release, delivery and/or blocking the reuptake of neurotransmitters by their respective plasma
	transporters/receptors. All stimulants increase dopamine and norepinephrine levels. Atomoxetine (Strattera), the only non-stimulant
	approved for ADHD in adults, works through modulating norepinephrine. Our preclinical studies indicate that metadoxine exerts
	its effects through a monoamine-independent mechanism of action. A single oral administration of metadoxine was found to have
	no effect on dopamine, norepinephrine, or serotonin levels, as measured by dual-probe microdialysis in the frontal cortex and
	striatum of rats and also by in vivo proton magnetic resonance spectroscopy (1H-MRS) in the striatum of rats. In addition, and
	in contrast to approved ADHD pharmacotherapies, in vitro binding assays further detailed below revealed that metadoxine does not
	bind to any dopamine, norepinephrine, or serotonin transporters, or dopamine and norepinephrine receptors, while it binds significantly
	to the GABA transporter. Metadoxine was also found to have no effect on in vivo metabolites in the 1H-MRS imaging study mentioned
	above. Furthermore, metadoxine displays a dose-dependent, reversible reduction in the overall excitability and enhancement of
	GABAergic inhibitory transmission via presynaptic modulation in striatal medium spiny neurons, as measured by electrophysiologic
	recordings from mice corticostriatal slices. These findings were confirmed by pharmacologic magnetic resonance imaging (phMRI)
	of conscious rats demonstrating that single administration of metadoxine produced a significant decrease in blood-oxygen-level
	dependent (BOLD) signal (indicating reduced brain activity) in highly selective regions of the brain (including the prefrontal
	cortex, striatum, thalamus and cerebellum) related to executive function, learning and memory, motivation, information integration
	and processing, attention, and cognition. These neuronal circuits are known to be dysregulated in ADHD patients. In addition,
	none of the mesolimbic dopamine system brain regions (such as the nucleus accumbens), known to be involved in the reinforcing
	effects of stimulant medications, were significantly affected by metadoxine.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	Metadoxine was
	further tested in multiple animal abuse liability studies in order to assess its abuse potential. The self-administration, dependence/tolerance
	and drug discrimination studies revealed that (i) metadoxine does not serve as a positive reinforce in rats in comparison to methylphenidate,
	(ii) metadoxine does not produce either tolerance during prolonged administration nor a syndrome of behavioral and/or physical
	dependence on abrupt withdrawal in comparison to morphine and (ii) metadoxine does not generalize to d-amphetamine, indicating
	that it does not generate the stimulant discriminative effect evoked by amphetamine and methylphenidate. Altogether, these findings
	confirm and extend the phMRI data and further demonstrate that metadoxine is likely to be devoid of recreational abuse potential
	in humans.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	The neural networks
	operating in the brain are directed by various receptors and associated signals. One way to affect these networks is to identify
	a drug that binds to a specific site and inhibits the action of a specific protein or signal. In further investigating the proposed
	mechanism of action for MDX, over 80 different cellular targets, such as receptors and transporters, were tested in the laboratory
	for binding with metadoxine. Binding of metadoxine was tested on targets that are part of the muscarinic, adrenergic, dopamine,
	serotonin, glutamate and GABA, noradrenaline, opioid and cannabinoid networks. These networks each function to orchestrate different
	activities and signals in different regions of the brain using different protein agents. Metadoxine displayed extensive and highly
	specific receptor binding to only one of the serotonin receptors family members, named 5-HT
<SUB>
	2B.
</SUB>
	Selectivity in binding
	is important because the goal is to bind only with the targeted receptor to achieve the desired therapeutic effect and not bind
	to other targets where it may have undesired side effects. The specific binding to 5-HT
<SUB>
	2B
</SUB>
	was further characterized
	by a functional test in rat stomach fundus aimed at measuring whether metadoxine is an activator (agonist) or a deactivator (antagonist)
	of the 5-HT
<SUB>
	2B
</SUB>
	receptor. This assay concluded that metadoxine shows no agonist activities on this receptor, while its
	entire activity is as an antagonist, thereby reducing binding of the natural molecules that normally attach this receptor. The
	dysregulation of serotonergic pathways has long been genetically implicated in the susceptibility of ADHD and the 5-HT
<SUB>
	2B
</SUB>
	receptor has been associated with ADHD in studies exploring the hereditary basis of ADHD, as well as in studies that attempt
	to understand the molecular basis of this and other cognitive disorders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	Certain serotonin
	receptors, including 5-HT
<SUB>
	2B
</SUB>
	, are purportedly capable of activating the ERK and Akt pathways directly, rather than exclusively
	through indirect activation via the synthesis of peptide growth factors. The reduction of ERK and Akt hyperactivation observed
	in
<I>
	Fmr1
</I>
	KO mice after metadoxine treatment may be due in part to antagonism of 5-HT
<SUB>
	2B
</SUB>
	receptors in the central
	nervous system. Therefore, the pro-cognitive effects of metadoxine may result from the normalization of these pathways thought
	to be involved in synaptic plasticity.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	Our working hypothesis
	is therefore that treatment of metadoxine, a selective antagonist of 5-HT
<SUB>
	2B
</SUB>
	receptors may inhibit Akt and ERK signaling,
	and thus mediate a potential therapeutic benefit in neuronal impairment by facilitating synaptic plasticity underlying learning
	and memory. In support of this hypothesis, we observed a dose-dependent reduction of the overall synaptic excitability, enhanced
	GABAergic inhibitory synaptic transmission and specific phMRI profile of reduced brain activity, indicating that metadoxine may
	rescue neuronal hyperexcitability and neuronal circuit dysfunctions and may be beneficial in several neurodevelopmental disorders,
	such as FXS in whom there is excitatory/inhibitory synaptic transmission imbalance.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	In summary, we
	believe that MDX demonstrates a novel and unique monoamine-independent mechanism of action characterized by selective antagonism
	of 5-HT
<SUB>
	2B
</SUB>
	receptor and facilitation of GABAergic inhibitory transmission. These characteristics indicate that metadoxine
	is a potential novel pro-cognitive agent with a well-established safety profile and putatively low risk of abuse with the potential
	to treat neurocognitive disorders such as ADHD and FXS.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Commercialization
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 24.5PT; TEXT-ALIGN: LEFT">
	Mr. David Baker,
	our Chief Commercial Officer, leads our pre-commercialization activity. However, we currently do not have any internal sales or
	distribution infrastructure. In the event we receive regulatory approval for MDX, we intend, where appropriate, to pursue commercialization
	relationships with pharmaceutical companies and other strategic partners providing for distribution through their sales and marketing
	organizations, or build an internal commercial infrastructure.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Third-Party Reimbursement
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	Sales of pharmaceutical products depend
	in significant part on the availability of coverage and adequate reimbursement by third-party payors, such as state and federal
	governments, including Medicare and Medicaid, managed care providers, and private insurance plans. Decisions regarding the extent
	of coverage and amount of reimbursement to be provided for MDX will be made on a plan by plan basis.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT; TEXT-ALIGN: LEFT">
	Within the Medicare
	program, as a self-administered drug, MDX would be reimbursed under the expanded prescription drug benefit known as Medicare Part
	D. This program is a voluntary Medicare benefit administered by private plans that operate under contracts with the federal government.
	These Part D plans negotiate discounts with drug manufacturers, which may be passed on to each of the plan&rsquo;s enrollees.
	Historically, Part D beneficiaries have been exposed to significant out-of-pocket costs after they surpass an annual coverage
	limit and until they reach a catastrophic coverage threshold. However, changes made by recent legislation will reduce this patient
	coverage gap, known as the donut hole, by reducing patient responsibility in that coverage range.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	An ongoing trend
	has been for third-party payors, including the United States government, to apply downward pressure on the reimbursement of pharmaceutical
	products. Also, the trend towards managed health care in the United States and the concurrent growth of organizations such as
	health maintenance organizations tend to result in lower reimbursement for pharmaceutical products. We expect that these trends
	will continue as these payors implement various proposals or regulatory policies, including various provisions of the recent health
	reform legislation that affect reimbursement of these products. There are currently, and we expect that there will continue to
	be, a number of federal and state proposals to implement controls on reimbursement and pricing, directly and indirectly.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Research and Development
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	We are conducting
	development activities to expand the commercial potential of MDX. We sponsor and conduct clinical research activities with investigators
	and institutions to measure key clinical outcomes that are necessary in order for us to be able to file an NDA with the FDA and
	equivalent filings with other regulatory authorities. For the years ended December 31, 2015, 2014 and 2013, we incurred $13,461,000
	$25,105,000, and $7,066,000, respectively, of research and development expense.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Grants from the Office of the Israeli Chief Scientist
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	Our research and
	development efforts, during the period between May 1, 2009 and April 30, 2010, were financed in part through royalty-bearing grants,
	in an amount of $106,494 that we received from the OCS. With respect to such grants we are committed to pay certain royalties.
	&nbsp;Regardless of any royalty payment, we are further required to comply with the requirements of the Research Law with respect
	to those past grants. When a company develops know-how, technology or products using OCS grants, the terms of these grants and
	the Research Law restrict the transfer of such know-how, and the transfer of manufacturing or manufacturing rights of such products,
	technologies or know-how outside of Israel, without the prior approval of the OCS. We do not believe that these requirements will
	materially restrict us in any way.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Manufacturing
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	We currently have
	no manufacturing facilities and no experience with commercial-scale manufacturing. We currently rely on third-party manufacturers
	to produce bulk drug substance and drug products required for our clinical trials, respectively. We have entered into a customary
	clinical trial material manufacturing agreement. Supply under the agreement is done by purchase orders, there are no minimum purchase
	requirements or unusual financial arrangements and the agreement is terminable at will by either party. We plan to continue to
	rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our drug product
	candidates if and when we receive approval for marketing by the applicable regulatory authorities.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	We have not identified
	secondary raw material supplier (for drug substance) nor manufacturer for drug substance and drug product. We do not have a long-term
	commercial supply arrangement in place with any of our contract manufacturers. If we need to identify additional suppliers and
	manufacturers, we would not be able to do so without significant delay and likely significant additional cost.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	Our third-party
	manufacturers, their facilities and all lots of drug substance and drug products used in our clinical trials are required to be
	in compliance with cGMP. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities,
	equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling
	controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. The manufacturing
	facilities for our products must meet, and continue to meet, cGMP requirements and FDA satisfaction before any product is approved
	and we can manufacture commercial products. Contract manufacturers often encounter difficulties involving production yields, quality
	control and quality assurance, as well as shortages of qualified personnel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	We face competition
	from established pharmaceutical companies that currently market a wide range of drugs to treat ADHD and symptoms of Fragile X.
	All of these competitors have far greater marketing and research capabilities than we do. We also face potential competition from
	academic institutions, government agencies and private and public research institutions, among others, which may in the future
	develop products to treat ADHD and Fragile X. All of these companies and institutions may have products in development that are
	superior to MDX. Our commercial opportunity would be reduced significantly if our competitors develop and commercialize products
	that are safer, more effective, more convenient, have fewer side effects or are less expensive than MDX. Public announcements
	regarding the development of competing drugs could adversely affect the price of our stock and the commercial potential of MDX.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	In addition, the
	following compounds are under development in clinical trials for ADHD: dasotraline (Sunovion) (Phase 3), eltoprazine (Ammarantus)
	(Phase 2), centanafadine (Neurovance) (Phase 2), and AR08 (Arbor) (Phase 2). These compounds are all non-stimulants, however,
	none of them have a similar mechanism of action as MDX. In addition, a number of formulations of amphetamine and methylphenidate
	stimulants are under development, although these are not considered to be direct competitors to MDX.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	The following
	compounds are under development in clinical trials for Fragile X: NNZ-2566 (Neuren) (Phase 2), ganoxalone (Marinus) (Phase 2).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	These lists of competitive compounds
	under development may not be exhaustive.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Intellectual Property
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	We seek patent
	protection in the United States and internationally for MDX and any other products that we may develop. Our policy is to pursue,
	maintain and defend patent rights developed internally and to protect the technology, inventions and improvements that are commercially
	important to the development of our business. Our portfolio of patent applications that cover the release formulations and pharmacokinetic
	profile of metadoxine, including our special sustained release, combined release and burst release formulations and the associated
	methods of treatment.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We currently have
	three issued U.S. patents, covering the composition of the sustained release form of MDX, the use of metadoxine for ADHD, and
	new molecular derivatives of metadoxine. We also have six issued patents in Australia, Japan, India, Mexico, Russia and Europe
	that cover the composition of the sustained release form of MDX. The European patent includes the following territories: Austria,
	Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece,
	Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Latvia, Luxembourg, Monaco, Malta, Netherlands, Norway, Poland, Portugal,
	Romania, Sweden, Slovenia, Slovakia and Turkey. Additionally, we have five issued patents in Australia, China, Japan, Mexico and
	New Zealand that cover the use of metadoxine for ADHD. We cannot be sure that any additional patents will be granted with respect
	to any of our pending patent applications or with respect to any patent applications filed by us in the future. There is also
	a significant risk that any issued patents will have substantially narrower claims than those that are currently sought. Even
	with respect to any patents that may be issued to us, we cannot be sure that any such patents will be commercially useful in protecting
	our technology. Any patents issued with respect to our current patent applications would expire from 2028 to 2030. We also rely
	on trade secrets to protect our product candidates. Our commercial success also depends in part on our non-infringement of the
	patents or proprietary rights of third parties. For a more comprehensive discussion of the risks related to our intellectual property,
	please see Item 3.D. Risk Factors &ldquo;Risks Related to Our Intellectual Property.&rdquo;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The laws of some
	foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies
	have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
	This risk is exacerbated for us because metadoxine is manufactured and used in a number of foreign countries in other applications
	and is widely available. The manufacture of metadoxine and its use in other indications will not infringe our intellectual property
	rights, and will make it more difficult to monitor and enforce any patent rights that may be issued to us.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Our success depends in part on our
	ability to:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	preserve
	trade secrets;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	prevent
	third parties from infringing upon our proprietary rights; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	operate
	our business without infringing the patents and proprietary rights of third parties, both in the United States and internationally.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We also protect
	our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees,
	consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies
	for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the
	extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in
	their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Regulation
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Clinical trials,
	the drug approval process, and the marketing of drugs are intensively regulated in the United States and in all major foreign
	countries.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the United
	States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and related regulations. Drugs are also
	subject to other federal, state and local statutes and regulations. Failure to comply with the applicable United States&nbsp;regulatory
	requirements at any time during the product development process, approval process or after approval may subject an applicant to
	administrative or judicial sanctions. These sanctions could include the imposition by the FDA or IRB of a clinical hold on trials,
	the FDA&rsquo;s refusal to approve pending applications or supplements, withdrawal of an approval, warning letters, product recalls,
	product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution.
	Any agency or judicial enforcement action could have a material adverse effect on us.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The FDA and comparable
	regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical
	development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities
	regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage,
	distribution, record keeping, approval, advertising and promotion of our products.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The FDA&rsquo;s
	policies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of MDX
	or any future product candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature
	or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the
	United States or abroad.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
<B>
<I>
	Marketing Approval
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	The process required by the FDA before new
	drugs may be marketed in the United States generally involves the following:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	nonclinical
	laboratory and animal tests;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	submission
	of an IND application which must become effective before clinical trials may begin;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	adequate
	and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use or
	uses;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	pre-approval
	inspection of manufacturing facilities and clinical trial sites; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FDA approval
	of an NDA which must occur before a drug can be marketed or sold.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The testing and
	approval process requires substantial time and financial resources, and we cannot be certain that any approvals for MDX will be
	granted on a timely basis if at all.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We will need to
	successfully complete extensive additional pre-clinical and clinical trials in order to be in a position to submit a new drug
	application to the FDA. Our planned future trials for MDX may not begin or be completed on schedule, if at all. Trials can be
	delayed for a variety of reasons, including delays in:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	obtaining
	regulatory approval to commence a study;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	reaching
	agreement with third-party clinical trial sites and vendors and their subsequent performance in conducting accurate and reliable
	studies on a timely basis;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	obtaining
	institutional review board approval to conduct a study at a prospective site;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	recruiting
	subjects to participate in a study; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	supply
	of the drug.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We must reach
	agreement with the FDA on the proposed protocols for our future clinical trials in the U.S. A separate submission to the FDA must
	be made for each successive clinical trial to be conducted during product development. Further, an independent IRB for each site
	proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that site.
	Informed consent must also be obtained from each study subject. Regulatory authorities, an IRB, a data safety monitoring board
	or the sponsor, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants
	are being exposed to an unacceptable health risk.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our objective
	is to conduct additional clinical trials for MDX in adults and children and, if those trials are successful, seek marketing approval
	from the FDA and other worldwide regulatory bodies. To achieve this objective, we plan to complete at least one additional Phase
	3 clinical trial of MDX for the treatment of ADHD in adults, and, if successful, proceed with two adequate and well controlled
	clinical trials in the pediatric ADHD population. The first marketing authorization application is expected to be NDA submission
	in the United States. We completed a Phase 2b trial in 2011 and a Phase 3 study in 2014. We plan to follow this process also with
	respect to the other cognitive disorders, such as Fragile X.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	For purposes of NDA approval, human
	clinical trials are typically conducted in phases that may overlap.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Phase
	1.&nbsp;&nbsp;&nbsp;
</I>
	&nbsp;&nbsp;The drug is initially introduced into healthy human subjects and tested for safety, dosage
	tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening
	diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial
	human testing is often conducted in patients.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Phase
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	This phase involves trials in a limited subject population to identify possible adverse
	effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine
	dosage tolerance and optimal dosage. Phase 2 studies may be sub-categorized to Phase 2a studies which are smaller, pilot studies
	to evaluate limited drug exposure and efficacy signals, and Phase 2b studies which are larger studies testing more rigorously
	both safety and efficacy.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Phase
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	This phase involves adequate and well controlled trials undertaken to further evaluate
	dosage, clinical efficacy and safety in an expanded subject population, often at geographically dispersed clinical trial sites.
	These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product
	labeling.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	All of these trials
	must be conducted in accordance with good clinical practice requirements in order for the data to be considered reliable for regulatory
	purposes.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Typically, if
	a drug product is intended to treat a chronic disease, as is the case with MDX when it is intended to treat ADHD and Fragile X,
	safety and efficacy data must be gathered over an extended period of time, which can range from 12 months to three years or more.
	Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period of time and
	impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will grant approvals
	for MDX or any future product candidates on a timely basis, if at all. Success in early stage clinical trials does not ensure
	success in later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible
	to varying interpretations, which could delay, limit or prevent regulatory approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
<B>
<I>
	The NDA Approval Process
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In order to obtain
	approval to market a drug in the United States, a marketing application must be submitted to the FDA that provides data establishing
	to the FDA&rsquo;s satisfaction the safety and effectiveness of the investigational drug for the proposed indication. Each NDA
	submission requires a substantial user fee payment unless a waiver or exemption applies (such as with Orphan Drug Designation).
	The application includes all relevant data available from pertinent non-clinical studies and clinical trials, including negative
	or ambiguous results as well as positive findings, together with detailed information relating to the product&rsquo;s chemistry,
	manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended
	to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated
	by investigators.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The FDA will initially
	review the NDA for completeness before it accepts it for filing. The FDA has 60&nbsp;days from its receipt of an NDA to determine
	whether the application will be accepted for filing based on the agency&rsquo;s threshold determination that the application is
	sufficiently complete to permit substantive review. After the NDA submission is accepted for filing, the FDA reviews the NDA to
	determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product
	is being manufactured in accordance with cGMP to assure and preserve the product&rsquo;s identity, strength, quality and purity.
	The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy
	to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation
	as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations
	of an advisory committee, but it considers such recommendations carefully when making decisions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Based on pivotal Phase
	3 trial results submitted in an NDA, upon the request of an applicant, the FDA may, subject to certain requirements, grant a priority
	review designation to a product, which sets the target date for FDA action on the application at six&nbsp;months, rather than
	the standard ten months. Priority review is given where preliminary estimates indicate that a product, if approved, has the potential
	to provide a significant improvement compared to marketed products or offers a therapy where no satisfactory alternative therapy
	exists. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary
	to support approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	After the FDA
	completes its initial review of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue
	a complete response letter to communicate that the NDA will not be approved in its current form and inform the sponsor of changes
	that must be made or additional clinical, nonclinical or manufacturing data that must be received before the application can be
	approved, with no implication regarding the ultimate approvability of the application.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;Before approving
	an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless
	it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
	consistent production of the product within required specifications.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Additionally,
	before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with good clinical practices, or
	GCPs. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it typically
	will outline the deficiencies and often will request additional testing or information. This may significantly delay further review
	of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may
	determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the NDA. Additionally,
	notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does
	not satisfy the regulatory criteria for approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The testing and
	approval process for a drug requires substantial time, effort and financial resources, and this process may take several years
	to complete. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations,
	which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter
	difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us
	from marketing our products.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The FDA may require,
	or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a
	condition to be satisfied for continuing drug approval. The results of Phase 4 studies can confirm the effectiveness of a product
	candidate and can provide important safety information. In addition, the FDA now has express statutory authority to require sponsors
	to conduct post-market studies to specifically address safety issues identified by the agency.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Any approvals
	that we may ultimately receive could be withdrawn if required post-marketing trials or analyses do not meet the FDA requirements,
	which could materially harm the commercial prospects for MDX.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The FDA also has
	authority to require a Risk Evaluation and Mitigation Strategy, or REMS, from manufacturers to ensure that the benefits of a drug
	or biological product outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need
	for a REMS is determined as part of the review of the NDA. Based on statutory standards, elements of a REMS may include &ldquo;dear
	doctor letters,&rdquo; a medication guide, more elaborate targeted educational programs, and in some cases restrictions on distribution.
	These elements are negotiated as part of the NDA approval, and in some cases if consensus is not obtained until after the Prescription
	Drug User Fee Act review cycle, the approval date may be delayed. Once adopted, REMS are subject to periodic assessment and modification.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Even if a product
	candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages,
	or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous
	risk management plans, restrictions on distribution, or post-marketing study requirements. Further, even after regulatory approval
	is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete
	withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for MDX, or obtaining
	approval but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental
	regulations may arise from future U.S. or foreign governmental action.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	Orphan Drug Designation
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We received Orphan
	Drug Designation for metadoxine, the active ingredient in MDX for the treatment of Fragile X in the United States.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Orphan
	Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
	which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000
	individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug
	or biological product available in the United States for this type of disease or condition will be recovered from sales of the
	product. Orphan Drug Designation is intended to assist and encourage companies to develop safe and effective therapies for the
	treatment of rare diseases and disorders. In addition to providing a seven year term of market exclusivity upon final FDA approval,
	orphan drug designation also positions a company to be able to leverage a wide range of financial and regulatory benefits, including
	government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug
	Application, and certain tax credits. Orphan product designation must be requested before submitting an NDA. After the FDA grants
	orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.
	Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If a product that has
	orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation,
	the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market
	the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing
	of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products
	for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication
	for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products
	for seven years if a competitor obtains approval of the same drug or biological product as defined by the FDA or if our drug or
	biological candidate is determined to be contained within the competitor's product for the same indication or disease. If a drug
	or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated,
	it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar but not identical benefits
	in the European Union.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
<B>
<I>
	Fast Track Designation
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We obtained a
	fast track designation for MDX for Fragile X. Fast track designation is intended to facilitate development and expedite review
	of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. This
	designation may involve frequent interactions with the FDA. If the product meets the regulatory requirements it may also be eligible
	for priority review or rolling review of the NDA.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Some products
	granted fast track designation will not continue to meet the criteria for fast track designation. A drug product in a fast track
	development program may not continue to meet the criteria if the drug: (i) no longer demonstrates a potential to address unmet
	medical need, or (ii) is not being studied in a manner that shows the drug product can treat a serious condition and meets an
	unmet medical need. The drug product may no longer demonstrate a potential to address unmet medical need, for example, if a new
	product was approved under a traditional approval that addressed the same need or if emerging clinical data failed to show that
	the product in a fast track development program had the anticipated advantage over available therapy. When fast track designation
	is no longer supported by emerging data or the designated drug development program is no longer being pursued, the FDA may choose
	to send a letter notifying the sponsor that the program is no longer designated as a fast track drug development program.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	FDA Post-Approval Requirements
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Any products manufactured
	or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including requirements for record-keeping
	and reporting of adverse experiences with the drug. Drug manufacturers are required to register their facilities with the FDA
	and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance
	with cGMPs, which impose certain quality processes, manufacturing controls and documentation requirements upon us and our third-party
	manufacturers in order to ensure that the product is safe, has the identity and strength, and meets the quality and purity characteristics
	that it purports to have. Certain states also impose requirements on manufacturers and distributors to establish the pedigree
	of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable
	of tracking and tracing product as it moves through the distribution chain. We cannot be certain that we or our present or future
	suppliers will be able to comply with the cGMP and other FDA regulatory requirements. If our present or future suppliers are not
	able to comply with these requirements, the FDA may halt our clinical trials, fail to approve any NDA or other application, require
	us to recall a drug from distribution, shut down manufacturing operations or withdraw approval of the NDA for that drug. Noncompliance
	with cGMP or other requirements can result in issuance of warning letters, civil and criminal penalties, seizures and injunctive
	action.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Labeling, Marketing and Promotion
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The FDA closely
	regulates the labeling, marketing and promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for
	any use, a company can only make claims relating to the safety and efficacy of a drug that are consistent with FDA approval, and
	is allowed to actively market a drug only for the particular use and treatment approved by the FDA. In addition, any claims we
	make for our products in advertising or promotion must be appropriately balanced with important safety information and otherwise
	be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective
	advertising, injunctions and potential civil and criminal penalties. Government regulators recently have increased their scrutiny
	of the promotion and marketing of drugs.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Pediatric Research Equity Act
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Pediatric
	Research Equity Act, or PREA, amended the FDCA to authorize the FDA to require certain research into drugs used in pediatric patients.
	The intent of the PREA is to compel sponsors whose drugs have pediatric applicability to study those drugs in pediatric populations,
	rather than ignoring pediatric indications for adult indications that could be more economically desirable. The Secretary of Health
	and Human Services may defer or waive these requirements under specified circumstances. The FDA may decide that an NDA will be
	approved only following completion of additional pediatric studies.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Anti-Kickback and False Claims
	Laws
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the United
	States, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject
	to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&nbsp;&amp;
	Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General),
	the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. For example, sales, marketing
	and scientific/educational grant programs must comply with the Anti-Kickback Statute, the False Claims Act, as amended, the privacy
	regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. Pricing
	and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of
	1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of
	the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities
	are also potentially subject to federal and state consumer protection and unfair competition laws.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the United
	States, we are subject to complex laws and regulations pertaining to healthcare &ldquo;fraud and abuse,&rdquo; including, but
	not limited to, the Anti-Kickback Statute, the federal False Claims Act, and other state and federal laws and regulations. The
	Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf)
	to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business,
	including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare
	program, such as Medicare or Medicaid.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The federal False
	Claims Act prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal programs (including
	Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services
	not provided as claimed, or claims for medically unnecessary items or services.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	There are also
	an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information.
	Many of these laws contain ambiguities as to what is required to comply with the laws. In addition, a similar federal requirement
	Section 6002 of the PPACA, commonly referred to as the &ldquo;Physical Payments Sunshine Act&rdquo; requires manufacturers to
	track and report to the federal government certain payments made to physicians and teaching hospitals made in the previous calendar
	year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens
	on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could
	be subject to the penalty provisions of the pertinent state, and soon federal, authorities.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Patient Protection and Affordable
	Health Care Act
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	As mentioned,
	in March 2010, the PPACA was enacted, which includes measures that have or will significantly change the way health care is financed
	by both governmental and private insurers. The fees, discounts and other provisions of this law are expected to have a significant
	negative effect on the profitability of pharmaceuticals.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	This legislation
	is expected to impact the scope of healthcare insurance, the insurance refunds from the insurance companies and possibly also
	on the costs of medical products.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Other Regulations
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20.3PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We are also subject
	to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental
	protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs
	to comply with such laws and regulations now or in the future.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	4.C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Organizational
	structure
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our sole wholly-owned
	subsidiary is Alcobra, Inc., incorporated in the United States.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	4.D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Property,
	plants and equipment&nbsp;&nbsp;
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our headquarters
	is currently located in Tel Aviv, Israel and consists of approximately 7,170 square feet of leased office space under a lease
	for five years, starting May 25, 2015. We have also leased an additional office in Petah Tikva, Israel of approximately 1,400
	square feet. Our wholly owned subsidiary, Alcobra Inc. leases an office for our U.S. employees in the greater Philadelphia area,
	with approximately 500 square feet. We believe that our existing and planned facilities are adequate to meet our current needs
	and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We consider that
	our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct
	of our business.
</P>
</EFX_COMPANY_INFORMATION>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_005">
</A>
	ITEM
	4A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	UNRESOLVED
	STAFF COMMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	None.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_OPERATING_AND_FINANCIAL_REVIEW>
<A NAME="FIS_OPERATING_AND_FINANCIAL_REVIEW"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_006">
</A>
	ITEM
	5.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	OPERATING
	AND FINANCIAL REVIEW AND PROSPECTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	We are an emerging biopharmaceutical
	company primarily focused on the development and commercialization of our proprietary oral drug candidate, MDX, to treat ADHD
	and other cognitive dysfunctions including Fragile X. To that end, we completed several pre-clinical and clinical studies in both
	ADHD and Fragile X. We have multiple claims in our issued and pending patents and patent applications that, if issued, would prevent
	the use by others of metadoxine and MDX to treat ADHD, Fragile X and other cognitive disorders. In addition, the FDA has granted
	Orphan Drug status to metadoxine for treatment of Fragile X.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	To date, we have
	not generated revenue from the sale of any product, and we do not expect to generate significant revenue unless and until we obtain
	marketing approval of, and commercialize, MDX. As of December 31, 2015, we had an accumulated deficit of $71 million.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Operating Expenses
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our current operating
	expenses consist of three components &ndash; research and development expenses, pre-commercialization expenses and general and
	administrative expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 38.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our research and
	development expenses consist primarily of expenses related to third party clinical consultants and expenses related to conducting
	clinical and preclinical trials, salaries and related personnel expenses, share-based compensation expenses, travel expenses and
	other research and development expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	The following table discloses the breakdown
	of research and development expenses:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands of U.S. dollars)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT; TEXT-INDENT: -17.1PT; PADDING-LEFT: 17.1PT">
	Cost to third party clinical consultants
	and expenses related to conducting clinical trials
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	9,733
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	21,239
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	5,841
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Salaries and related personnel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,179
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,521
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	590
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	768
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,773
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	430
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Travel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	240
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	541
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	382
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	108
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	13,461
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	25,105
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7,066
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Pre-commercialization Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;Pre-commercialization expenses
	consist primarily salary and related expenses, share-based compensation expense and professional services fees in connection with
	business development and market research for our product.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	The following table discloses the breakdown
	of pre commercialization expenses:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands of U.S. dollars)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	308
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	616
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Professional services
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	310
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Salaries and related personnel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	538
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	355
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Travel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	27
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,245
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	2,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.5PT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	General and Administrative Expenses
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	General and administrative
	expenses consist primarily of salaries and related personnel expenses, share-based compensation expense, professional service
	fees for accounting, legal and bookkeeping and other general and administrative expenses.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	The following table discloses the breakdown
	of general and administrative expenses:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands of U.S. dollars)
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,289
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,700
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,110
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Professional services
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,813
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Salaries and related personnel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,418
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,498
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	789
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Travel expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	131
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	312
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	245
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	129
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	4,992
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	5,839
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	3,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands of U.S.
	dollars)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Research and development expenses
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	13,461
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	25,105
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	7,066
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Pre-commercialization expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,245
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	General and administrative expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,992
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,839
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,224
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,698
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,290
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial Expense (Income), net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	197
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Tax Expenses (Benefits)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	61
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss attributable to holders of ordinary shares
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	19,449
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	32,834
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,548
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Comparison of the Year ended December 31, 2015 to the
	Year Ended December&nbsp;31, 2014 to the Year Ended December&nbsp;31, 2013
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Research and development
	expenses&#9;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our research and
	development expenses for the year ended December 31, 2015, amounted to $13,461,000, representing a decrease of $11,644,000, or
	46%, compared to $25,105,000 for the year ended December 31, 2014. The difference is primarily due to a decrease in third party
	clinical expenses related to the completion of our first Phase 3 study in adult ADHD in October 2014.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	research and development expenses for the year ended December 31, 2014, amounted to $25,105,000, representing an increase of $18,039,000,
	or 255% compared to $7,066,000 for the year ended December 31, 2013.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	difference is primarily due to an increase in third party clinical expenses related to conducting our first Phase 3 study in adult
	ADHD in 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Pre-commercialization expenses
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our pre-commercialization
	expenses for the year ended December 31, 2015, amounted to $1,245,000, representing a decrease of $889,000, or 42%, compared to
	$2,134,000 for the year ended December 31, 2014. The difference is primarily due to a decrease in share-based compensation and
	professional services expenses in the amount of $757,000.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	pre-commercialization expenses for the year ended December 31, 2014, amounted to $2,134,000 and consisted primarily of expense
	related to professional services in the amount of $1,067,000, expense related to share-based compensation in the amount of $616,000
	and salaries and related personnel expenses in the amount of $355,000.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	No
	pre-commercialization expenses were incurred in 2013
</FONT>
	.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	General and administrative expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our general and
	administrative expenses totaled $4,992,000 for the year ended December 31, 2015, a decrease of $847,000 or 14.5%, compared to
	$5,839,000 for the year ended December 31, 2014. The difference resulted primarily from a decrease of $411,000 in share-based
	compensation expenses and a decrease of $359,000 in professional services expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our general and
	administrative expenses totaled $5,839,000 for the year ended December 31, 2014, an increase of $2,615,000, or 81%, compared to
	$3,224,000 for the year ended December 31, 2013. The increase resulted primarily from an increase of $1,107,000 in professional
	services, an increase of $590,000 in share-based compensation expenses and an increase of $709,000 in salaries and related personnel
	expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Operating loss
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	As a result of
	the foregoing, our operating loss for the year ended December 31, 2015, was $19,698,000, as compared to an operating loss of $33,078,000
	for the year ended December 31, 2014, a decrease of $13,380,000, or 40%.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Operating loss
	for the year ended December 31, 2014, was $33,078,000, as compared to an operating loss of $10,290,000 for the year ended December
	31, 2013, an increase of $22,788,000, or 221%.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Financial income
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	recognized financial income of $300,000 for the year ended December 31, 2015, representing an increase of $73,000, compared to
	financial income of $227,000 for the year ended December 31, 2014. The increase is primarily due to interest income on bank deposits
	during 2015.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We recognized financial income of
	$227,000 for the year ended December 31, 2014, representing an increase of $424,000, compared to financial expenses of $197,000
	for the year ended December 31, 2013. The increase is primarily due to interest income on bank deposits during 2014 and conversion
	of our convertible notes in 2013.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Tax Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We recognized
	$51,000 of tax expenses for the year ended December 31, 2015, as compared to tax benefits of $17,000 for the year ended December
	31, 2014, an increase of $68,000.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We recognized
	$17,000 of tax benefits for the year ended December 31, 2014, as compared to tax expenses of $61,000 for the year ended December
	31, 2013, a decrease of $78,000. Our tax expenses consist of tax liabilities of our wholly owned subsidiary, Alcobra Inc., resulting
	from services Alcobra Inc. provides to us in accordance with an arms&rsquo; length services agreement.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Loss
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	As a result of
	the foregoing, our loss for the year ended December 31, 2015 was $19,449,000 as compared to $32,834,000 for the year ended December
	31, 2014, a decrease of $13,385,000 or 41%.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our loss for the
	year ended December 31, 2014 was $32,834,000, as compared to $10,548,000 for the year ended December 31, 2013, an increase of
	$22,286,000, or 211%.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Critical Accounting Policy and Estimates
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	We describe our
	significant accounting policies more fully in Note&nbsp;2 to our consolidated financial statements for the year ended December
	31, 2015. We believe that the accounting policy below is critical in order to fully understand and evaluate our financial condition
	and results of operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	We prepare our
	consolidated financial statements in accordance with accounting principles generally accepted in the United States, or U.S. GAAP.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	The preparation
	of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. Our
	management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the
	time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
	of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the
	reporting period. Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Share-Based Compensation and
	Fair Value of Ordinary Shares
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	We account for
	share-based compensation in accordance with ASC 718, &ldquo;Compensation - Stock Compensation,&rdquo; or ASC 718, which requires
	companies to estimate the fair values of equity-based payments awards on the date of grant using an option-pricing model. The
	value of the stock options is recognized as an expense over the requisite service periods in our statement of operations. We recognize
	compensation expenses for the value of our awards granted based on the accelerated method over the requisite service period of
	each of the awards.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	We selected the
	Black-Scholes-Merton option-pricing model, or Black-Scholes, as a fair value method for our options awards. The option-pricing
	model requires a number of assumptions:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: LEFT">
<I>
	Expected dividend yield
</I>
	- The expected dividend yield assumption is based on our historical experience and expectation of no future dividend payouts.
	We have historically not paid cash dividends and have no foreseeable plans to pay cash dividends in the future.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: LEFT">
<I>
	Volatility -
</I>
	Since
	our shares started trading on a stock exchange market only in May 2013, quoted prices data of our shares is limited. According
	to ASC 718-10-30-20, in case of insufficient historical data for a company, the expected volatility was based on a weighted average
	of our and similar companies' stock volatility.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-INDENT: 0.55PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-INDENT: 0.55PT; TEXT-ALIGN: LEFT">
<I>
	Risk
	free interest rate
</I>
	- The risk free interest rate is based on the yield of U.S. Treasury bonds with equivalent terms.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: LEFT">
<I>
	Expected term
</I>
	-
	ASC 718 provides the factors to consider when estimating the expected term of an option: An option&rsquo;s expected term must
	at least include the vesting period and the Employees&rsquo; historical exercise and post-vesting employment termination behavior
	for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently
	large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to
	consider external data or the SEC staff&rsquo;s &ldquo;simplified&rdquo; method for the expected term. Accordingly, we used the
	&ldquo;simplified&rdquo; method, meaning the expected life is set as the average of the vesting period for each vested tranche
	of options and the contractual term for those options.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: LEFT">
<I>
	Share price
</I>
	&ndash;
	Up until our initial public offering, because there had been no public market for our ordinary shares, the fair value of the ordinary
	shares underlying the options had been determined by our management, using the assistance of an independent valuation firm. Following
	our initial public offering, fair market value has been determined by NASDAQ Capital Market and NASDAQ Global Market quotes.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	Emerging Growth Company
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Subject to certain
	conditions set forth in the JOBS Act, as an &ldquo;emerging growth company&rdquo;, we elected to rely on other exemptions, including
	without limitation, (i) providing an auditor&rsquo;s attestation report on our internal control over financial reporting pursuant
	to Section 404 of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the PCAOB regarding mandatory
	audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial
	statements (auditor discussion and analysis). These exemptions will apply for a period of five years following the completion
	of our initial public offering or until we are no longer an &ldquo;emerging growth company,&rdquo; whichever is earlier.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 35.45PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Liquidity and Capital Resources
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Overview
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Since our inception
	through December 31, 2015, we have funded our operations principally with $129.6 million from the sale of ordinary shares, preferred
	shares and convertible notes. As of December 31, 2015, we had $16.7 million in cash and cash equivalents and an additional amount
	of $53.0 million in short-term and long-term bank deposits.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Years Ended December
	31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	(in thousands of U.S.
	dollars)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; TEXT-ALIGN: LEFT">
	Operating activities
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(18,148
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(28,326
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(7,353
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(33,842
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,407
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(28,047
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,472
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57,398
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net increase (decrease) in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,482
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,919
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,998
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Operating Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash used
	in operating activities of $18.1 million during the year ended December 31, 2015 was primarily used for payment of $13.5 million
	for clinical trials and other third party related expenses and for professional services, $0.4 million for travel expenses, $0.5
	million for rent expenses and of $3.1 million in salary payments. The remaining amount of $0.6 million was for miscellaneous expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash used
	in operating activities of $28.3 million during the year ended December 31, 2014 was primarily used for payment of $24.2 million
	for clinical trials and other third party related expenses and for professional services, $0.5 million for travel expenses and
	an aggregate of $3.3 million in salary payments. The remaining amount of $0.3 million was for other miscellaneous expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash used
	in operating activities of $7.4 million during the year ended December 31, 2013 was primarily used for payment of $5.7 million
	for clinical trials and other third party related expenses and for professional services, $0.2 million for travel expenses and
	an aggregate of $1.3 million in salary payments. The remaining amount of $0.2 million was for other miscellaneous expenses.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Investing Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash used
	in investing activities of $33.8 million during 2015 reflected the investment of cash into short-term deposits and long term deposits
	in the amount of $14.5 million and $19 million, respectively, the purchase of property and equipment of $0.2 million and the investment
	in a restricted bank deposit of $0.1 million.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash provided by
	investing activities of $8.4 million during 2014 reflected the withdrawal of short-term deposits into cash in the amount of $8.5
	million and the purchase of property and equipment of $0.1 million.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash used in investing
	activities of $28.0 million during 2013 reflected our use of cash to invest in short-term deposits.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Financing Activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash provided
	by financing activities of $66.5 million in the year ended December 31, 2015, consisted of net proceeds from two follow on public
	offerings. On January 14, 2015, we completed a public offering of 7,475,000 ordinary shares. The offering price was $4.00 per
	share, and the net proceeds to us from the sale of the shares were approximately $27.9 million. On November 18, 2015, we completed
	a public offering of 6,379,198 ordinary shares. The offering price was $6.50 per share, and the net proceeds to us from the sale
	of the shares were approximately $38.6 million.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	There were no
	financing activities in the year ended December 31, 2014. &nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Net cash provided
	by financing activities of $57.4 million in the year ended December 31, 2013, consisted of a $21.9 million of proceeds from our
	initial public offering, $0.1 million of proceeds from issuance of convertible notes (that were converted into our ordinary shares
	at the time of our initial public offering), and $35.4 million of proceeds from a follow on public offering of our ordinary shares.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Current Outlook
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We have financed
	our operations to date primarily through proceeds from sales of our ordinary shares, loans and issuances of convertible notes.
	We have incurred losses and generated negative cash flows from operations since inception. To date, we have not generated any
	revenue from the sale of products and we do not expect to generate revenues from sale of our products in the next two years. We
	believe that we will need to raise additional funds before we have positive cash flow from operations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	As of December
	31, 2015, our cash, cash equivalents, short-term and long-term deposits totaled $69.7 million. Our current investment policy has
	the following objectives: (i) preserve principal (capital); (ii) maintain liquidity in accordance with cash flow requirements;
	and (iii) maximize the rate of return within the stated guidelines in the policy. To achieve these goals, we invest available
	cash in bank deposits with banks that have a credit rating of at least Baa1/BBB+ and in tradable securities with high credit quality
	and trading liquidity, including U.S. Treasury bonds, money market funds, and corporate debt instruments that carry a rating of
	A2/A or better. As of December 31, 2015, we did not hold any tradable securities in our investment portfolio. Our cash management
	is monitored by the Audit Committee.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We believe that
	our existing cash resources will be sufficient to fund our projected cash requirements approximately through 2017, including the
	cost of our ongoing Phase 3 trial in adult ADHD and our planned registration study in pediatric ADHD, as well as a registration
	study in Fragile X. Nevertheless, we will require significant additional financing in the future to fund our operations, clinical
	development plan, and to commercialize MDX after we obtain regulatory approval. Our future capital requirements will depend on
	many factors, including:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	progress and costs of our pre-clinical studies, clinical trials and other research and development activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	scope, prioritization and number of our clinical trials and other research and development programs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any
	cost that we may incur under in- and out-licensing arrangements relating to our drug candidate that we may enter into in the future;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT FONT-SIZE...">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the costs and timing of obtaining regulatory approval for our drug candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical and commercial
	quantities of our drug candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	potential costs of contracting with third parties to provide marketing and distribution services for us or for building such
	capacities internally;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the costs
	of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications
	of our drug candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; PADDING-LEFT: 0; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	magnitude of our general and administrative expenses; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	payments
	to the OCS.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Until we can generate
	significant recurring revenues, we expect to satisfy our future cash needs through our existing cash, cash equivalents and short-term
	deposits, the net proceeds from the current offering, debt or equity financings, or by out-licensing applications of our drug
	candidate. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not
	available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
	efforts with respect to, one or more applications of our drug candidate.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	5.E
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Off-Balance
	Sheet Arrangements
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	We currently do not have any off-balance
	sheet arrangements.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	5.F
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Contractual
	Obligations
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	The following
	table summarizes our contractual obligations at December 31, 2015:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Less than 1
<BR>
	year
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	1-3 years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	4-5 years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	More than 5
<BR>
	years
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="18" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	(in thousands)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating leases:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
	Facility
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,100
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	511
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	589
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Motor Vehicles
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_LIQUIDITY_CAPITAL>
</EFX_OPERATING_AND_FINANCIAL_REVIEW>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_007">
</A>
	ITEM
	6.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	DIRECTORS,
	SENIOR MANAGEMENT AND EMPLOYEES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Directors
	and senior management
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN">
	&nbsp;&nbsp;
<B>
	Executive Officers and Directors
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The
	following table sets forth information regarding our executive officers, key employees and directors as of March 1, 2016:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29%; BORDER-BOTTOM: BLACK 1PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; BORDER-BOTTOM: BLACK 1PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Age
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 61%; BORDER-BOTTOM: BLACK 1PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Position
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Howard B. Rosen&nbsp;(1)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	58
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chairman of the Board
	of Directors
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Daniel E. Geffken
	(1)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	59
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Joao Siffert (1)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	51
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Aharon Schwartz
	(1)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	73
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Hadas Gelander
	(1) (2) (3)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	50
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Arieh Ben Yosef (1)
	(2) (3)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	63
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ori Mor (1) (2) (3)
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	45
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Yaron Daniely
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	40
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Executive Officer,
	President and Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Tomer Berkovitz
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	36
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Financial Officer,
	Chief Operating Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	David Baker
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	52
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Commercial Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Jonathan Rubin
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	54
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Medical Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Hanna Ron
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	65
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SVP Chemistry, Manufacturing
	and Control
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Johanna
	Schumann
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	35
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 61%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SVP Preclinical
	Development
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Hagit Marchaim
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SVP Regulatory Affairs
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Irena Katsman
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	35
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	VP Finance
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Shlomi Ianovitz
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	34
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director Quality Assurance
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Indicates
	independent director under NASDAQ rules.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Member
	of our Audit Committee.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3)
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Member
	of our Compensation Committee.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Howard
	B. Rosen
</I>
	has served on our Board since the closing of our initial public offering in May 2013 and as our Chairman since February
	2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology industry. He has also served
	as a lecturer at Stanford University in Chemical Engineering since 2008 and in Management since 2011. Mr. Rosen has served as
	interim CEO of AcelRx Pharmaceuticals (Nasdaq: ACRX), Inc., a company developing products for pain relief, since April 2015 and
	served as interim President and Chief Executive Officer of Pearl Therapeutics, Inc., a company focused on developing combination
	therapies for the treatment of highly prevalent chronic respiratory diseases, from June 2010 to March 2011. From 2004 to 2008,
	Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. From 2003 until 2004,
	Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged with Johnson &amp; Johnson,
	a global healthcare company, in 2001. Prior to that, from 1994 until 2003, Mr. Rosen held various positions at ALZA Corporation.
	Mr. Rosen is also a member of the board of directors of AcelRx Pharmaceuticals, Inc and a number of private biotechnology companies
	as follows: Entrega, Inc. and Kala Pharmaceuticals, Inc. Previously, Mr. Rosen served on the board of directors of a number of
	public companies, as follows: Pharsight Corporation, a company focused on providing software products and consulting services
	to biopharmaceutical companies that was acquired by Tripos International in 2008 and CoTherix, Inc., a biopharmaceutical company
	that was acquired by Actelion Pharmaceuticals Ltd. in 2007. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University,
	an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from the Stanford Graduate School
	of Business.&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Daniel
	E. Geffken
</I>
	has served on our Board since our initial public offering in May 2013. Since October 2011, he has been Managing
	Director of Danforth Advisors, LLC, a management consulting firm that provides financial and strategic support to emerging life
	science companies.&nbsp; Mr. Geffken has also been the chief financial officer or chief operating officer of eight companies,
	four of which were U.S. public reporting companies and six of which were life science companies.&nbsp; He has a B.S. in Economics
	from The Wharton School, University of Pennsylvania, and a M.B.A. from Harvard Business School.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Dr.
	Joao Siffert
</I>
	joined our Board in July 2015. Since August 2011, Dr. Siffert has led the Research and Development Organization
	at Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company focused on development and commercialization of neurology
	products. Dr. Siffert is currently the Executive Vice President, R&amp;D and Chief Medical Officer, responsible for R&amp;D, regulatory,
	quality, CMC and commercial supply, as well as medical affairs and pharmacovigilance. Prior to joining Avanir, Dr. Siffert served
	as Vice President and Chief Medical Officer at Ceregene, Inc., a biotechnology company focused on the development of neurotrophic
	gene therapies for Alzheimer&rsquo;s and Parkinson&rsquo;s diseases, from September 2007 to August 2011. Prior to his work at
	Ceregene, Dr. Siffert served as the Chief Medical Officer at Avera Pharmaceuticals, a specialty pharmaceutical company, from May
	2005 to September 2007. Prior to joining Avera, Dr. Siffert held positions with Pfizer (from February 2002 to May 2005) first
	as a medical director for Relpax and subsequently as the worldwide medical team leader of Lyrica and Neurontin, focusing in areas
	of pain and epilepsy. Prior to Pfizer, Dr. Siffert held academic positions at Beth Israel Medical Center, NY where he served as
	director of the Adult Neuro-Oncology program, and Albert Einstein College of Medicine, where he was an assistant professor of
	neurology. Dr. Siffert completed residencies in pediatrics at New York University School of Medicine and in neurology at Harvard
	Medical School. Dr. Siffert was certified by the American Board of Neurology and Psychiatry in 1996. He holds an M.D. from the
	University of Sao Paulo School of Medicine, Brazil as well as an M.B.A. from Columbia University Graduate School of Business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Dr.
	Aharon Schwartz
</I>
	joined our Board as Chairman in January 2013, serving as our chairman until February 2014. He retired from
	Teva Pharmaceutical Industries Ltd where he served in a number of positions from 1957 through 2011, the most recent being Vice
	President, Head of Teva Innovative Ventures from 2008. He is also the chairman of the board of directors of BioLineRx Ltd., BioCancell
	Therapeutics Inc., CureTech Ltd. and several other biotechnology companies. Dr. Schwartz received his Ph.D. in Organic Chemistry
	from the Weizmann Institute, his M.Sc. in organic chemistry from the Technion Institute of Technology and a B.Sc. in Chemistry
	and Physics from the Hebrew University of Jerusalem. He has received a second Ph.D. in the History and Philosophy of Science from
	the Hebrew University of Jerusalem.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Dr.
	Hadas Gelander
</I>
	serves as one of our external directors, a member of our Audit Committee and the Chairperson of our Compensation
	Committee. Dr. Gelander currently serves as the Head of the Accounting Department at the College of Management, Academic Studies,
	School of Business Administration where she is also a professor. Dr. Gelander serves as an Independent Director on the Boards
	of Infimer Technologies Ltd. (TASE: INFR), Eldav (TASE: ELDAV), Gindi Investments, Hilan, Leumi Partners Underwriters, arm of
	Leumi Partners (merchant and investment banking arm of Leumi and Direct Capital) and Ashtrom Properties. Dr. Gelander is a certified
	public accountant and since 2000 has served on the Israeli Council of Public Accountants, or CPA, where she is the Coordinator
	of Examinations of the Israeli CPA. Dr. Gelander earned her Ph.D. summa cum laude from Ben Gurion University, an MBA in Accounting
	and Finance from the Hebrew University of Jerusalem, and a Bachelor of Business degree from the College of Management Academic
	Studies.
</P>
<!-- FIELD: PAGE; SEQUENCE: 51 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Arieh
	Ben Yosef
</I>
	joined our Board in May 2014. Mr. Ben Yosef has served as a director of Insuline Medical Ltd. (TASE: INSL) since
	October 2010, which is focused on improving the performance of current insulin treatment methods. From 2014 to 2015, Mr. Ben Yosef
	served as the Chief Financial Officer of Yazamtech Ltd. From August 2000 to July 2014, Mr. Ben Yosef served as a director of Microwave
	Networks Inc., a provider of microwave communications products and services. From 2006 to 2012, Mr. Ben Yosef was employed by
	Teledata Networks Ltd., a global provider of access network products and solutions for Telecom Service Providers, in the positions
	of Chief Financial Officer, Executive Vice President for Finance &amp; Operations and later on as the General Manager of the company.
	From 2000 to 2004, Mr. Ben Yosef served as the President of Elisra Inc. and from 1998 to 2000 as the CFO of Tadiran Electronic
	Industries Inc. Mr. Ben Yosef holds an M.B.A. from the Hebrew University of Jerusalem.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Ori
	Mor
</I>
	serves as one of our external directors, a member of our Compensation Committee and the Chairperson of our Audit
	Committee. Mr. Mor recently founded and currently serves as the Chief Executive Officer of Mor-Langerman Ltd., a capital
	market advisory firm. Mr. Mor served as the CFO of Medical Compression Systems Ltd. (TASE: MDCL), a leader in innovative,
	non-invasive solutions for the prevention of venous thromboembolism (VTE), from 2009 to 2014. Mr. Mor also serves as an
	External Director on the Boards of Birman Wood &amp; Hardware Ltd. (TASE: BIRM), Angel Ltd, and as an external director and a
	chairperson of the investment committee of Excellence Nessuah Gemel &amp; Pension Ltd. and as Chairperson of the Board of Mordechai Aviv Taasiot Beniy Ltd. (TASE: AVIV). Mr. Mor previously served as CIO at Halman Aldubi
	and FIBI Provident Fund and has worked as a macro analyst at the Provident Funds of Bank Leumi and Mizrahi Bank. Mr. Mor is
	also a member of the Board of the Israeli Association of Publicly Traded Companies. He holds an M.A. in Economics from Ben
	Gurion University.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Dr.
	Yaron Daniely
</I>
	became our President and Chief Executive Officer and a Director in March 2010. Immediately prior to joining
	us and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal
	delivery technologies based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was the General Manager of Gamida
	Cell&mdash;Teva Joint Venture Ltd., a joint venture company that acquired an exclusive license to develop and commercialize a
	Phase 3-stage cell therapy product for treatment of Leukemia and Lymphoma based in Jerusalem, Israel. From 2003-2007, Dr. Daniely
	also served as the Vice President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial
	transactions for the Company. In addition, he is a director of Bioblast Ltd, a private company incorporated in Israel. Dr. Daniely
	holds a B.Sc. degree in Biological Sciences from Florida International University, and holds a Ph.D. from the Sackler Institute
	of Graduate Biomedical Sciences at the New York University School of Medicine. Following his doctoral program, Dr. Daniely served
	as an NIH Visiting Fellow in its Cell Biology section and a Postdoctoral Fellow in the Department of Molecular Cell Biology at
	The Weizmann Institute for Science in Israel. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute
	of Technology.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Dr.
	Tomer Berkovitz
</I>
	joined Alcobra in May 2014 as the Chief Financial Officer and in January 2016 was appointed to the additional
	position of Chief Operating Officer. Immediately prior to joining Alcobra, and from 2008, he was an Executive Director in J.P.
	Morgan&rsquo;s Investment Banking Division in New York, where he played a leading role in numerous capital market and mergers
	and acquisitions transactions. In this capacity, he advised senior management and boards of directors of J.P. Morgan's key U.S.
	clients, including several S&amp;P 500 healthcare firms. Prior to joining J.P. Morgan, Dr. Berkovitz worked in Citigroup's Investment
	Bank in New York
<FONT STYLE="COLOR: #676767">
	.
</FONT>
	From 2000 to 2003, he served as an economist in the Financial Advisory Unit
	to the Chief of Staff of the Israel Defense Forces. Dr. Berkovitz holds a Ph.D. in Finance and Economics from Columbia Business
	School and has published a number of corporate finance articles in leading academic and practitioner journals. He also holds an
	M.Sc. in Finance and Accounting and a B.A. in Economics and Management, both from Tel-Aviv University.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	David
	Baker
</I>
	serves as our Chief Commercial Officer. He joined us in January 2014 after working at Shire Pharmaceuticals for ten
	years, most recently as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In this role
	he led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline CNS products,
	and led the long term strategic planning process. Previously, he served as Global General Manager for Vyvanse&reg; where he led
	the launch of Vyvanse in 2007, oversaw the launch of the adult indication for Vyvanse in 2008, and led global expansion efforts
	to take Shire's ADHD portfolio beyond North America including successful establishment of a partnership in Japan and launches
	in Canada and Brazil. Prior to that, Mr. Baker served as Vice President of Marketing for all of Shire's ADHD products. Under his
	leadership, Adderall XR became the number one selling ADHD brand in the US. From 1990 - 2004, Mr. Baker worked at Merck where
	he held positions of increasing responsibility in marketing, sales, market research, and business development. In addition to
	his knowledge and experience with CNS medications, Mr. Baker's therapeutic expertise includes osteoporosis, migraine, and hyperlipidemia.
	He has been directly involved with the marketing of five leading prescription drugs with annual sales in excess of $1 billion
	each: Mevacor&reg;, Zocor&reg;, Fosamax&reg;, Adderall XR, and Vyvanse.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	He
	holds a bachelor's degree in Economics and Computer Science from Duke University and an M.B.A in Marketing from Duke's Fuqua School
	of Business.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Dr.
	Jonathan Rubin
</I>
	serves as our Chief Medical Officer. He joined us in August 2013 after working at Shire Pharmaceuticals for
	more than six years, from 2007 through 2013, serving as a Medical Director in Global Medical Affairs supporting multiple products
	within the ADHD portfolio. As a Medical Director in Global Medical Affairs at Shire Pharmaceuticals, Dr. Rubin developed and implemented
	Global Medical Affairs strategic plans, planned and supervised medical launch activities in the United States and assisted with
	the design, execution and interpretation of Phase 2, 3 and Phase 4 studies. Dr. Rubin also served as the Director of Scientific
	Licensing Assessment at Shire Pharmaceuticals in 2011 where he identified and evaluated new opportunities for business development.
	Dr. Rubin began his pharmaceutical industry career as a medical consultant for Noven Pharmaceuticals in 2002. Until 2007 Dr. Rubin
	cared for children and adolescents with ADHD for 15 years at his General and Developmental-Behavioral Pediatric practice in Margate
	and Coconut Creek, Florida. He graduated with a B.S. from Yale University and an M.D. from the University of Connecticut, completed
	a pediatric residency at Albert Einstein/Montefiore, completed an Ambulatory Pediatric Fellowship at Boston Children&rsquo;s Hospital
	and received an M.B.A. from Columbia Business School.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<I>
	Hanna
	Ron
</I>
	serves as our Senior Vice President for Chemistry, Manufacturing and Control. She has over 28 years of experience in the
	pharmaceutical industry and is an expert in chemistry, manufacturing and controls and pre-clinical studies. She has been providing
	full-time services to the Company since 2011 and has been a consultant to the pharmaceutical industry since 2009. From 2004 to
	2009, she was the Vice President of Chemistry, Manufacturing and Controls at Bioline Innovations, an Israeli biotechnology company.
	She has held other positions in biotechnology and pharmaceutical companies, including being a chief research and development manager
	and a pharmaceutical product development manager at Teva Pharmaceuticals. Ms. Ron holds a B.Sc. in Pharmacy from Hebrew University
	in Jerusalem, an M.Sc. in Pharmaceutical Sciences (Clinical Pharmacy) from the Hebrew University and M.Sc. in Chemical Engineer
	from School of Engineering Tel Aviv University. She is licensed as a pharmacist by the the Ministry of Health, Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
<I>
	Dr. Johanna
	Schumann
</I>
	serves as our Senior Vice President for Preclinical Development. She joined us in August 2013 after working at BioLineRx,
	an Israeli drug development company, from 2010 through 2013, serving as Preclinical Development Manager. In this role, she designed,
	managed and executed preclinical activities, including toxicology, pharmacokinetics and pharmacodynamics studies, in accordance&nbsp;with&nbsp;the&nbsp;relevant
	regulatory&nbsp;authorities' guidelines, for multiple preclinical phase drug development projects and medical indications. Dr
	Schumann holds a B.Sc. in Life Sciences from the Hebrew University of Jerusalem, and an M.Sc. and Ph.D. in Pharmacology from the
	School of Pharmacy, The Hebrew University of Jerusalem.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
<I>
	Dr Hagit Marchaim
</I>
	serves as our Senior Vice President for Regulatory Affairs. She joined us in May 2014 and brings 10 years of regulatory affairs
	experience to Alcobra. Prior to joining Alcobra, and from 2011 to 2013, Dr. Marchaim was the Vice President Regulatory Affairs
	at CureTech Ltd. Before that, and from 2009 to 2011, she was the Regulatory Affairs Department Head at Omrix Biopharmaceuticals,
	a Johnson &amp; Johnson company. Her first regulatory affairs positions were at Makhteshim Agan Industries Ltd., from 2004 to
	2007, and at Kamada Ltd., from 2007 to 2009, where she was also responsible for management of non-clinical studies. Dr. Marchaim
	has a broad experience as a Regulatory Affairs Consultant, working with companies ranging from startups at early development stages
	to global companies at post approval stages worldwide. Dr. Marchaim holds a B.Sc. in Biological Sciences from The Hebrew University
	of Jerusalem, a M.Sc. in Microbiology from The Hebrew University of Jerusalem, a Ph.D. from the Hebrew University of Jerusalem
	and a M.B.A. from the College of Management. In addition, Dr. Marchaim was a postdoctoral fellow at The Weizmann Institute for
	Science in Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
<I>
	Irena Katsman,
</I>
	our Vice President for Finance, joined Alcobra in April 2015. Immediately prior to joining Alcobra and since 2008, Ms. Katsman
	served as Finance Manager of Omrix Biopharmaceuticals, a Johnson &amp; Johnson company. Ms. Katsman is a certified public accountant
	and holds a B.A. in Economics and Accounting from the Hebrew University in Jerusalem and an M.B.A. from Tel Aviv University.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
	&nbsp;
<I>
	Shlomi
	Ianovitz
</I>
	serves as our Director of Quality Assurance. He joined us in October 2015. From 2012 until 2015, Mr. Ianovitz served
	as a Quality Assurance Manager and Qualified Person at Dexcel Pharma., and prior to that and from 2010 he served as a Qualified
	Person at Dexcel Pharma. From 2009 to 2010, Mr. Ianovitz served as the Production Pharmacist and Deputy Qualified Person at CTS
	Chemical Industries Ltd. Mr. Ianovitz holds a B.Sc. Pharm from the School of Pharmacy of the Hebrew University of Jerusalem.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Compensation
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
	The table below
	reflects the compensation granted to our five most highly compensated officers during or with respect to the year ended December
	31, 2015. All amounts reported in the table reflect the cost to us, in U.S. Dollars, as recognized in our financial statements
	for the year ended December 31, 2015. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.89 = U.S.$1.00,
	based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel in
	the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27.5PT">
	&nbsp;
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
	Name and Position
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Salary
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Share-Based
<BR>
	Payment (1)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Bonus (2)
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT">
	Dr. Yaron Daniely
<BR>
	Chief Executive Officer, President and Director
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	490,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	829,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	157,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,476,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Dr. Tomer Berkovitz
<BR>
	Chief Financial Officer, Chief Operating Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	373,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	377,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	138,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	888,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	David Baker
<BR>
	Chief Commercial Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	365,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	307,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	146,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	818,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Dr. Jonathan Rubin
<BR>
	Chief Medical Officer
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	357,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	188,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	107,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	652,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Dr. Hagit Marchaim
<BR>
	SVP Regulatory Affairs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	185,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	76,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	55,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	316,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 22.3PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(1)
</TD>
<TD>
	Represents the equity-based compensation expenses recorded
	in our consolidated financial statements for the year ended December 31, 2015 based on
	the options&rsquo; grant date fair value in accordance with accounting guidance for equity-based
	compensation.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 22.3PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	(2)
</TD>
<TD>
	Does not include bonus payments for 2015 not yet granted, which
	are subject to the approval of our shareholders.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
	The aggregate
	amount of compensation paid or accrued to all of our directors and executive officers as a group with respect to the year ended
	December&nbsp;31, 2015 was approximately $3.2 million. This amount includes salaries, consulting fees, directors' fees, car expenses
	and vacation, pension, severance, retirement or similar benefits or expenses, employer&rsquo;s taxes, and bonuses expenses in
	an amount of $0.8 million. The amount does not include business travel, relocation, professional and business association due
	and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	In addition, share-based compensation
	in the amount of $2.2 million was recorded in 2015.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
	Employment Agreements with Executive
	Officers
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We have entered
	into written employment agreements with all of our executive officers. Each of these agreements contains provisions regarding
	non-competition, confidentiality of information and ownership of inventions. The non-competition provision applies for a period
	that is generally 12 months following termination of employment. The enforceability of covenants not to compete in Israel and
	the United States is subject to limitations. In addition, we are required to provide notice prior to terminating the employment
	of our executive officers, other than in the case of a termination for cause.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
	Directors&rsquo; Service Contracts
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Other than with
	respect to our directors that are also executive officers, we do not have written agreements with any director providing for benefits
	upon the termination of his employment with our company.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In December 2012,
	an amendment to the Israeli Companies Law, or Amendment 20, became effective, requiring companies to appoint a compensation committee.
	Our existing compensation committee as detailed in Item 6.C. Board Practices &ldquo;Board Committees &ndash; Compensation Committee&rdquo;
	below meets this requirement.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Amendment 20 also
	requires us to adopt an office holder compensation policy, no later than nine months from our initial public offering, that will
	set forth company policy, or the Compensation Policy, regarding the terms of office and employment of office holders, including
	compensation, equity awards, severance and other benefits, exemption from liability and indemnification, referred to as the Terms
	of Office and Employment. The term &ldquo;office holder,&rdquo; as defined in the Israeli Companies Law, includes directors, executive
	officers and any manager directly subordinate to the chief executive officer.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Compensation
	Policy must be approved by the board of directors, after considering the recommendations of the compensation committee. The Compensation
	Policy must also be approved by a majority of the company&rsquo;s shareholders, provided that (i)&nbsp;such majority includes
	at least a majority of the shareholders who are not controlling shareholders and who do not have a personal interest in the matter,
	present and voting (abstentions are disregarded), or (ii)&nbsp;the non-controlling shareholders and shareholders who do not have
	a personal interest in the matter who were present and voted against the policy hold two percent or less of the voting power of
	the company. The Compensation Policy must be approved by the board of directors and the shareholders every three years. If the
	Compensation Policy is not approved by the shareholders, the compensation committee and the board of directors may nonetheless
	approve the policy, following further discussion of the matter and for specified reasons.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under Amendment
	20, the Terms of Office and Employment of office holders require the approval of the compensation committee and the board of directors.
	The Terms of Office and Employment of directors and the chief executive officer must also be approved by shareholders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Changes to existing
	Terms of Office and Employment of office holders (other than directors) can be made with the approval of the compensation committee
	only, if the committee determines that the change is not substantially different from the existing terms.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under certain
	circumstances, the compensation committee and the board of directors may approve an arrangement that deviates from the Compensation
	Policy, provided that such arrangement is approved by the special majority of the company&rsquo;s shareholders mentioned above.
	Such shareholder approval will also be required with respect to determining the Terms of Office and Employment of a director or
	the chief executive officer during the transition period until the company adopts a Compensation Policy. Notwithstanding the foregoing,
	a company may be exempted from receiving shareholder approval with respect to the Terms of Office and Employment of a candidate
	for chief executive officer if such candidate meets certain independence criteria, the terms are in line with the Compensation
	Policy and the compensation committee has determined for specified reasons that shareholder approval would prevent the engagement.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law and related regulations, the compensation payable to statutory independent directors and independent directors is
	subject to certain further limitations.&nbsp;See Item 6.C. Board Practices &ldquo;External Directors.&rdquo;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our shareholders
	approved a Compensation Policy in February 2014, which was subsequently amended in July 2015 that meets the above requirements.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Board
	practices
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Board of Directors
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, setting up the Company's policy and oversight of our business is vested in our Board of Directors. Our Board of
	Directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management.
	Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our Board
	of Directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our Board of Directors, subject to
	the employment agreement that we have entered into with him. All other executive officers are appointed by our Chief Executive
	Officer, and are subject to the terms of any applicable employment agreements that we may enter into with them.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under our amended
	and restated articles of association, our Board of Directors must consist of at least five and not more than eleven directors,
	including at least two external directors required to be appointed under the Israeli Companies Law. Accordingly, at any time,
	the minimum number of directors (other than the external directors) may not fall below three. Currently, our Board of Directors
	consists of eight directors, including two external directors. We have only one class of directors.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Other than external
	directors, for whom special election requirements and terms of office apply under the Israeli Companies Law as detailed below,
	our directors are each elected at a general meeting of our shareholders and serve for a term of roughly one year. Directors may
	nevertheless be removed prior to the end of their term by the majority of our shareholders at a general meeting of our shareholders
	or upon the occurrence of certain events, all in accordance with the Israeli Companies Law and our amended and restated articles
	of association.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In addition, our
	amended and restated articles of association allow our Board of Directors to appoint directors, other than external directors,
	to fill vacancies on our Board of Directors, for a term of office which shall continue until the next annual meeting following
	his or her appointment. External directors are elected for an initial term of three years and may be elected for up to two additional
	three-year terms (or more) under the circumstances described below. External directors may be removed from office only under the
	limited circumstances set forth in the Israeli Companies Law. See &ldquo;External Directors,&rdquo; below.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In accordance
	with the exemption available to foreign private issuers under NASDAQ rules, we do not follow the requirements of the NASDAQ rules
	with regard to the process of nominating directors, and instead, follow Israeli law and practice, in accordance with which our
	Board of Directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election. Under
	the Israeli Companies Law and our amended and restated articles of association, nominations for directors may also be added to
	the agenda of future general meetings, which has yet to have been summoned, upon the request of any shareholder holding at least
	one percent (1%) of our outstanding voting power. However, any such shareholder may make such a nomination only if a written notice
	of such shareholder's intent to make such nomination has been given to our chairman of the board (or, if we have no chairman of
	the board, our chief executive officer). Any such notice must include certain information we are required under the Israeli Companies
	Law to provide to our shareholders, the consent of the proposed director nominee(s) to serve as our director(s) if elected and
	a declaration signed by the nominee(s) declaring that there is no limitation under the Israeli Companies Law preventing their
	election and that all of the information that is required under the Israeli Companies Law to be provided to us in connection with
	such election has been provided.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In addition to
	its role in making director nominations, under the Israeli Companies Law, our Board of Directors must determine the minimum number
	of directors who are required to have accounting and financial expertise. Under applicable regulations, a director with accounting
	and financial expertise is a director who, by reason of his or her education, professional experience and skill, has a high level
	of proficiency in and understanding of business accounting matters and financial statements, sufficient to be able to thoroughly
	comprehend the financial statements of the Company and initiate debate regarding the manner in which financial information is
	presented. In determining the number of directors required to have such expertise, our Board of Directors must consider, among
	other things, the type and size of our company and the scope and complexity of its operations. Our Board of Directors has determined
	that our company requires one director with such expertise. Mr. Mor has such accounting and financial expertise.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	External Directors
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, the boards of directors of companies whose shares are publicly traded, including companies with shares listed on
	the NASDAQ Global Market, are required to include at least two members elected to serve as external directors. Accordingly, Mr.
	Mor and Dr. Gelander have been elected to serve as external directors.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The definitions
	of an external director under the Israeli Companies Law and independent director under NASDAQ listing rules are similar to such
	an extent that it would be generally expected that our two external directors will also comply with the independence requirement
	under the NASDAQ Stock Market rules. The definition of an external director includes a set of statutory criteria that must be
	satisfied, while the definition of an independent director also requires the board to consider any factor which would impair the
	ability of a director to exercise independent judgment. In addition, while external directors serve for a period of three years
	pursuant to the requirements of Israeli law, independent directors serve for one year pursuant to the provisions of our amended
	and restated articles of association. However, external directors must be elected by a special majority of shareholders while
	independent directors are elected by an ordinary majority.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law provides that external directors must be elected by a majority vote of the shares present and voting at a shareholders meeting,
	provided that either:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	majority voted in favor of election includes a majority of the shares held by non-controlling shareholders who do not have
	a personal interest in the election of the external director (other than a personal interest not deriving from a relationship
	with a controlling shareholder) that are voted at the meeting, excluding for such purpose any abstentions, which we refer
	to as a disinterested majority; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	total number of shares held by non-controlling disinterested shareholders (as described in the previous bullet-point) that
	voted against the election of the director does not exceed two percent (2%) of the aggregate voting rights in the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The term controlling
	shareholder is defined in the Israeli Companies Law as a shareholder with the ability to direct the activities of the Company,
	other than by virtue of being an office holder. A shareholder is in any case deemed to be a controlling shareholder if the shareholder
	holds 50% or more of the means of control, which include the right to vote at a shareholders meeting and the right to appoint
	the directors of the Company or its general manager. In connection with approval of certain extraordinary and interested party
	transactions as well as corporate approval of executive compensation, by shareholders, any shareholder (or group of shareholders
	having interest in the same matter being brought for approval) who hold(s) in the aggregate 25% or more of the means of control
	if no other shareholder holds more than 50% of the voting rights, would be deemed a controlling shareholder.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	After an initial
	term of three years, external directors may be reelected to serve in that capacity for up to two additional three year terms,
	provided that either (i) (1)&nbsp;his or her service for each such additional term is recommended by one or more shareholders
	holding in aggregate at least one percent (1%) of the Company's voting rights and is approved at a shareholders meeting by a majority
	of the shares held by non-controlling shareholders who do not have a personal interest in the election of the external director
	(other than a personal interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting,
	excluding for such purpose any abstentions, where the total number of shares held by non-controlling, disinterested shareholders
	voting for such reelection exceeds two percent (2%) of the aggregate voting rights in the Company, and (2) the external director
	who has been nominated in such fashion by the shareholders is not a linked or competing shareholder, and does not have or has
	not had, on or within the two years preceding the date of such person&rsquo;s appointment to serve as another term as external
	director, any affiliation with a linked or competing shareholder. The term &ldquo;linked or competing shareholder&rdquo; means
	the shareholder(s) who nominated the external director for reappointment or a material shareholder of the company holding more
	than 5% of the shares in the company, provided that at the time of the reappointment, such shareholder(s) of the company, the
	controlling shareholder of such shareholder(s) of the company, or a company under such shareholder(s) of the company&rsquo;s control,
	has a business relationship with the company or are competitors of the company; the Israeli Minister of Justice, in consultation
	with the Israeli Securities Authority, may determine that certain matters will not constitute a business relationship or competition
	with the company; or (ii)&nbsp;his or her service for each such additional term is recommended by the board of directors and is
	approved at a shareholders meeting by the same non-controlling and disinterested majority required for the initial election of
	an external director (as described above). The term of office for external directors for Israeli companies traded on certain foreign
	stock exchanges, including the NASDAQ Global Market, may be further extended, indefinitely, in increments of additional three-year
	terms, in each case provided that, in addition to reelection in such manner described above, (i) the audit committee and subsequently
	the board of directors of the Company confirm that, in light of the external director's expertise and special contribution to
	the work of the board of directors and its committees, the reelection for such additional period is beneficial to the Company,
	and (ii) prior to the approval of the reelection of the external director, the Company's shareholders have been informed of the
	term previously served by such nominee and of the reasons why the board of directors and audit committee recommended the extension
	of such nominee&rsquo;s term.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If the Board of
	Directors resolves that an external director no longer complies with the requirement of qualification as an external director,
	or that such external director has breached any fiduciary duty, a special general meeting shall be convened at which the termination
	of such external director&rsquo;s service shall be included in the agenda.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If an external
	directorship becomes vacant and there are less than two external directors on the board of directors at the time, then the board
	of directors is required under the Israeli Companies Law to call a shareholders' meeting as soon as possible to appoint a replacement
	external director.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Each committee
	of the board of directors that is authorized to exercise the powers of the board of directors must include at least one external
	director, except that the audit committee and the compensation committee must each include all external directors then serving
	on the board of directors. Under the Israeli Companies Law, external directors of a company are prohibited from receiving, directly
	or indirectly, any compensation for their services as external directors, other than compensation and reimbursement of expenses
	pursuant to applicable regulations promulgated under the Israeli Companies Law. Compensation of an external director is determined
	prior to his or her appointment and may not be changed during his or her term subject to certain exceptions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law provides that a person is not qualified to serve as an external director if (i)&nbsp;the person is a relative of the controlling
	shareholder of the Company, or (ii)&nbsp;if that person or his or her relative, partner, employer, another person to whom he or
	she was directly or indirectly subject, or any entity under the person's control, has or had, during the two years preceding the
	date of appointment as an external director: (a)&nbsp;any affiliation or other prohibited relationship with the Company, with
	any person or entity who is a controlling shareholder of the Company at the date of appointment or a relative of such person,
	or with any entity controlled, during the two years preceding the date of appointment as an external director, by the Company
	or a controlling shareholder of the Company; or (b)&nbsp;in the case of a company with no controlling shareholder, any affiliation
	or other prohibited relationship with a person serving, at the date of appointment as external director, as chairman of the board,
	chief executive officer, a substantial shareholder or the most senior office holder in the Company's finance department.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The term relative
	is defined as a spouse, sibling, parent, grandparent or descendant; spouse's sibling, parent or descendant; and the spouse of
	each of the foregoing persons. The term affiliation and the similar types of prohibited relationships include (subject to certain
	exemptions):
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	an employment
	relationship;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a
	business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	control;
	and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	service
	as an office holder, excluding service as a director in a private company prior to the first offering of its shares to the
	public if such director was appointed as a director of the private company in order to be nominated to serve as an external
	director following the initial public offering.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The term office
	holder is defined under the Israeli Companies Law as the general manager (chief executive officer), chief business manager, deputy
	general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of
	that person's title, a director, or a manager directly subordinate to the general manager.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In addition, no
	person may serve as an external director if that person's position or professional or other activities create, or may create,
	a conflict of interest with that person's responsibilities as a director or otherwise interfere with that person's ability to
	serve as an external director or if the person is an employee of the Israel Securities Authority or of an Israeli stock exchange.
	A person may furthermore not continue to serve as an external director if he or she received direct or indirect compensation for
	his or her role as a director, other than compensation paid or given in accordance with Israeli Companies Law regulations or amounts
	paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage. Following the termination
	of an external director's service on a board of directors, such former external director and his or her spouse and children may
	not be provided with direct or indirect benefit by the Company, its controlling shareholder or any entity under its controlling
	shareholder's control. This includes appointment as an office holder of the Company or a company controlled by its controlling
	shareholder, employment as an employee, or receipt of professional services for consideration, either directly or indirectly,
	including through a corporation in his or her control. These restrictions extend for a period of two years with regard to the
	former external director and his or her spouse or child, and for one year with respect to other relatives of the former external
	director.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If at the time
	at which an external director is appointed all members of the board of directors, who are not controlling shareholders or relatives
	thereof, are of the same gender, the external director must be of the other gender. A director of one company may not be appointed
	as an external director of another company if a director of the other company is acting as an external director of the first company
	at such time.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	According to the
	Israeli Companies Law, a person may be appointed as an external director only if he or she has professional qualifications or
	if he or she has accounting and financial expertise (each, as defined below). In addition, at least one of the external directors
	must be determined by our Board of Directors to have accounting and financial expertise. However, if at least one of our other
	directors (i)&nbsp;meets the independence requirements under the Exchange Act, (ii)&nbsp;meets the standards of the NASDAQ Listing
	Rules for membership on the audit committee, and (iii)&nbsp;has accounting and financial expertise as defined under Israeli law,
	then neither of our external directors is required to possess accounting and financial expertise as long as both possess other
	requisite professional qualifications.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A director with
	accounting and financial expertise is a director who, due to his or her education, experience and skills, possesses an expertise
	in, and an understanding of, financial and accounting matters and financial statements, in such a manner which allows him or her
	to understand the financial statements of the Company and initiate a discussion about the presentation of financial data. A director
	is deemed to have professional qualifications if he or she has any of (i)&nbsp;an academic degree in economics, business management,
	accounting, law or public service, (ii)&nbsp;an academic degree or has completed other higher education, in the main field of
	business of the Company or a field relevant for the position, or (iii)&nbsp;at least five years of experience as one of the following,
	or at least five years accumulated experience as two or more of the following &ndash; (a) a senior officer in the business management
	of a company with a significant volume of business, (b) a senior public officer or senior position in the public service, and
	(c) a senior position in the Company's main line of business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our Board of Directors
	has determined that Mr. Mor possesses the requisite accounting and financial expertise and that Dr. Gelander possesses the requisite
	professional qualifications.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Leadership Structure of the Board
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In accordance
	with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint
	one of its members to serve as Chairman of the Board of Directors. Our board of directors has appointed Mr. Howard Rosen to serve
	as Chairman of the Board of Directors.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Role of Board in Risk Oversight
	Process
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Risk assessment
	and oversight are an integral part of our governance and management processes. Our Board of Directors encourages management to
	promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management
	discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning and review
	sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management
	reviews these risks with the Board of Directors at regular board meetings as part of management presentations that focus on particular
	business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Board Committees
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Audit Committee
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, the board of directors of a public company must appoint an audit committee. The audit committee must be comprised
	of at least three directors, including all of the external directors, one of whom must serve as chairman of the committee. The
	audit committee may not include the chairman of the board, any director employed by or otherwise providing services on a regular
	basis to the Company, to a controlling shareholder or to any entity controlled by a controlling shareholder, any director whose
	main livelihood is dependent on a controlling shareholder, nor a controlling shareholder or a relative thereof.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, the audit committee of a publicly traded company must consist of a majority of unaffiliated directors. An &ldquo;unaffiliated
	director&rdquo; is defined as either an external director or as a director, classified as an &ldquo;unaffiliated director&rdquo;
	by the Company, who meets the following criteria:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	he
	or she meets the qualifications for being appointed as an external director, except for (i)&nbsp;the requirement that the
	director be an Israeli resident (which in any event does not apply to companies such as ours whose securities have been offered
	outside of Israel or are listed outside of Israel) and (ii)&nbsp;the requirement for accounting and financial expertise or
	professional qualifications, and the audit committee of the company confirmed such qualifications; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	he
	or she has not served as a director of the Company for a period exceeding nine consecutive years. For this purpose, a break
	of less than two years in the service shall not be deemed to interrupt the continuation of the service.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our Board of Directors
	has adopted an audit committee charter setting forth the responsibilities of the Audit Committee consistent with the rules of
	the SEC and the Listing Rules of the NASDAQ Stock Market, as well as the requirements for such committee under the Israeli Companies
	Law, as described below.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our Audit Committee
	consists of Mr. Mor, who serves as the chairperson of the committee, Mr. Ben Yosef and Dr. Gelander.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our Audit Committee
	provides assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting,
	auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our
	independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial
	reporting. Our Audit Committee also oversees the audit efforts of our independent accountants and takes those actions that it
	deems necessary to satisfy itself that the accountants are independent of management.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, our Audit Committee is responsible for (i)&nbsp;determining whether there are deficiencies in the business management
	practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations
	to the Board of Directors to improve such practices, (ii)&nbsp;determining whether to approve certain related party transactions
	(including transactions in which an office holder has a personal interest) and whether such transaction should be deemed as material
	or extraordinary (according to certain criteria set by our Audit Committee on an annual basis) (see Item 16.G. Corporate Governance
	&ldquo;Approval of Related Party Transactions under Israeli Law&rdquo;), (iii)&nbsp;establishing procedures regarding related
	party transactions with a controlling shareholder, which may include, the establishment of a competitive process for such transaction,
	under the supervision of the audit committee or another individual or committee selected by the audit committee, in accordance
	with criteria determined by the audit committee; (iv) determining procedures for approving certain related party transactions
	with a controlling shareholder, which have been determined by the audit committee to not be extraordinary transactions, nor negligible
	transactions; (v) where the Board of Directors approves the working plan of the internal auditor, to examine such working plan
	before its submission to the Board and propose amendments thereto, (vi)&nbsp;examining our internal controls and internal auditor's
	performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities, (vii)&nbsp;examining
	the scope of our auditor's work and compensation and submitting a recommendation with respect thereto to our Board of Directors
	or shareholders, depending on which of them is considering the appointment of our auditor, and (viii)&nbsp;establishing procedures
	for the handling of employees' complaints as to the management of our business and the protection to be provided to such employees.
	In compliance with regulations promulgated under the Israeli Companies Law, our Audit Committee will also approve our financial
	statements, thereby fulfilling the requirement that a board committee provide such approval. Our Audit Committee may not approve
	an action or a related party transaction, or take any other action required under the Israeli Companies Law, unless at the time
	of approval a majority of the committee's members are present, which majority consists of unaffiliated directors including at
	least one external director, and it further complies with the committee composition set forth above.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<I>
	NASDAQ requirements
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Nasdaq
	Marketplace Rules, we are required to maintain an audit committee consisting of at least three independent directors, all of whom
	are financially literate and one of whom has accounting or related financial management expertise.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	As noted above, our audit
	committee consists of Dr. Gelander, Mr. Mor and Mr. Ben Yosef. Mr. Mor is an audit committee financial expert as defined by SEC
	rules and has the requisite financial sophistication as defined by the Nasdaq Marketplace Rules. All of the members of our audit
	committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Listing Rules
	of the NASDAQ Stock Market.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Dr. Gelander,
	Mr. Mor and Ben Yosef are independent as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and under the Listing
	Rules of the NASDAQ Stock Market.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Compensation Committee
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We chose to rely
	upon the exemption available to foreign private issuers under the Listing Rules of the NASDAQ Stock Market with respect to the
	determination of the compensation of our Chief Executive Officer and other executive officers, and, in lieu of forming a compensation
	committee consisting entirely of independent directors (or the determination of such compensation solely by the independent members
	of our Board of Directors), we have a compensation committee in compliance with the Israeli Companies Law. See Item 16.G. Corporate
	Governance. However, all of the current members of our compensation committee are independent.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, the board of directors of a public company must appoint a compensation committee. The compensation committee must
	be comprised of at least three directors, including all of the external directors, which shall be a majority of the members of
	the compensation committee and one of whom must serve as chairman of the committee. The rest of the members of the compensation
	committee shall be directors who do not receive direct or indirect compensation for their role as directors (other than compensation
	paid or given in accordance with Israeli Companies Law regulations applicable to the compensation of external directors, or amounts
	paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The compensation
	committee may not include the chairman of the board, any director employed by or otherwise providing services on a regular basis
	to the Company, to a controlling shareholder or to any entity controlled by a controlling shareholder, any director whose main
	livelihood is dependent on a controlling shareholder, nor a controlling shareholder or a relative thereof.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our compensation
	committee has adopted a compensation committee charter setting forth the responsibilities of the compensation committee consistent
	with the rules of the SEC and the Listing Rules of the NASDAQ Stock Market, as well as the Israeli Companies Law, as described
	below.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our Compensation
	Committee consists of Dr. Gelander, who serves as the chairperson of the committee, Mr. Ben Yosef and Mr. Mor, all of whom are
	independent under the listing standards of the NASDAQ Global Market.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, our compensation committee is responsible for (i)&nbsp;proposing a Compensation Policy to the board of directors,
	(ii) propose necessary revisions to the Compensation Policy and examine its implementation, (iii) determining whether to approve
	transactions with respect to compensation of office holders, and (iv)&nbsp;determining, in accordance with our office holder compensation
	policy, whether to exempt an engagement with an unaffiliated nominee for the position of chief executive officer from requiring
	shareholders&rsquo; approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We have adopted
	an office holder compensation policy as required under the Israeli Companies Law.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Nominating Committee
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our Board of Directors
	does not currently have a nominating committee, as director nominees are presented by our Board of Directors to our shareholders
	based upon the nominations made by the Board of Directors itself. We currently rely upon the exemption available to foreign private
	issuers under the Listing Rules of the NASDAQ Stock Market relating to independent director oversight of nominations to our Board
	of Directors and the adoption of a formal written charter or board resolution addressing the nominations process. See Item 16.G.
	Corporate Governance.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We do not have
	service contracts with any of our directors, except for Dr. Yaron Daniely. The remaining directors&rsquo; compensation has been
	approved by our shareholders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Internal auditor
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee
	and nominated by the board of directors. An internal auditor may not be:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a
	person (or a relative of a person) who holds more than 5% of the Company's outstanding shares or voting rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a
	person (or a relative of a person) who has the power to appoint a director or the general manager of the Company;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	an office
	holder (including a director) of the Company (or a relative thereof); or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a member
	of the Company's independent accounting firm, or anyone on his or her behalf.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Guy Sapir, CPA,
	a partner at PWC Israel, was appointed as our internal auditor. The role of the internal auditor is to examine, among other things,
	our compliance with applicable law and orderly business procedures.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
</TD>
<TD STYLE="WIDTH: 6%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Employees
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
	As of the date
	hereof we have 19 employees. Our management consists of our Chief Executive Officer, Chief Financial Officer, Chief Medical Officer,
	Chief Commercial Officer, SVP CMC (chemistry manufacturing and controls), SVP for Finance, SVP for Preclinical Development, SVP
	for Regulatory Affairs as well as our Director of Quality Assurance. We further have service agreements with U.S.-based regulatory
	consultants as well as additional U.S.-based clinical consultants who are members of our clinical advisory board. We believe that
	we maintain good relations with all of them.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
</TD>
<TD STYLE="WIDTH: 6%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Share
	ownership
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	As of March 2,
	2016, each of our executive officers and directors, other than Dr. Daniely, beneficially owned less than 1% of our Ordinary Shares.
	Dr. Daniely owned 2%.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
	The following
	table summarizes information about the options to purchase our Ordinary Shares owned by Dr. Daniely that were outstanding as of
	March 2, 2016:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; COLOR: #1F497D">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 70%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NUMBER
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	OUTSTANDING
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	EXERCISE
	PRICE
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	EXPIRATION
	DATE
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	340,460
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; LINE-HEIGHT: 107%">
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.33
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 51%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	November
	15, 2020
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	89,553
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8.00
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	January
	2, 2023
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	37,500
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	23.85
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	February
	17, 2020
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	400,000
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.63
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	30, 2020
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; COLOR: #1F497D">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	On March 2, 2016,
	additional 192,487 options were granted to Dr. Daniely with an exercise price of $4.55. Such grant of options is subject
	to the approval of our shareholders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	2010 Incentive Option Plan
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We maintain one
	equity incentive plan - our 2010 Incentive Option Plan, or our 2010 Plan. As of March 2, 2016, a total of 3,078,102 shares were
	reserved for issuance under our 2010 Plan, of which options to purchase 2,781,549 ordinary shares were issued and outstanding
	thereunder (out of which 276,487 options are subject to the approval of our shareholders). Of such outstanding options, options
	to purchase 857,957 ordinary shares were vested as of March 2, 2016, with a weighted average exercise price of $6.454 per share.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our 2010 Plan,
	which was adopted by our Board of Directors in February, 2010, and approved by our shareholders in July 2015, provides for the
	grant of options to our and our affiliates&rsquo; respective directors, employees, office holders, service providers and consultants.
	On December 16, 2014, our Board of Directors adopted an appendix to the 2010 Plan for U.S. residents, which was later approved
	by our shareholders. The initial reserved pool under our 2010 plan has been increased by our Board of Directors a number of times,
	and most recently on March 2, 2016.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The 2010 Plan
	is administered by our Board of Directors or by a committee thereof, which shall determine, subject to Israeli and U.S. law, the
	grantees of awards and various terms of the grant. The 2010 Plan provides for granting options in compliance with Section&nbsp;102
	of the Israeli Income Tax Ordinance, 1961, or the Ordinance, and under the United States Revenue Code of 1986, as amended.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Options granted
	under the 2010 Plan to Israeli employees have been granted under the capital gains track of Section&nbsp;102 of the Ordinance.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Section&nbsp;102
	of the Ordinance allows employees, directors and officers, who are not controlling shareholders and are considered Israeli residents,
	to receive favorable tax treatment for compensation in the form of shares or options. Our Israeli non-employee service providers
	and controlling shareholders may only be granted options under Section&nbsp;3(9) of the Ordinance, which does not provide for
	similar tax benefits. Section&nbsp;102 of the Ordinance includes two alternatives for tax treatment involving the issuance of
	options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of
	options or shares directly to the grantee. Section&nbsp;102(b)(2) of the Ordinance, the most favorable tax treatment for grantees,
	permits the issuance to a trustee under the &ldquo;capital gains track.&rdquo; However, under this track we are not allowed to
	deduct an expense with respect to the issuance of the options or shares. In order to comply with the terms of the capital gains
	track, all options granted under the 2010 Plan pursuant and subject to the provisions of Section&nbsp;102 of the Ordinance, as
	well as the ordinary shares issued upon exercise of these options and other shares received subsequently following any realization
	of rights with respect to such options, such as share dividends and share splits, must be granted to a trustee for the benefit
	of the relevant employee, director or officer and should be held by the trustee for at least two years after the date of the grant.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Options granted
	under the 2010 Plan will generally vest over four years commencing on the date of grant such that 25% vest after one year and
	an additional 6.25% vest at the end of each subsequent three-month period thereafter for 36&nbsp;months, or pursuant to a vesting
	schedule that is determined according to pre-specified performance milestones in accordance with company&rsquo;s objectives. Options
	that are not exercised within the pre-specified option term (generally five or ten years from the grant date) expire, unless otherwise
	determined by the Board or its designated committee, as applicable. In case of termination for reasons of disability or death,
	the grantee or his legal successor may exercise options that have vested prior to termination within a period of six months from
	the date of disability or death. If we terminate a grantee's employment or service for cause, all of the grantee's vested and
	unvested options will expire on the date of termination. If a grantee's employment or service is terminated for any other reason,
	the grantee may exercise his or her vested options within 30&nbsp;days of the date of termination. Any expired or unvested options
	return to the pool for reissuance.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the event of
	a merger or consolidation of our company subsequent to which we shall no longer exist as a legal entity, or a sale of all, or
	substantially all, of our shares or assets or other transaction having a similar effect on us, then: (i) pursuant to resolutions
	of our board of directors, 1,836,330 options will become fully vested; (ii) other outstanding options shall be assumed, or an
	equivalent option shall be substituted, by such successor corporation or an affiliate thereof or, in case the successor corporation
	refuses to assume or substitute the option, our Board of Directors or its designated committee may (a)&nbsp;provide the grantee
	with the opportunity to exercise the option as to all or part of the shares, vested or otherwise, and (b)&nbsp;specify a period
	of time, no less than seven days, following which all outstanding options shall terminate.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_008">
</A>
	ITEM
	7.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	MAJOR
	SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	7.A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Major
	shareholders
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: LEFT">
	The following
	table sets forth information regarding the beneficial ownership by each person or entity known to beneficially own more than 5%
	of our ordinary shares as of March 1, 2016, or a different date, if so provided in the table below or footnotes thereof.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	According
	to our transfer agent, as of March 1, 2016, there were three record holders of our ordinary shares, one of which (Cede &amp; Co.,
	the nominee of the Depositary Trust Company) is a U.S. holder holding 99% of our ordinary shares.&nbsp; The number of record holders
	in the United States is not representative of the number of beneficial holders nor is it representative of where such beneficial
	holders are resident since many of these ordinary shares are held by brokers or other nominees. None of our shareholders have different
	voting rights from other shareholders.
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We are not owned
	or controlled, directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement
	that may, at a subsequent date, result in a change of control of our company.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Except as indicated
	in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect
	to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise
	noted below, each beneficial owner&rsquo;s address is: c/o Alcobra Ltd., Azrieli Triangle Building, 132 Derech Menachem Begin,
	39th Floor, Tel Aviv 6701101 Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 92%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Ordinary Shares
<BR>
	Beneficially
	Owned
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Percentage
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT">
	RA Capital Management, LLC, RA Capital Healthcare Fund, L.P and Peter Kolchinsky
	(1)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,032,911
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	11.1
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Franklin Resources, Inc., Charles B. Johnson, Rupert H. Johnson, Jr., Franklin Advisers, Inc.
	(2)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,848,581
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Udi Gilboa (3)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,360,816
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker, Julian C. Baker (4)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,336,359
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Great Point Partners, LLC, Jeffrey R. Jay and David Kroin (5)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,012,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	David M. Slager, Regals Fund LP and Regals Capital Management LP (6)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,716,377
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Venrock Healthcare Capital Partners, L.P., VHCP Co-Investment Holdings, LLC, Venrock Healthcare
	Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, VHCP Management, LLC, VHCP Management II, LLC, Bong Koh and
	Anders Hove (7)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,615,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler (8)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,557,106
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Knoll Capital Management (9)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,115,315
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(1)
</I>
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based
	solely on an Amendment 1 to Schedule 13G filed with the SEC November 18, 2015, and which reflects holdings as of November
	13, 2015.&nbsp;&nbsp;
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(2)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	a Schedule 13G filed with the SEC January 8, 2016, and which reflects holdings as of December 31, 2015.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(3)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	an Amendment 2 to Schedule 13G filed with the SEC on February 16, 2016, and which reflects holdings as of December 31, 2015.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(4)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	a Schedule 13G filed with the SEC on February 16, 2016, and which reflects holdings as of December 31, 2015
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(5)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	an Amendment 1 to Schedule 13G filed with the SEC on February 16, 2016, and which reflects holdings as of December 31, 2015.
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(6)
</I>
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based
	solely on an Amendment 1 to Schedule 13G filed with the SEC on February 16, 2016, and which reflects holdings as of December
	31, 2015.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(7)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	an Amendment 1 to Schedule 13G filed with the SEC on February 16, 2016, and which reflects holdings as of December 31, 2015.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(8)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	an Amendment 1 to Schedule 13G filed with the SEC on February 11, 2016, and which reflects holdings as of December 31, 2015.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(9)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Based solely on
	an Amendment 2 to Schedule 13G filed with the SEC on February 17, 2016, and which reflects holdings as of February 17, 2015.
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	7.B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Related
	party transactions
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Employment Agreements
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	We have entered
	into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying
	duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer
	will continue to receive base salary and benefits. We have also entered into customary non-competition, confidentiality of information
	and ownership of inventions arrangements with our executive officers. However, the enforceability of the noncompetition provisions
	may be limited under applicable law.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Options
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Since our inception
	we have granted options to purchase our ordinary shares to our officers and certain of our directors. Such option agreements may
	contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option plans
	under Item 6.E. Share Ownership &ldquo;Share Option Plans&rdquo; above. If the relationship between us and an executive officer
	or a director is terminated, except for cause (as defined in the various option plan agreements), options that are vested will
	generally remain exercisable for ninety days after such termination.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Indemnification Agreements and Insurance Coverage
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Our amended and
	restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the
	fullest extent permitted by the Israeli Companies Law. We have entered into indemnification agreements with each of our directors
	and other office holders, undertaking to indemnify them to the fullest extent permitted by Israeli law. We have also obtained
	Directors&nbsp;&amp; Officers insurance for each of our officers and directors.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	7.C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Interests
	of experts and counsel
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_009">
</A>
	ITEM
	8.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	FINANCIAL
	INFORMATION
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	8.A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Consolidated
	statements and other financial information
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	See Item 18. Financial Statements.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Legal Proceedings
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	On December 16,
	2014, a class action lawsuit was filed against us and certain of our current and former officers and directors in the United States
	District Court for the Southern District of New York. The complaint, brought by a putative class of investors, alleges, among
	other things, that our officers and directors made false or misleading statements relating to the results of our Phase 3 study
	for our MDX drug candidate. On May 20, 2015, we moved to dismiss the complaint. The motion to dismiss has been fully briefed,
	and oral argument occurred on September 22, 2015, and the court&rsquo;s decision remains pending. Such legal proceedings, regardless
	of their outcome, could be costly, divert management attention, or damage our reputation and demand for our products. Litigation,
	particularly in the United States, is inherently unpredictable and unexpectedly high awards of damages can result if we receive
	an adverse verdict. In many cases, particularly in the United States, the practice of the plaintiffs&rsquo; bar is to claim damages
	(compensatory, punitive and statutory) in extremely high amounts. Accordingly, it is difficult to quantify the potential exposure
	to claims in many proceedings of the type mentioned above. Unfavorable resolution of current and similar future proceedings could
	have a material adverse effect on our financial condition and results of operations. See Item 3.D. Risk Factors &ldquo;We may
	be subject to any number of legal proceedings, which may be expensive and could divert management attention.&rdquo;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Dividends
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We have never
	declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable
	future. Payment of cash dividends, if any, in the future will be at the discretion of our Board of Directors and will depend on
	then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements,
	business prospects and other factors our Board of Directors may deem relevant.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law imposes further restrictions on our ability to declare and pay dividends. See Item 10.B. Articles of Association &ldquo;Dividend
	and Liquidation Rights&rdquo; for additional information.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 23.1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Payment of dividends
	may be subject to Israeli withholding taxes. See Item 10.E. Taxation, for additional information.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	8.B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Significant
	changes
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Except as disclosed
	elsewhere in this annual report, there have been no other significant changes from December 31, 2015, until the date of the filing
	of this annual report.
</P>
</EFX_LEGAL_PROCEEDINGS>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_LISTING>
<A NAME="FIS_LISTING"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_010">
</A>
	ITEM
	9.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	THE
	OFFER AND LISTING
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Offer
	and listing details
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Our ordinary shares
	have been listed on the NASDAQ Capital Market under the symbol &ldquo;ADHD&rdquo; since May 22, 2013. Starting from March 28,
	2014, our ordinary shares have been be listed on the NASDAQ Global Market. Prior to that date, there was no public trading market
	for our ordinary shares. Our initial public offering was priced at $8.00 per share on May 21, 2013. The following table sets forth
	for the periods indicated the high and low sales prices per ordinary share as reported on the NASDAQ Capital Market and the NASDAQ
	Global Market:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Annual Information:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; TEXT-ALIGN: LEFT">
	2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3.12
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	25.44
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Quarterly Information
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	First Quarter 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	17.11
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25.44
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Second Quarter 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	13.63
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Third Quarter 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14.77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	22.19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Fourth Quarter 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	First Quarter 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Second Quarter 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.84
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Third Quarter 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Fourth Quarter 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Monthly Information:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	September 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	October 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	November 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	December 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.66
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	January 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.27
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	February 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.66
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Plan
	of distribution
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Market
	for Ordinary Shares
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Our Ordinary Shares have been quoted
	on the NASDAQ Capital Market since May 22, 2013 under the symbol ADHD. Starting from March 28, 2014, our Shares have been quoted
	on the NASDAQ Global Market.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Selling
	shareholders
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Dilution
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.F.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Expenses
	of the issue
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.3IN; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_LISTING>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_ADDITIONAL_INFORMATION>
<A NAME="FIS_ADDITIONAL_INFORMATION"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_011">
</A>
	ITEM
	10.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	ADDITIONAL
	INFORMATION
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Share
	capital
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.25IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Articles
	of Association
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Securities Register
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT; TEXT-ALIGN: LEFT">
	We are registered
	with the Israeli Registrar of Companies. Our registration number is 51-409899-5. Section 1.2 of our articles of association provides
	that we may engage in any type of lawful business.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Board of Directors
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 21.3PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law requires that certain transactions, actions and arrangements be approved as provided for in a company's articles of association
	and in certain circumstances by the audit committee, the compensation committee, by the board of directors itself and by the shareholders.
	The vote required by the audit committee and the board of directors for approval of such matters, in each case, is a majority
	of the disinterested directors participating in a duly convened meeting. If, however, a majority of the members participating
	in such meeting have a personal interest in the approval of such matter, then all directors may participate in the discussions
	and the voting on approval thereof and in such case the matter shall be subject to further shareholder approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may have concerning
	any existing or proposed transaction with the Company, as well as any substantial information or document with respect thereof.
	An interested office holder's disclosure must be made promptly and in any event no later than the first meeting of the board of
	directors at which the transaction is considered. A personal interest includes an interest of any person in an act or transaction
	of a company, including a personal interest of one's relative or of a corporate body in which such person or a relative of such
	person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one
	director or the general manager, but excluding a personal interest stemming from one's ownership of shares in the Company. A personal
	interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the interest
	of the office holder with respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such
	shareholder itself has no personal interest in the approval of the matter. An office holder is not, however, obliged to disclose
	a personal interest if it derives solely from the personal interest of a relative of such office holder in a transaction that
	is not considered an extraordinary transaction. Under the Israeli Companies Law, an extraordinary transaction is defined as any
	of the following:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.3PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a transaction
	other than in the ordinary course of business;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a transaction
	that is not on market terms; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a transaction
	that may have a material impact on a company's profitability, assets or liabilities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If it is determined
	that an office holder has a personal interest in a transaction, approval by the board of directors is required for the transaction,
	unless the Company's articles of association provide for a different method of approval. Further, so long as an office holder
	has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder
	that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is
	adverse to the Company's interest or that is not performed by the office holder in good faith. Approval first by the Company's
	audit committee and subsequently by the board of directors is required for an extraordinary transaction in which an office holder
	has a personal interest. Arrangements regarding the compensation, indemnification or insurance of an office holder require the
	approval of the compensation committee, board of directors and, in certain circumstances, the shareholders, in that order.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Pursuant to Israeli
	law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling
	shareholder of a public company. In the context of a transaction involving a controlling shareholder or an officer who is a controlling
	shareholder of the Company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting rights
	if no other shareholder holds more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval
	of the same transaction are deemed to be a single shareholder and may be deemed a controlling shareholder for the purpose of approving
	such transaction. Extraordinary transactions, including private placement transactions, with a controlling shareholder or in which
	a controlling shareholder has a personal interest, and engagements with a controlling shareholder or his or her relative, directly
	or indirectly, including through a corporation in his or her control, require the approval of the audit committee, the board of
	directors and the shareholders of the Company, in that order.&nbsp;In addition, the shareholder approval must fulfill one of the
	following requirements:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a disinterested
	majority; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	votes of shareholders who have no personal interest in the transaction and who are present and voting, in person, by proxy
	or by voting deed at the meeting, and who vote against the transaction may not represent more than two percent (2%) of the
	voting rights of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	To the extent
	that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once
	every three years, unless the audit committee determines that the duration of the transaction is reasonable given the circumstances
	related thereto.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Arrangements regarding
	the terms of engagement and compensation of a controlling shareholder who is an office holder, and the terms of employment of
	a controlling shareholder who is an employee of the Company, require the approval of the compensation committee, board of directors
	and, generally, the shareholders, in that order.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our articles of
	association provide that, all actions done bona fide at any meeting of the board of directors or by a committee thereof or by
	any person(s) acting as director(s) will, notwithstanding that it may afterwards be discovered that there was some defect in the
	appointment of the participants in such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them
	were disqualified, be as valid as if there were no such defector disqualification.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Pursuant to the
	Israeli Companies Law, generally a director who has a personal interest in an extraordinary transaction which is brought for discussion
	before our board of directors or its committees shall neither vote in nor attend discussions concerning the approval of such transaction.
	If the director did vote or attend as aforesaid, the approval given to the aforesaid activity or arrangement will generally be
	invalid.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our articles of
	association provide that, subject to the Israeli Companies Law, our board of directors may delegate its authority, in whole or
	in part, to such committees of the board of directors as it deems appropriate, and it may from time to time revoke such delegation.
	To the extent permitted by the Israeli Companies Law, our board of directors may from time to time confer upon and delegate to
	a President, Chief Executive Officer, Chief Operating Officer or other executive officer then holding office, such authorities
	and duties of the board of directors as it deems fit, and they may delegate such authorities and duties for such period and for
	such purposes and subject to such conditions and restrictions which they consider in our best interests, without waiving the authorities
	of the board of directors with respect thereto.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Arrangements regarding
	compensation of directors require the approval of the compensation committee, audit committee, our board of directors and the
	shareholders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Rights, Preferences and Restrictions of Shares
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	General.
</U>
	Our share capital is NIS 500,000, divided into 50,000,000 Ordinary shares NIS 0.01 par value per share.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Ordinary Shares do not have cumulative voting rights in the election of directors. As a result, the holders of Ordinary Shares
	that represent more than 50% of the voting power have the power to elect all the Directors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Dividend
	and liquidation rights.
</U>
	Our board of directors may declare a dividend to be paid to the holders of our Ordinary Shares
	according to their rights and interests in our profits and may fix the record date for eligibility and the time for payment.
	The directors may from time to time pay to the shareholders on account of the next forthcoming dividend such interim dividends
	as, in their judgment, our position justifies. All dividends unclaimed for one year after having been declared may be invested
	or otherwise used by the directors for our benefit until claimed. No unpaid dividend or interest shall bear interest as against
	us. Our board of directors may determine that a dividend may be paid, wholly or partially, by the distribution of certain
	of our assets or by a distribution of paid up shares, debentures or debenture stock or any of our securities or of any other
	companies or in any one or more of such ways in the manner and to the extent permitted by the Israeli Companies Law.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Transfer
	of shares; record dates.
</U>
	Fully paid up Ordinary Shares may be freely transferred pursuant to our amended and restated
	articles of association unless such transfer is restricted or prohibited by another instrument or securities laws. Each shareholder
	who would be entitled to attend and vote at a General Meeting of shareholders is entitled to receive notice of any such meeting.
	For purposes of determining the shareholders entitled to notice and to vote at such meeting, the board of directors will fix
	a record date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Voting;
	annual general and extraordinary meetings.
</U>
	Subject to any rights or restrictions for the time being attached to any class
	or classes of shares, each shareholder shall have one vote for each share of which he or she is the holder, whether on a show
	of hands or on a poll. Our articles of association do not permit cumulative voting and it is not mandated by Israeli law.
	Votes may be given either personally or by proxy. A proxy need not be a shareholder. If any shareholder is without legal capacity,
	he may vote by means of a trustee or a legal custodian, who may vote either personally or by proxy. If two or more persons
	are jointly entitled to a share then, in voting upon any question, the vote of the senior person who tenders a vote, whether
	in person or by proxy, shall be accepted to the exclusion of the votes of the other registered holders of the share and, for
	this purpose seniority shall be determined by the order in which the names stand in the shareholder register.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Quorum
	for general meetings.
</U>
	The quorum required for our general meetings of shareholders consists of at least two shareholders
	present in person, by proxy or written ballot who holds or represent between them at least one-third of the total outstanding
	voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the
	same time and place or to a later time/date if so specified in the summons or notice of the meeting. At the reconvened meeting,
	any two or more shareholders present in person or by proxy shall constitute a lawful quorum.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.3IN">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notice
	of general meetings.
</U>
	Unless a longer period for notice is prescribed by the Israeli Companies Law, at least 10 days and
	not more than 60 days&rsquo; notice of any general meeting shall be given, specifying the place, the day and the hour of the
	meeting and, in the case of special business, the nature of such business, shall be given in the manner hereinafter mentioned,
	to such shareholders as are under the provisions of our articles of association, entitled to receive notices from us. Only
	shareholders of record as reflected on our share register at the close of business on the date fixed by the board of directors
	as the record date determining the then shareholders who will be entitled to vote, shall be entitled to notice of, and to
	vote, in person or by proxy, at a general meeting and any postponement or adjournment thereof.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Annual;
	agenda; calling a general meeting.
</U>
	General Meetings are held at least once in every calendar year at such time (within
	a period of 15 months after the holding of the last preceding General Meeting), and at such time and place as may be determined
	by the board of directors. At a General Meeting, decisions shall be adopted only on matters that were specified on the agenda.
	The board of directors is obligated to call extraordinary general meeting of the shareholders upon a written request in accordance
	with the Israeli Companies Law. The Israeli Companies Law provides that an extraordinary general meeting of shareholder may
	be called by the board of directors or by a request of two directors or 25% of the directors in office, or by shareholders
	holding at least 5% of the issued share capital of the company and at least 1% of the voting rights, or of shareholders holding
	at least 5% of the voting rights of the company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Majority
	vote.
</U>
	Except as otherwise provided in the articles of association, any resolution at a General Meeting shall be deemed
	adopted if approved by the holders of a majority of our voting rights represented at the meeting in person or by proxy and
	voting thereon. In the case of an equality of votes, the chairman of the meeting shall not be entitled to a further vote.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; TEXT-DECORATION: NONE; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Discrimination
	against shareholders.
</U>
	According to our articles of association, there are no discriminating provisions against any existing
	or prospective holders of our shares as a result of a shareholder holding a substantial number of shares.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Modification of Class Rights
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If, at any time,
	the share capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by
	the terms of issuance of the shares of that class) may be varied with the consent in writing of the holders of all the issued
	shares of that class, or with the sanction of a majority vote at a meeting of the shareholders passed at a separate meeting of
	the holders of the shares of the class. The provisions of our articles of association relating to general meetings shall apply,
	mutatis mutandis, to every such separate general meeting. Any holder of shares of the class present in person or by proxy may
	demand a secret poll.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Unless otherwise
	provided by the conditions of issuance, the enlargement of an existing class of shares, or the issuance of additional shares thereof,
	shall not be deemed to modify or abrogate the rights attached to the previously issued shares of such class or of any other class.
	These conditions provide for the minimum shareholder approvals permitted by the Israeli Companies Law.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Restrictions on Shareholders Rights to Own Securities
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our articles of
	association and the laws of the State of Israel do not restrict in any way the ownership or voting or our shares by non-residents
	of Israel, except with respect to subjects of countries which are in a state of war with Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Acquisitions under Israeli Law
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Full tender offer
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A person wishing
	to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s issued and
	outstanding share capital is required by the Israeli Companies Law to make a tender offer to all of the company&rsquo;s shareholders
	for the purchase of all of the issued and outstanding shares of the company.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A person wishing
	to acquire shares of an Israeli public company and who would as a result hold over 90% of the issued and outstanding share capital
	of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the same class for
	the purchase of all of the issued and outstanding shares of the same class.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If the shareholders
	who do not respond to or accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the
	applicable class of the shares, and more than half of the shareholders who do not have a personal interest in the offer accept
	the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However,
	a tender offer will be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share
	capital of the company or of the applicable class of the shares.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Upon a successful
	completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted
	the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition the Israeli court to
	determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court.
	However, under certain conditions, the offeror may determine in the terms of the tender offer that an offeree who accepted the
	offer will not be entitled to petition the Israeli court as described above.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If the shareholders
	who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or
	of the applicable class, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of
	the company&rsquo;s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender
	offer.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Special tender offer
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as
	a result of the acquisition the purchaser would become a holder of at least 25% of the voting rights in the company. This rule
	does not apply if there is already another holder of at least 25% of the voting rights in the company.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Similarly, the
	Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer
	if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if
	there is no other shareholder of the company who holds more than 45% of the voting rights in the company.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	These requirements
	do not apply if the acquisition (i)&nbsp;occurs in the context of a private offering, on the condition that the shareholders meeting
	approved the acquisition as a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the
	company if there is no person who holds at least 25% of the voting rights in the company, or as a private offering whose purpose
	is to give the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the
	company; (ii)&nbsp;was from a shareholder holding at least 25% of the voting rights in the company and resulted in the acquirer
	becoming a holder of at least 25% of the voting rights in the company; or (iii)&nbsp;was from a holder of more than 45% of the
	voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The special tender
	offer may be consummated only if (i)&nbsp;at least 5% of the voting power attached to the company&rsquo;s outstanding shares will
	be acquired by the offeror and (ii)&nbsp;the special tender offer is accepted by a majority of the votes of those offerees who
	gave notice of their position in respect of the offer; in counting the votes of offerees, the votes of a holder of control in
	the offeror, a person who has personal interest in acceptance of the special tender offer, a holder of at least 25% of the voting
	rights in the company, or any person acting on their or on the offeror&rsquo;s behalf, including their relatives or companies
	under their control, are not taken into account.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the event that
	a special tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability of
	the offer or shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	An office holder
	in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure
	of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser
	and shareholders for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds
	to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with
	the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties
	in order to obtain a competing offer.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If a special tender
	offer was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who did not respond
	to the special offer or had objected to the special tender offer may accept the offer within four days of the last day set for
	the acceptance of the offer.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the event that
	a special tender offer is accepted, then the purchaser or any person or entity controlling it and any corporation controlled by
	them shall refrain from making a subsequent tender offer for the purchase of shares of the target company and may not execute
	a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity
	undertook to effect such an offer or merger in the initial special tender offer.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Merger
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law permits merger transactions if approved by each party&rsquo;s board of directors and, unless certain requirements described
	under the Israeli Companies Law are met, a majority of each party&rsquo;s shareholders, by a majority of each party&rsquo;s shares
	that are voted on the proposed merger at a shareholders&rsquo; meeting.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The board of directors
	of a merging company is required pursuant to the Israeli Companies Law to discuss and determine whether in its opinion there exists
	a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations
	towards its creditors, taking into account the financial condition of the merging companies. If the board of directors has determined
	that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of
	the merging companies, the boards of directors must jointly prepare a merger proposal for submission to the Israeli Registrar
	of Companies.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	For purposes of
	the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares voting
	at the shareholders meeting (excluding abstentions) that are held by parties other than the other party to the merger, any person
	who holds 25% or more of the means of control of the other party to the merger or any one on their behalf including their relatives
	or corporations controlled by any of them, vote against the merger.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If the transaction
	would have been approved but for the separate approval of each class of shares or the exclusion of the votes of certain shareholders
	as provided above, a court may still rule that the company has approved the merger upon the request of holders of at least 25%
	of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal
	of the merging companies&rsquo; value and the consideration offered to the shareholders.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Israeli
	Companies Law, each merging company must send a copy of the proposed merger plan to its secured creditors. Unsecured creditors
	are entitled to receive notice of the merger, as provided by the regulations promulgated under the Israeli Companies Law. Upon
	the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that
	there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations
	of the target company. The court may also give instructions in order to secure the rights of creditors.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In addition, a
	merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed
	with the Israeli Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Potential Issues that Could Delay a Merger
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Certain provisions
	of Israeli corporate and tax law may have the effect of delaying, preventing or making more difficult any merger or acquisition
	of us. For example, any merger or acquisition of us will require the prior consent of the Chief Scientist, as well as the Investment
	Center. See Item 3.D. Risk factors &ldquo;We are subject to anti-takeover provisions that could delay or prevent our acquisition
	by another entity.&rdquo;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Requirement of Disclosure of Shareholder Ownership
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	There are no provisions
	of our articles of association governing the ownership threshold above which shareholder ownership must be disclosed. We are subject,
	however, to U.S. securities rules that require beneficial owners of more than 5% of our ordinary Shares to make certain filings
	with the SEC.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Changes in Capital
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our articles of
	association do not impose any conditions governing changes in capital that are more stringent than required by the Israeli Companies
	Law.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Material
	contracts
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	None.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exchange
	controls
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	There are currently
	no Israeli currency control restrictions on payments of dividends or other distributions with respect to our ordinary shares or
	the proceeds from the sale of shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding
	certain transactions. However, legislation remains in effect pursuant to which currency controls can be imposed by administrative
	action at any time.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Non-residents
	of Israel who purchase our securities with non-Israeli currency will be able to repatriate dividends (if any), liquidation distributions
	and the proceeds of any sale of such securities, into non-Israeli currencies at the rate of exchange prevailing at the time of
	repatriation, provided that any applicable Israeli taxes have been paid (or withheld) on such amounts.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Neither our articles
	of association nor the laws of the State of Israel restrict in any way the ownership or voting of ordinary shares by non-residents
	of Israel, except with respect to citizens of countries that are in a state of war with Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Taxation
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The following
	is a summary of the current tax structure, which is applicable to companies in Israel, with special reference to its effect on
	us. The following also contains a discussion of material Israeli and U.S. tax consequences to persons purchasing our Ordinary
	Shares and government programs from which we and some of our group companies benefit. To the extent that the discussion is based
	on new tax legislation, which has yet to be subject to judicial or administrative interpretation, there can be no assurance that
	the views expressed in the discussion will accord with any such interpretation in the future. The discussion is not intended and
	should not be construed as legal or professional tax advice and is not exhaustive of all possible tax considerations. An Israeli
	company that is subject to Israeli taxes on the income of its non-Israeli subsidiaries will receive a credit for income taxes
	paid/withheld or that will be paid/withheld by the subsidiary in its country of residence, according to the terms and conditions
	determined in the Israeli Tax Ordinance.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The following
	summary is included herein as general information only and is not intended as a substitute for careful tax planning. Accordingly,
	each investor should consult his or her own tax advisor as to the particular tax consequences to such investor of the purchase,
	ownership or sale of an ordinary share, including the effect of applicable state, local, foreign or other tax laws and possible
	changes in tax laws.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<U>
	Israeli Taxation Considerations
</U>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The following
	is a summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli
	income tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the
	aspects of Israeli income tax law that may be relevant to a particular investor in light of his or her personal investment circumstances
	or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents
	of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. To the extent that the
	discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot
	assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. This summary
	is based on laws and regulations in effect as of the date of this annual report and does not take into account possible future
	amendments which may be under consideration.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	General corporate tax structure in Israel
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	As of January
	1, 2016, Israeli resident companies, such as us, are generally subject to corporate tax at the rate of 25%. Between January 1,
	2014 and December 31, 2015, the corporate tax rate was 26.5%.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Capital gains
	derived by an Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli
	tax legislation, a corporation will be considered as an &ldquo;Israeli Resident&rdquo; if it meets one of the following: (a) it
	was incorporated in Israel; or (b) the control and management of its business are exercised in Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Taxation of our Israeli individual shareholders on receipt
	of dividends
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Israeli residents
	who are individuals are generally subject to Israeli income tax for dividends paid on our ordinary shares (other than bonus shares
	or share dividends) at a rate of 25%, or 30% if the recipient of such dividend is a &quot;substantial shareholder&rdquo; (as defined
	below) at the time of distribution or at any time during the preceding 12-month period.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	As of January
	1, 2016, an additional income tax at a rate of 2% will be imposed on high earners whose annual income or gain exceeds NIS 803,520.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A &ldquo;substantial
	Shareholder&rdquo; is generally a person who alone, or together with his relative or another person who collaborates with him
	on a regular basis, holds, directly or indirectly, at least 10% of any of the &ldquo;means of control&rdquo; of the corporation.
	&ldquo;Means of control&rdquo; generally include the right to vote in a general meeting of shareholders, receive profits, nominate
	a director or an officer, receive assets upon liquidation, or instruct someone who holds any of the aforesaid rights regarding
	the manner in which he or she is to exercise such right(s), and all regardless of the source of such right.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The term &ldquo;Israeli
	Resident&rdquo; is generally defined under Israeli tax legislation with respect to individuals as a person whose center of life
	is in Israel. The Israeli Tax Ordinance New Version, 1961 (as amended by Amendment Law No. 132 of 2002) (the &ldquo;Israeli Tax
	Ordinance&rdquo;) determines that in order to determine the center of life of an individual, account will be taken of the individual&rsquo;s
	family, economic and social connections, including: (a) place of permanent home; (b) place of residential dwelling of the individual
	and the individual&rsquo;s immediate family; (c) place of the individual&rsquo;s regular or permanent occupation or the place
	of his permanent employment; (d) place of the individual&rsquo;s active and substantial economic interests; (e) place of the individual&rsquo;s
	activities in organizations, associations and other institutions. The center of life of an individual will be presumed to be in
	Israel if: (a) the individual was present in Israel for 183 days or more in the tax year; or (b) the individual was present in
	Israel for 30 days or more in the tax year, and the total period of the individual&rsquo;s presence in Israel in that tax year
	and the two previous tax years is 425 days or more. The presumption in this paragraph may be rebutted either by the individual
	or by the assessing officer.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Taxation of Israeli Resident Corporations on Receipt
	of Dividends
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Israeli resident
	corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on our ordinary shares.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Capital Gains Taxes Applicable to Israeli Resident Shareholders
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The income tax
	rate applicable to Real Capital Gain derived by an Israeli individual from the sale of shares which had been purchased after January
	1, 2012, whether listed on a stock exchange or not, is 25%. However, if such shareholder is considered a &ldquo;Substantial Shareholder&rdquo;
	(as defined above) at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate
	of 30%. As of January 1, 2016, an additional tax at a rate of 2% will be imposed on high earners whose annual income or gains
	exceed NIS 803,520.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Moreover, capital
	gains derived by a shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary
	business income, are taxed in Israel at ordinary income rates (currently, 25% for corporations and up to 50% for individuals).
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Taxation of Non-Israeli Shareholders on Receipt of Dividends
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Non-Israeli residents
	are generally subject to Israeli income tax on the receipt of dividends paid on our Shares at the rate of 25% (or 30% for individuals,
	if such person is a &ldquo;substantial shareholder&rdquo; at the time receiving the dividend or on any date in the 12 months preceding
	such date), which tax will be withheld at source, unless a lower tax rate is provided in a tax treaty between Israel and the shareholder&rsquo;s
	country of residence.
</P>
<!-- FIELD: PAGE; SEQUENCE: 69 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A non-Israeli
	resident who receives dividends from which tax was withheld is generally exempt from the duty to file returns in Israel in respect
	of such income; provided such income was not derived from a business conducted in Israel by the taxpayer, and the taxpayer has
	no other taxable sources of income in Israel.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	For example, under
	the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes on Income,
	as amended (the &ldquo;U.S.-Israel Tax Treaty&rdquo;), Israeli withholding tax on dividends paid to a U.S. resident for treaty
	purposes may not, in general, exceed 25%, or 15% in the case of dividends paid out of the profits of a Benefited Enterprise, subject
	to certain conditions. Where the recipient is a U.S. corporation owning 10% or more of the voting shares of the paying corporation
	during the part of the paying corporation&rsquo;s taxable year which precedes the date of payment of the dividend and during the
	whole of its prior taxable year (if any) and the dividend is not paid from the profits of a Benefited Enterprise, the Israeli
	tax withheld may not exceed 12.5%, subject to certain conditions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Capital gains income taxes applicable to non-Israeli
	shareholders.
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Non-Israeli resident
	shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of
	our ordinary shares, provided that such gains were not derived from a permanent establishment or business activity of such shareholders
	in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions if an Israeli resident (i) has a
	controlling interest of more than 25% in such non-Israeli corporation or (ii) is the beneficiary of or is entitled to 25% or more
	of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Regardless of
	whether shareholders may be liable for Israeli income tax on the sale of our ordinary shares, the payment of the consideration
	may be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they
	are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Estate and gift tax
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Israeli law presently does not impose
	estate or gift taxes.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<U>
	United States Federal Income Tax Consequences
</U>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	THE FOLLOWING
	SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX
	ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES
	OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX
	LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	U.S. Federal Income Taxation
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Subject to the
	limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences
	to a &quot;U.S. Holder&quot; arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &quot;U.S.
	Holder&quot; is a holder of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an
	alien individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under
	U.S. federal income tax laws; (2) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes)
	or a partnership (other than a partnership that is not treated as a U.S. person under any applicable U.S. Treasury Regulations)
	created or organized in or under the laws of the United States or the District of Columbia or any political subdivision thereof;
	(3) an estate, the income of which is subject to U.S. federal income tax regardless of source; (4) a trust if a court within the
	United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority
	to control all substantial decisions of the trust; (5) a trust that has a valid election in effect to be treated as a U.S. person
	to the extent provided in U.S. Treasury regulations; or (6) any person otherwise subject to U.S. federal income tax on a net income
	basis in respect of the Ordinary Shares, if such status as a U.S. Holder is not overridden pursuant to the provisions of an applicable
	tax treaty.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	This summary is
	for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income
	tax considerations that may be relevant to a decision to purchase or hold our Ordinary Shares. This summary generally considers
	only U.S. Holders that will own our Ordinary Shares as capital assets. Except to the limited extent discussed below, this summary
	does not consider the U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable
	to determine a taxpayer's status as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986,
	as amended, or the Code, final, temporary and proposed U.S. Treasury Regulations promulgated thereunder, administrative and judicial
	interpretations thereof, and the U.S./Israel Income Tax Treaty, all as in effect as of the date hereof and all of which are subject
	to change, possibly on a retroactive basis, and all of which are open to differing interpretations. The Company will not seek
	a ruling from the U.S. Internal Revenue Service, or the IRS, with regard to the U.S. federal income tax treatment of an investment
	in our Ordinary Shares by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions
	set forth below.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	This discussion
	does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular shareholder based on
	such shareholder's particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer,
	state, local or foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment
	of a U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution or &ldquo;financial
	services entity&rdquo;; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares
	in connection with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum
	tax; (5) a U.S. Holder that holds our Ordinary Shares as a hedge or as part of a hedging, straddle, conversion or constructive
	sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate
	investment trusts; (8) a U.S. Holder that expatriates out of the United States or a former long-term resident of the United States;
	or (9) a person having a functional currency other than the U.S. dollar. This discussion does not address the U.S. federal income
	tax treatment of a U.S. Holder that owns, directly or constructively, at any time, Ordinary Shares representing 10% or more of
	our voting power. Additionally, the U.S. federal income tax treatment of persons who hold Ordinary Shares through a partnership
	or other pass-through entity are not considered.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	You are encouraged
	to consult your own tax advisor with respect to the specific U.S. federal and state income tax consequences to you of purchasing,
	holding or disposing of our Ordinary Shares, including the effects of applicable state, local, foreign or other tax laws and possible
	changes in the tax laws.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Distributions on Ordinary Shares
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Subject to the
	discussion under the heading &ldquo;Passive Foreign Investment Companies&rdquo; below, a U.S. Holder will be required to include
	in gross income as ordinary income the amount of any distribution paid on Ordinary Shares (including the amount of any Israeli
	tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current and accumulated
	earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings
	and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder's tax basis for the Ordinary Shares
	to the extent thereof, and then capital gain. Corporate holders generally will not be allowed a deduction for dividends received.
	For noncorporate U.S. Holders, to the extent that their total adjusted income does not exceed applicable thresholds, the maximum
	federal income tax rate for &ldquo;qualified dividend income&rdquo; and long-term capital gains is generally 15%. For those noncorporate
	U.S. Holders whose total adjusted income exceeds such income thresholds, the maximum federal income tax rate for &ldquo;qualified
	dividend income&rdquo; and long-term capital gains is generally 20%. For this purpose, &ldquo;qualified dividend income&rdquo;
	means,
<I>
	inter alia
</I>
	, dividends received from a &ldquo;qualified foreign corporation.&rdquo; A &ldquo;qualified foreign corporation&rdquo;
	is a corporation that is entitled to the benefits of a comprehensive tax treaty with the United States which includes an exchange
	of information program. The IRS has stated that the Israel/U.S. Tax Treaty satisfies this requirement and we believe we are eligible
	for the benefits of that treaty.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In addition, our
	dividends will be qualified dividend income if our Ordinary Shares are readily tradable on NASDAQ or another established securities
	market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend
	is paid or in the prior year, as a passive foreign investment company, or PFIC. A U.S. Holder will not be entitled to the preferential
	rate: (1) if the U.S. Holder has not held our Ordinary Shares or ADRs for at least 61 days of the 121 day period beginning on
	the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related
	payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our Ordinary
	Shares are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income
	as &ldquo;investment income&rdquo; pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The amount of
	a distribution with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property distributed,
	and for U.S. federal income tax purposes, the amount of any Israeli taxes withheld therefrom. (See discussion above under &ldquo;Israeli
	Taxation Considerations - Taxation of Our Shareholders &ndash; Dividends.&rdquo;) Cash distributions paid by us in NIS will be
	included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the
	dividend is includible in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income
	tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently converts the NIS, any subsequent gain or loss in
	respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Distributions
	paid by us will generally be foreign source income for U.S. foreign tax credit purposes. Subject to the limitations set forth
	in the Code, U.S. Holders may elect to claim a foreign tax credit against their U.S. income tax liability for Israeli income tax
	withheld from distributions received in respect of the Ordinary Shares. In general, these rules limit the amount allowable as
	a foreign tax credit in any year to the amount of regular U.S. tax for the year attributable to foreign source taxable income.
	This limitation on the use of foreign tax credits generally will not apply to an electing individual U.S. Holder whose creditable
	foreign taxes during the year do not exceed $300, or $600 for joint filers, if such individual's gross income for the taxable
	year from non-U.S. sources consists solely of certain passive income. A U.S. Holder will be denied a foreign tax credit with respect
	to Israeli income tax withheld from dividends received with respect to the Ordinary Shares if such U.S. Holder has not held the
	Ordinary Shares for at least 16 days out of the 31-day period beginning on the date that is 15 days before the ex-dividend date
	or to the extent that such U.S. Holder is under an obligation to make certain related payments with respect to substantially similar
	or related property. Any day during which a U.S. Holder has substantially diminished his or her risk of loss with respect to the
	Ordinary Shares will not count toward meeting the 16-day holding period. A U.S. Holder will also be denied a foreign tax credit
	if the U.S. Holder holds the Ordinary Shares in an arrangement in which the U.S. Holder's reasonably expected economic profit
	is insubstantial compared to the foreign taxes expected to be paid or accrued. The rules relating to the determination of the
	U.S. foreign tax credit are complex, and U.S. Holders should consult with their own tax advisors to determine whether, and to
	what extent, they are entitled to such credit. U.S. Holders that do not elect to claim a foreign tax credit may instead claim
	a deduction for Israeli income taxes withheld, provided such U.S. Holders itemize their deductions.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Disposition of Shares
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Except as provided
	under the PFIC rules described below, upon the sale, exchange or other disposition of our Ordinary Shares, a U.S. Holder will
	recognize capital gain or loss in an amount equal to the difference between such U.S. Holder's tax basis in the sold Ordinary
	Shares and the amount realized on the disposition of such Ordinary Shares (or its U.S. dollar equivalent determined by reference
	to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The gain
	or loss realized on the sale or exchange or other disposition of Ordinary Shares will be long-term capital gain or loss if the
	U.S. Holder has a holding period of more than one year at the time of the disposition.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In general, gain
	realized by a U.S. Holder on a sale, exchange or other disposition of Ordinary Shares will generally be treated as U.S. source
	income for U.S. foreign tax credit purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of Ordinary
	Shares is generally allocated to U.S. source income. However, U.S. Treasury Regulations require such loss to be allocated to foreign
	source income to the extent specified dividends were received by the taxpayer within the 24-month period preceding the date on
	which the taxpayer recognized the loss. The deductibility of a loss realized on the sale, exchange or other disposition of Ordinary
	Shares is subject to limitations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Tax on Net Investment Income
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	U.S. Holders who
	are individuals, estates or trusts will generally be required to pay a 3.8% tax on their net investment income (including dividends
	on and gains from the sale or other disposition of our Ordinary Shares), or in the case of estates and trusts on their net investment
	income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder's total adjusted
	income exceeds applicable thresholds.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Passive Foreign Investment Companies
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Special U.S. federal
	income tax laws apply to a U.S. Holder who owns shares of a corporation that was (at any time during the U.S. Holder's holding
	period) a PFIC. We would be treated as a PFIC for U.S. federal income tax purposes for any tax year if, in such tax year, either:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	75%
	or more of our gross income (including our pro rata share of gross income for any company, U.S. or foreign, in which we are
	considered to own 25% or more of the shares by value), in a taxable year is passive (the &ldquo;Income Test&rdquo;); or
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: SYMBOL; FONT-SIZE: 10PT">
	&middot;
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	At
	least 50% of our assets, averaged over the year and generally determined based upon value (including our pro rata share of
	the assets of any company in which we are considered to own 25% or more of the shares by value), in a taxable year are held
	for the production of, or produce, passive income (the &ldquo;Asset Test&rdquo;).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-INDENT: -0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	For this purpose,
	passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions
	and from notional principal contracts. Cash is treated as generating passive income.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	If we are or become
	a PFIC, each U.S. Holder who has not elected to treat us as a qualified electing fund by making a &ldquo;QEF election&rdquo;,
	or who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions by us and
	upon disposition of our Ordinary Shares at a gain, be liable to pay U.S. federal income tax at the then prevailing highest tax
	rates on ordinary income plus interest on such tax, as if the distribution or gain had been recognized ratably over the taxpayer's
	holding period for the Ordinary Shares. In addition, when shares of a PFIC are acquired by reason of death from a decedent that
	was a U.S. Holder, the tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent's
	death, but instead would be equal to the decedent's basis if lower, unless all gain were recognized by the decedent. Indirect
	investments in a PFIC may also be subject to special U.S. federal income tax rules.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The PFIC rules
	would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the Ordinary Shares
	while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such
	a QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder's
<I>
	pro rata
</I>
	share
	of our ordinary earnings as ordinary income and such U.S. Holder's
<I>
	pro rata
</I>
	share of our net capital gains as long-term
	capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective
	only if we make available certain required information. The QEF election is made on a shareholder-by-shareholder basis and generally
	may be revoked only with the consent of the IRS. U.S. Holders should consult with their own tax advisors regarding eligibility,
	manner and advisability of making a QEF election if we are treated as a PFIC.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A U.S. Holder
	of PFIC shares which are traded on qualifying public markets, including the NASDAQ, can elect to mark the shares to market annually,
	recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between
	the fair market value of the PFIC shares and the U.S. Holder's adjusted tax basis in the PFIC shares. Losses are allowed only
	to the extent of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Based on the nature
	of our business, the projected composition of our income and the projected composition and estimated fair market values of our
	assets, we believe that we may be deemed a PFIC. In particular, in light of the complexity of PFIC rules, we cannot assure you
	that we have not been a PFIC in prior years or are not a PFIC or will avoid becoming a PFIC in the future. U.S. Holders who hold
	Ordinary Shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC, subject
	to specified exceptions for U.S. Holders who made a QEF or mark-to-market election. U.S. Holders are strongly urged to consult
	their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences
	to them of making a QEF or mark-to-market election with respect to our Ordinary Shares in the event we that qualify as a PFIC.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Information Reporting and Withholding
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A U.S. Holder
	may be subject to backup withholding (at a rate of 28%) with respect to cash dividends and proceeds from a disposition of Ordinary
	Shares. In general, back-up withholding will apply only if a U.S. Holder fails to comply with specified identification procedures.
	Backup withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt
	organizations. Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax
	liability of a U.S. Holder, provided that the required information is timely furnished to the IRS.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Under the Hiring
	Incentives to Restore Employment Act of 2010 (the &ldquo;HIRE Act&rdquo;), some payments made to &ldquo;foreign financial institutions&rdquo;
	in respect of accounts of U.S. stockholders at such financial institutions may be subject to withholding at a rate of 30%. U.S.
	Treasury Regulations provide that such withholding will only apply to distributions paid on or after January 1, 2014, and to other
	&ldquo;withholdable payments&rdquo; (including payments of gross proceeds from a sale or other disposition of our Ordinary Shares)
	made on or after January 1, 2017. U.S. Holders should consult their tax advisors regarding the effect, if any, of the HIRE Act
	on their ownership and disposition of our Ordinary Shares. See &ldquo;Non-U.S. Holders of Ordinary Shares,&rdquo; below.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Non-U.S. Holders of Ordinary Shares
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Except as provided
	below, an individual, corporation, estate or trust that is not a U.S. Holder generally will not be subject to U.S. federal income
	or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our Ordinary Shares.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A non-U.S. Holder
	may be subject to U.S. federal income or withholding tax on a dividend paid on our Ordinary Shares or the proceeds from the disposition
	of our Ordinary Shares if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business
	in the United States or, in the case of a non-U.S. Holder that is a resident of a country which has an income tax treaty with
	the United States, such item is attributable to a permanent establishment or, in the case of gain realized by an individual non-U.S.
	Holder, a fixed place of business in the United States; (2) in the case of a disposition of our Ordinary Shares, the individual
	non-U.S. Holder is present in the United States for 183 days or more in the taxable year of the sale and other specified conditions
	are met; (3) the non-U.S. Holder is subject to U.S. federal income tax pursuant to the provisions of the U.S. tax law applicable
	to U.S. expatriates.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In general, non-U.S.
	Holders will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares if payment is
	made through a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United
	States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides
	on an applicable Form W-8 (or a substantially similar form) a taxpayer identification number, certifies to its foreign status,
	or otherwise establishes an exemption. A U.S. related person for these purposes is a person with one or more current relationships
	with the United States.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The amount of
	any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder's U.S. federal income
	tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The HIRE Act may
	impose withholding taxes on some types of payments made to &ldquo;foreign financial institutions&rdquo; and some other non-U.S.
	entities. Under the HIRE Act, the failure to comply with additional certification, information reporting and other specified requirements
	could result in withholding tax being imposed on payments of dividends and sales proceeds to U.S. Holders that own Ordinary Shares
	through foreign accounts or foreign intermediaries and specified non-U.S. Holders. The HIRE Act imposes a 30% withholding tax
	on dividends on, and gross proceeds from the sale or other disposition of, Ordinary Shares paid from the United States to a foreign
	financial institution or to a foreign nonfinancial entity, unless (1) the foreign financial institution undertakes specified diligence
	and reporting obligations or (2) the foreign nonfinancial entity either certifies it does not have any substantial U.S. owners
	or furnishes identifying information regarding each substantial U.S. owner. In addition, if the payee is a foreign financial institution,
	it generally must enter into an agreement with the U.S. Treasury that requires, among other things, that it undertake to identify
	accounts held by specified U.S. persons or U.S.-owned foreign entities, annually report certain information about such accounts,
	and withhold 30% on payments to other specified account holders. U.S. Treasury Regulations provide that such withholding will
	only apply to distributions paid on or after January 1, 2014, and to other &ldquo;withholdable payments&rdquo; (including payments
	of gross proceeds from a sale or other disposition of our Ordinary Shares) made on or after January 1, 2017. You should consult
	your tax advisor regarding the HIRE Act.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.F.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Dividends
	and paying agents
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.G.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Statement
	by experts
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 73 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.H.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Documents
	on display
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We are subject
	to certain of the information reporting requirements of the Exchange Act, or the Exchange Act. As a foreign private issuer, we
	are exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and
	our officers, directors and principal shareholders are exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery
	provisions contained in Section 16 of the Exchange Act, with respect to their purchase and sale of our shares. In addition, we
	are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
	are registered under the Exchange Act. However, we are required to file with the SEC, within four months after the end of each
	fiscal year, an annual report on Form 20-F containing financial statements audited by an independent accounting firm. We publish
	unaudited interim financial information after the end of each quarter. We furnish this quarterly financial information to the
	SEC under cover of a Form 6-K.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	You may read and
	copy any document we file with the SEC at its public reference facilities at 100 F Street, NE, Washington, D.C. 20549. You may
	also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street,
	NE, Washington, D.C. 20549. The SEC also maintains a website that contains reports, proxy and information statements and other
	information regarding registrants that file electronically with the SEC. The address of this website is http://www.sec.gov. Please
	call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.I.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Subsidiary
	information
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Not applicable.
</P>
</EFX_ADDITIONAL_INFORMATION>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_012">
</A>
	ITEM
	11.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	QUANTITATIVE
	AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In the ordinary course of our operations,
	we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Quantitative and Qualitative Disclosure About Market
	Risk
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We are exposed
	to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
	position due to adverse changes in financial market prices and rates. Our current investment policy was drafted to: (i) preserve
	principal (capital); (ii) maintain liquidity in accordance with cash flow requirements; and (iii) maximize the rate of return
	within the stated guidelines in the policy. Accordingly, a majority of our cash and cash equivalents is held in deposits that
	bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced.
	Our investment policy is monitored by the Company&rsquo;s Audit Committee.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our market risk
	exposure is primarily a result of foreign currency exchange rates, which is discussed in detail in the following paragraph.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Foreign Currency Exchange Risk
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	Our results of
	operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. The vast majority of our
	liquid assets is held in U.S. dollars, and a certain portion of our expenses is denominated in NIS. For instance, in 2015, approximately
	20% of our expenses were denominated in NIS. Changes of 5% and 10% in the $/NIS exchange rate would have increased/decreased the
	operation expenses by 0.95% and 1.81%, respectively. However, these historical figures may not be indicative of future exposure,
	as we expect that the percentage of our NIS denominated expenses will decrease in the future, therefore further reducing our exposure
	to exchange rate fluctuations.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	We do not hedge
	our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk
	of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however,
	may not adequately protect us from the material adverse effects of such fluctuations.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_OTHER_SECURITIES>
<A NAME="FIS_OTHER_SECURITIES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_013">
</A>
	ITEM
	12.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	DESCRIPTION
	OF SECURITIES OTHER THAN EQUITY SECURITIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 22.5PT">
	The Company does
	not have any outstanding American Depositary Shares or American Depositary Receipts.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: CENTER; TEXT-INDENT: -1IN">
<B>
<U>
<A NAME="V432397_20F_HTM_NOTE_014">
</A>
	PART
	TWO
</U>
</B>
</P>
</EFX_OTHER_SECURITIES>
</EFX_PART_I>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<EFX_DEFAULTS>
<A NAME="FIS_DEFAULTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_015">
</A>
	ITEM
	13.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	DEFAULTS,
	DIVIDEND ARREARAGES AND DELINQUENCIES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	None.
</P>
</EFX_DEFAULTS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 70.9PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -70.9PT">
	&nbsp;
</P>
<EFX_MATERIAL_MODIFICATIONS>
<A NAME="FIS_MATERIAL_MODIFICATIONS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_016">
</A>
	ITEM
	14.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	MATERIAL
	MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	None.
</P>
</EFX_MATERIAL_MODIFICATIONS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_017">
</A>
	ITEM
	15.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	CONTROLS
	AND PROCEDURES
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	(a) Disclosure Controls and Procedures
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our management,
	with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure
	controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2015,
	or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure
	controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required
	to be included in periodic filings under the Exchange Act and that such information is accumulated and communicated to management,
	including our principal executive and financial officers,&nbsp;as appropriate to allow timely decisions regarding required disclosure.
</P>
<!-- FIELD: PAGE; SEQUENCE: 74 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	(b) Management's Annual Report on
	Internal Control over Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our management
	is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in
	Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief
	Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial
	reporting based principally on the framework and criteria established in Internal Control - Integrated Framework (2013) issued
	by the Committee of Sponsoring Organizations of the Treadway Commission as of the end of the period covered by this report. Based
	on that evaluation, our management has concluded that our internal control over financial reporting was effective as of December
	31, 2015 at providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
	for external purposes in accordance with generally accepted accounting principles.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	(c) Attestation Report of the Registered
	Public Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	This annual report
	does not include an attestation report of our independent registered public accounting firm regarding internal control over financial
	reporting due to an exemption for emerging growth companies provided in the JOBS Act.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
	(d) Changes in Internal Control
	over Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	During the year ended December 31,
	2015, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably
	likely to materially affect, our internal control over financial reporting.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_AUDIT_COMMITTEE_EXPERT>
<A NAME="FIS_AUDIT_COMMITTEE_EXPERT"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_018">
</A>
	ITEM
	16A.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Audit
	Committee Financial Expert
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our board of directors
	has determined that Mr. Mor, a member of our audit committee, is an audit committee financial expert, as defined under the rules
	under the Exchange Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq rules.
</P>
</EFX_AUDIT_COMMITTEE_EXPERT>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_CODE_OF_ETHICS>
<A NAME="FIS_CODE_OF_ETHICS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_019">
</A>
	ITEM
	16B.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Code
	of Ethics
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	We have adopted
	a written code of ethics that applies to our officers and employees, including our principal executive officer, principal financial
	officer, principal controller and persons performing similar functions as well as our directors. Our Code of Business Conduct
	and Ethics is posted on our website at www.alcobra-pharma.com.
</P>
</EFX_CODE_OF_ETHICS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_020">
</A>
	ITEM
	16C.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Principal
	Accountant Fees and Services
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Kost Forer Gabbay
	&amp; Kasierer (a Member of EY Global), has served as our principal independent registered public accounting firm for each of
	the two years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The following
	table provides information regarding fees paid by us to Kost Forer Gabbay &amp; Kasierer and/or other member firms of EY Global
	for all services, including audit services, for the years ended December&nbsp;31, 2015 and 2014: &nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP>
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended
<BR>
	December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT; TEXT-INDENT: -12.25PT; PADDING-LEFT: 12.25PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Audit
	fees
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	87
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	75
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Audit-related
	fees
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Tax
	fees
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	63
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	All other fees
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -12PT; PADDING-LEFT: 12PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	212
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	138
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(1)
</I>
</FONT>
</TD>
<TD STYLE="WIDTH: 96%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Includes
	professional services rendered in connection with the audit of our annual financial statements and the review of our interim
	financial statements.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(2)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Includes fees in
	connection with two public offerings in 2015.
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	(3)
</I>
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Includes
	professional fees related to tax returns, transfer pricing and consulting on state and sales tax in the United States and
	Israeli tax.
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
<B>
<I>
	Pre-Approval of Auditors' Compensation
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Our audit committee
	has a pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and
	non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence
	of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories
	of audit services, audit-related services and tax services that may be performed by our independent registered public accounting
	firm. If a type of service, that is to be provided by our auditors, has not received such general pre-approval, it will require
	specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm
	to perform the prohibited non-audit functions defined in applicable SEC rules.
</P>
</EFX_ACCOUNTANT_FEES>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_EXEMPTIONS_FROM_LISTING>
<A NAME="FIS_EXEMPTIONS_FROM_LISTING"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_021">
</A>
	ITEM
	16D.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exemptions
	from the Listing Standards for Audit Committees
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Not applicable.
</P>
</EFX_EXEMPTIONS_FROM_LISTING>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_PURCHASES_OF_EQUITY>
<A NAME="FIS_PURCHASES_OF_EQUITY"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_022">
</A>
	ITEM
	16E.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Purchases
	of Equity Securities by the Issuer and Affiliated Purchasers
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Not applicable.
</P>
</EFX_PURCHASES_OF_EQUITY>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CHANGE_IN_ACCOUNTANT>
<A NAME="FIS_CHANGE_IN_ACCOUNTANT"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_023">
</A>
	ITEM
	16F.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Change
	in Registrant's Certifying Accountant
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Not applicable.
</P>
</EFX_CHANGE_IN_ACCOUNTANT>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_CORPORATE_GOVERNANCE>
<A NAME="FIS_CORPORATE_GOVERNANCE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_024">
</A>
	ITEM
	16G.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Corporate
	Governance
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Sarbanes-Oxley
	Act, as well as related rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply with
	various corporate governance practices. In addition, we are required to comply with the Listing Rules of the NASDAQ Stock Market.
	Under those Listing Rules, we may elect to follow certain corporate governance practices permitted under the Israeli Companies
	Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the Listing Rules of the NASDAQ
	Stock Market for U.S. domestic issuers.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In accordance
	with Israeli law and practice and subject to the exemption set forth in Rule&nbsp;5615 of the Listing Rules of the NASDAQ Stock
	Market, we have elected to follow the provisions of the Israeli Companies Law, rather than the Listing Rules of the NASDAQ Stock
	Market, with respect to the following requirements:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Distribution
	of periodic reports to shareholders; proxy solicitation.
</I>
	As opposed to the Listing Rules of the NASDAQ Stock Market, which
	require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law
	does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice
	in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In
	addition to making such reports available on a public website, we currently make our audited financial statements available
	to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer,
	we are generally exempt from the SEC's proxy solicitation rules.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Nomination
	of our directors.
</I>
	With the exception of our external directors and directors elected by our Board of Directors due to
	vacancy, our directors are elected by an annual meeting of our shareholders to hold office until the next annual meeting following
	one year from his or her election. See Item 6.C. Board Practices &ldquo;Board of Directors.&rdquo; The nominations for directors,
	which are presented to our shareholders by our Board of Directors, are generally made by the Board of Directors itself, in
	accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law. Nominations
	need not be made by a nominating committee of our Board of Directors consisting solely of independent directors, or by a majority
	of independent directors, as required under the Listing Rules of the NASDAQ Stock Market.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Compensation
	of officers.
</I>
	Israeli law and our amended and restated articles of association do not require that the independent members
	of our Board of Directors (or a compensation committee composed solely of independent members of our Board of Directors) determine
	an executive officer&rsquo;s compensation, as is generally required under the Listing Rules of the NASDAQ Stock Market with
	respect to the Chief Executive Officer and all other executive officers. Instead, compensation of executive officers is determined
	and approved by our Compensation Committee and our Board of Directors, and in certain circumstances by our shareholders, either
	in consistency with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into
	account certain considerations stated in the Israeli Companies Law.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Shareholder approval
	is generally required for executive officer compensation in the event (i) approval by our Board of Directors and our Compensation
	Committee is not consistent with our office holders compensation policy, or (ii) compensation required to be approved is that
	of our chief executive officer who is not a director or an executive officer who is also the controlling shareholder of our company
	(including an affiliate thereof). Such shareholder approval shall require a majority vote of the shares present and voting at
	a shareholders meeting, provided either (i) such majority includes a majority of the shares held by non-controlling shareholders
	who do not otherwise have a personal interest in the compensation arrangement that are voted at the meeting, excluding for such
	purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling and disinterested shareholders
	voted against the arrangement does not exceed two percent (2%) of the voting rights in our company.
</P>
<!-- FIELD: PAGE; SEQUENCE: 76 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	Additionally,
	approval of the compensation of an executive officer, who is also a director, shall generally require a simple majority vote of
	the shares present and voting at a shareholders meeting, if consistent with our office holders compensation policy. Our Compensation
	Committee and Board of Directors may, in special circumstances, approve the compensation of an executive officer (other than a
	director, a chief executive officer or a controlling shareholder) or approve the compensation policy despite shareholders&rsquo;
	objection, based on specified arguments and taking shareholders&rsquo; objection into account. Our Compensation Committee may
	further exempt an engagement with a nominee for the position of chief executive officer, who meets the non-affiliation requirements
	set forth for an external director, from requiring shareholders&rsquo; approval, if such engagement is consistent with our office
	holders compensation policy and our Compensation Committee determines based on specified arguments that presentation of such engagement
	to shareholders&rsquo; approval is likely to prevent such engagement. To the extent that any such transaction with a controlling
	shareholder is for a period extending beyond three years, approval is required once every three years.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	A director or
	executive officer may not be present when the board of directors of a company discusses or votes upon the terms of his or her
	compensation, unless the chairman of the board of directors determines that he or she should be present to present the transaction
	that is subject to approval.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Independent
	directors.
</I>
	Israeli law does not require that a majority of the directors serving on our Board of Directors be &ldquo;independent,&rdquo;
	as defined under NASDAQ Listing Rule&nbsp;5605(a)(2), and rather requires we have at least two external directors who meet
	the requirements of the Israeli Companies Law, as described above under Item 6.C. Board Practices &ldquo;External Directors.&rdquo;
	We are required, however, to ensure that all members of our Audit Committee are &ldquo;independent&rdquo; under the applicable
	NASDAQ and SEC criteria for independence (as we cannot exempt ourselves from compliance with that SEC independence requirement,
	despite our status as a foreign private issuer), and we must also ensure that a majority of the members of our Audit Committee
	are &ldquo;unaffiliated directors&rdquo; as defined in the Israeli Companies Law. Furthermore, Israeli law does not require,
	nor do our independent directors conduct, regularly scheduled meetings at which only they are present, which the NASDAQ Listing
	Rules otherwise require.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Shareholder
	approval.
</I>
	We will seek shareholder approval for all corporate actions requiring such approval under the requirements of
	the Israeli Companies Law, rather than seeking approval for corporation actions in accordance with NASDAQ Listing Rule&nbsp;5635.
	In particular, under this NASDAQ rule, shareholder approval is generally required for: (i)&nbsp;an acquisition of shares/assets
	of another company that involves the issuance of 20% or more of the acquirer's shares or voting rights or if a director, officer
	or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii)&nbsp;the
	issuance of shares leading to a change of control; (iii)&nbsp;adoption/amendment of equity compensation arrangements; and
	(iv)&nbsp;issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for,
	equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity
	is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Israeli Companies Law,
	shareholder approval is required for, among other things: (i)&nbsp;transactions with directors concerning the terms of their
	service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company),
	for which approvals of the compensation committee, board of directors and shareholders are all required, (ii)&nbsp;extraordinary
	transactions with controlling shareholders of publicly held companies, which require the special approval described below
	under &ldquo;Approval of Related Party Transactions under Israeli Law
<B>
	&ndash;
</B>
	Disclosure of personal interests of controlling
	shareholders,&rdquo; and (iii)&nbsp;terms of employment or other engagement of the controlling shareholder of the Company
	or such controlling shareholder's relative, which require the special approval described below under &ldquo;Approval of Related
	Party Transactions under Israeli Law
<B>
	&ndash;
</B>
	Disclosure of personal interests of controlling shareholders.&rdquo; In
	addition, under the Israeli Companies Law, a merger requires approval of the shareholders of each of the merging companies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Approval of Related Party Transactions under Israeli
	Law
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
<I>
	Disclosure of personal interests of a controlling
	shareholder and approval of transactions
</I>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law also requires that a controlling shareholder promptly disclose to the company any personal interest that he or she may have
	and all related material information or documents relating to any existing or proposed transaction by the company. A controlling
	shareholder&rsquo;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors
	at which the transaction is considered. Extraordinary transactions with a controlling shareholder or in which a controlling shareholder
	has a personal interest, including a private placement in which a controlling shareholder has a personal interest, and the terms
	of engagement of the company, directly or indirectly, with a controlling shareholder or a controlling shareholder&rsquo;s relative
	(including through a corporation controlled by a controlling shareholder), regarding the company&rsquo;s receipt of services from
	the controlling shareholder, and if such controlling shareholder is also an office holder of the company, regarding his or her
	terms of employment, require the approval of each of (i) the audit committee or the compensation committee with respect to the
	terms of the engagement of the company, (ii) the board of directors and (iii) the shareholders, in that order. In addition, the
	shareholder approval must fulfill one of the following requirements:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a
	majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting
	must be voted in favor of approving the transaction, excluding abstentions; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; LINE-HEIGHT: 107%">
	&bull;
</TD>
<TD STYLE="WIDTH: 92%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no
	more than 2.0% of the voting rights in the company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 77 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	In addition, any
	extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a
	term of more than three years requires the abovementioned approval every three years, however, such transactions not involving
	the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such
	longer term is reasonable under the circumstances.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The Israeli Companies
	Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
	with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest
	in the vote in question. Failure to so indicate will result in the invalidation of that shareholder&rsquo;s vote.
</P>
</EFX_CORPORATE_GOVERNANCE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_025">
</A>
	ITEM
	16H.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Mine
	Safety Disclosure
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Not applicable.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<U>
<A NAME="V432397_20F_HTM_NOTE_026">
</A>
	PART THREE
</U>
</B>
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_II>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_030">
</A>
	ITEM
	17.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	FINANCIAL
	STATEMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT">
	Not applicable.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_027">
</A>
	ITEM
	18.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	FINANCIAL
	STATEMENTS
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1IN; TEXT-ALIGN: LEFT; TEXT-INDENT: -1IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 22.5PT; TEXT-ALIGN: LEFT">
	The following consolidated
	financial statements, and the related notes thereto, and the Reports of Independent Public Accountants are filed as a part of
	this annual report.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 90%; LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_A_001">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Report of Independent Registered Public Accounting Firm
</FONT>
</A>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-2
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_A_002">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Balance Sheets
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-3
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_A_003">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Statements of Operations
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-4
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_A_004">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Statements of Changes in Shareholders' Equity
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_A_005">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consolidated Statements of Cash Flows
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="LINE-HEIGHT: 107%">
<A HREF="#V432397_20F_HTM_A_006">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Notes to Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-7
	- F-23
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 11%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<A NAME="V432397_20F_HTM_NOTE_028">
</A>
	ITEM
	19.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 89%; TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	EXHIBITS
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_EXHIBITS>
</EFX_PART_III>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<U>
	EXHIBIT INDEX
</U>
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	EXHIBIT
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	NUMBER
</B>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 88%; BORDER-BOTTOM: BLACK 1PT SOLID; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	DESCRIPTION
	OF DOCUMENT
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.1
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Articles
	of Association of the Company, filed as Exhibit 3.2 to Form F-1/A filed on March 19, 2013 (File No. 333-186003) and incorporated
	herein by reference &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Representative&rsquo;s Warrant Agreement, filed as Exhibit 4.2 to Form F-1/A filed on April 25, 2013 (File No. 333-186003)
	and incorporated herein by reference
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consulting
	Agreement between the Company and Adler Consulting LLC, dated November 2010, filed as Exhibit 10.1 to Form F-1/A filed on
	January 14, 2013 (File No. 333-186003) and incorporated herein by reference
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Alcobra
	Ltd. 2010 Incentive Option Plan, as amended
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Indemnification Agreement, filed as Exhibit 10.4 to Form F-1/A filed on February 19, 2013 (File No. 333-186003) and incorporated
	herein by reference
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.5&infin;
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Letter
	of Approval from the Office of Chief Scientist, filed as Exhibit 10.8 to Form F-1/A filed on February 19, 2013 (File No. 333-186003)
	and incorporated herein by reference
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Employment
	agreement between the Company and Yaron Daniely, dated March 4, 2010, filed as Exhibit 10.9 to Form F-1/A filed on April 25,
	2013 (File No. 333-186003) and incorporated herein by reference
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Employment
	agreement between the Company and Jonathan Rubin, dated July 25, 2013, filed as Exhibit 10.13 to Form F-1/A filed on October
	22, 2013 (File No. 333-191714) and incorporated herein by reference
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 78 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 10%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.8
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 88%; LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Alcobra
	Ltd. Amended and Restated Compensation Policy for Company Office Holders, filed as Exhibit 99.2 to Form 6-K filed on June
	3, 2015 and incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12.1
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12.2
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	13.1
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of the Chief Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	13.2
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of the Chief Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15.1
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consent
	of Kost, Forer, Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	101
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following materials from our Annual Report on Form 20-F for the year ended December 31, 2015 formatted in XBRL (eXtensible
	Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Comprehensive Loss,
	(iii) the Consolidated Statements of Changes in Shareholders' Equity, (iv) the Consolidated Statements of Cash Flows and (v)
	the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT">
	&infin; English translation of original Hebrew
	document.
</P>
</EFX_EXHIBIT_INDEX>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 27PT; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	SIGNATURES
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	Alcobra Ltd. hereby certifies that
	it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
	annual report on its behalf.
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ALCOBRA
	LTD.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 51%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 44%; LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	/s/
	Dr. Yaron Daniely
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Yaron Daniely
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Executive Officer
	and President
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Date:
	March 4, 2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 3.25IN; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 79 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: CENTER">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	AS OF DECEMBER 31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	U.S. DOLLARS IN THOUSANDS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	INDEX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 79%; PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-SIZE: 10PT">
	Page
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
<A HREF="#V432397_20F_HTM_A_001">
<B>
	Report of Independent Registered Public Accounting Firm
</B>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	F-2
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
<B>
<A HREF="#V432397_20F_HTM_A_002">
	Consolidated Balance Sheets
</A>
</B>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	F-3
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
<A HREF="#V432397_20F_HTM_A_003">
<B>
	Consolidated Statements of Operations
</B>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	F-4
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
<A HREF="#V432397_20F_HTM_A_004">
<B>
	Statements of Changes in Shareholders' Equity
</B>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	F-5
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
<A HREF="#V432397_20F_HTM_A_005">
<B>
	Consolidated Statements of Cash Flows
</B>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	F-6
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 11.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT">
<A HREF="#V432397_20F_HTM_A_006">
<B>
	Notes to Consolidated Financial Statements
</B>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	F-7 - F-23
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	- - -
	- - - - - - - - - - -
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 80 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 20%; FONT-SIZE: 10PT; COLOR: #666666">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/04/0001144204-16-086094_TLOGO.JPG" ALT="">
</TD>
<TD STYLE="WIDTH: 35%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Kost
	Forer Gabbay &amp; Kasierer
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3
	Aminadav St.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Tel-Aviv
	6706703, Israel
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; COLOR: #666666">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 42%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Tel: +972-3-6232525
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Fax: +972-3-5622555
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	ey.com
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_SIGNATURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="V432397_20F_HTM_A_001">
</A>
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	To the Shareholders and Board of Directors
	of
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: CENTER">
<B>
	ALCOBRA LTD.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	We have audited the
	accompanying consolidated balance sheets of Alcobra Ltd. and its subsidiary as of December&nbsp;31, 2015 and 2014, and the related
	consolidated statements of operations, shareholders' equity and cash flows for each of the three years in the period ended December
	31, 2015. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion
	on these financial statements based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	We conducted our
	audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require
	that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
	We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audits included consideration
	of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
	but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.
	Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
	disclosures in the financial statements assessing the accounting principles used and significant estimates made by management,
	and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	In our opinion,
	the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Alcobra
	Ltd. and its subsidiary at December 31, 2015 and 2014, and the consolidated results of their operations and their cash flows for
	each of the three years in the period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; FONT-VARIANT: NORMAL">
	Tel-Aviv,
	Israel
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
	/s/
	KOST FORER GABBAY &amp; KASIERER
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	March 4, 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	A Member of EY Global
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
<A NAME="V432397_20F_HTM_A_002">
</A>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	CONSOLIDATED
	BALANCE SHEETS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands (except share
	and per share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 28.35PT">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	CURRENT ASSETS:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	16,658
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,176
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Short-term bank deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,022
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,522
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Prepaid expenses and other receivables
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,666
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	428
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Total current assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	52,346
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,126
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	LONG-TERM ASSETS:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Long-term bank deposits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Property and equipment, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Other long-term assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	110
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	95
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Total long-term assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,337
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	192
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	TOTAL ASSETS
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	71,683
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	22,318
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 28.35PT">
<A NAME="FIS_BALANCE_SHEET_2"></A>
	LIABILITIES AND SHAREHOLDERS' EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	CURRENT LIABILITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Trade payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	305
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Accrued expenses and other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,295
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,070
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Total current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,352
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,375
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	SHAREHOLDERS' EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Ordinary shares of NIS 0.01 par value -
<BR>
	50,000,000 shares authorized at December&nbsp;31, 2015 and 2014; 27,865,244 and 14,007,046 issued shares at December&nbsp;31, 2015 and 2014, respectively; 27,560,920 and 13,702,722 shares outstanding at December&nbsp;31, 2015 and 2014, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	74
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Treasury shares - 304,324 ordinary shares at December 31, 2015&nbsp;&nbsp;and 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	140,274
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	71,472
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(71,017
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(51,568
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Total shareholders' equity
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	69,331
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	19,943
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	71,683
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	22,318
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	*)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents an amount less than $&nbsp;1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<A NAME="V432397_20F_HTM_A_003">
</A>
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	CONSOLIDATED
	STATEMENTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands (except share
	and per share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Research and development expenses
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,461
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25,105
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,066
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Pre-commercialization expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,245
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,134
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	General and administrative expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,992
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,839
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,224
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Operating loss
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,698
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	33,078
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,290
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Financial expenses (income), net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(300
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(227
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	197
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Net loss before taxes
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,398
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	32,851
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,487
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Tax expenses (benefits)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(17
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	61
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,449
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	32,834
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,548
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Basic and diluted net loss per share
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(0.90
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2.40
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.04
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Weighted average number of ordinary shares used in computing basic and diluted net loss per share
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,638,207
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,674,818
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,177,786
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
<A NAME="V432397_20F_HTM_A_004">
</A>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	STATEMENTS
	OF CHANGES IN SHAREHOLDERS' EQUITY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands (except share
	and per share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Ordinary Shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<B>
	Treasury shares
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<B>
	Additional
<BR>
	paid-in
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<B>
	Accumulated
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<B>
	Total
<BR>
	shareholders'
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Number
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Amount
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<B>
	Number
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<B>
	amoun
</B>
	t
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	capital
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	equity
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 37%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Balance as of January 1, 2013
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,794,256
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	304,324
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,615
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(8,186
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(567
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon exercise of options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	208,708
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon cashless exercise of warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	85,192
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon conversion of convertible notes
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	123,553
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	980
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	980
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon initial public offering ($8.00 per share), net of $3,080 issuance expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,125,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,892
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21,920
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon secondary public offering ($16.50 per share), net of $2,616 issuance expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,300,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	35,328
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	35,334
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,540
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,540
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,548
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(10,548
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Balance as of December 31, 2013
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,636,709
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	304,324
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	67,383
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18,734
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	48,688
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon exercise of options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,174
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon cashless exercise of warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64,839
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,089
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,089
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(32,834
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(32,834
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Balance as of December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,702,722
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	304,324
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	71,472
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(51,568
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19,943
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon exercise of options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon public offering ($4.00 per share), net of $203 issuance expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,475,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	19
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,884
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,903
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Issuance of shares upon public offering ($6.50 per share), net of $421 issuance expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,379,198
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38,540
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38,556
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Share-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,365
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,365
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net loss
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(19,449
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(19,449
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,560,920
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	74
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	304,324
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	*)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	140,274
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(71,017
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	69,331
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	*)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents an amount less than $&nbsp;1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The accompanying notes
	are an integral part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
<A NAME="V432397_20F_HTM_A_005">
</A>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	CONSOLIDATED
	STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Year ended
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Cash flows from operating activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(19,449
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(32,834
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(10,548
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Share based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,365
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,089
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,540
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Increase in prepaid expenses and other receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,077
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(313
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(32
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Increase in other long-term assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Increase (decrease) in trade payables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	258
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Increase in accrued expenses and other liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	225
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,505
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Interest on convertible notes
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	203
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 28.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Net cash used in operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(18,148
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(28,326
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(7,353
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Cash flows from investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Purchase of property and equipment, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(181
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(79
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Proceeds from (investment in) short-term bank deposit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,486
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(28,008
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Investment in long-term bank deposit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Investment in restricted bank deposit
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(161
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Net cash provided by (used in) investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(33,842
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,407
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(28,047
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Cash flows from financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Proceeds from issuance of convertible notes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Issuance of share capital upon public offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	57,254
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Exercise of options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	66,472
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	57,398
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Increase (decrease) in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,482
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,919
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,998
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Cash and cash equivalents at the beginning of the year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,176
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22,095
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	Cash and cash equivalents at the end of the year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,658
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,176
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	22,095
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Non-cash transactions:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Issuance of ordinary shares upon conversion of&nbsp;&nbsp;convertible notes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	980
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The accompanying notes are an integral
	part of the consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
<A NAME="V432397_20F_HTM_A_006">
</A>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 1:-
</TD>
<TD>
	GENERAL
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Alcobra Ltd. was incorporated in Israel and commenced its operation on February 7, 2008. During
	July 2013, a wholly-owned subsidiary was established in the state of Delaware named Alcobra Inc. (the &quot;Subsidiary&quot;).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Alcobra Ltd. and its Subsidiary (collectively the &ldquo;Company&rdquo;) are an emerging biopharmaceutical
	company primarily focused on the development and commercialization of a proprietary drug candidate, to treat Attention Deficit
	Hyperactivity Disorder, (&quot;ADHD&quot;), and other cognitive dysfunctions including Fragile X. The Company's objective is to
	conduct additional clinical trials for its drug called MDX (the &quot;Drug&quot;) and, if those trials are successful, seek marketing
	approval from the U.S. Food and Drug Administration (the &quot;FDA&quot;) and other worldwide regulatory bodies.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 92.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company has not generated revenue from the sale of any product, and does not expect to generate
	significant revenue unless and until the Company obtains marketing approval and commercializes the Drug. During the year ended
	December 31, 2015, the Company has incurred losses of $ 19,449 and had a negative cash flow from operating activities of $ 18,148.
	The accumulated deficit as of December 31, 2015 is $ 71,017.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During January and November 2015, the Company completed public offerings and issued 7,475,000
	ordinary shares and 6,379,198 ordinary shares, respectively. Net proceeds from these transactions amounted to $ 27,903 and $ 38,556, respectively.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	NOTE 2:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	SIGNIFICANT ACCOUNTING POLICIES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The consolidated
	financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&quot;U.S.
	GAAP&quot;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.85PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Use of estimates:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The preparation of the financial
	statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management
	believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are
	made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
	assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period.
	Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.85PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Financial statements in U.S. dollars:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company finances its operations
	in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's
	expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the
	primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus,
	the functional and reporting currency of the Company is the U.S.&nbsp;dollar.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	NOTE 2:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company's transactions
	and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been
	remeasured to U.S. dollars in accordance with ASC 830, &quot;Foreign Currency Matters&quot;, of the Financial Accounting Standards
	Board (&quot;FASB&quot;). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar
	currencies are reflected in the statements of operations as financial income or expenses, as appropriate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Principles of consolidation:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The consolidated
	financial statements include the accounts of Alcobra Ltd. and its Subsidiary. Intercompany transactions and balances have been
	eliminated upon consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Cash equivalents:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Cash equivalents
	are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less
	at acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Bank deposits:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Bank deposits
	with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
	are stated at cost which approximates market values.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 85.05PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Bank deposits
	with maturities of more than one year are included in long-term bank deposits. Deposits as of December 31, 2015 do not have contractual
	maturities that exceed 2&nbsp;years. Such long-term deposits are stated at cost which approximates market values.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	As of December&nbsp;31,
	2015, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average annual interest rate of 1.24%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	f.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Property and equipment, net:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Property and equipment are
	stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
	lives of the assets at the following rates:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE; MARGIN-LEFT: 1.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 48%; TEXT-ALIGN: LEFT; TEXT-INDENT: 9.9PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
<B>
	%
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: LEFT">
	Computers and electronic equipment
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	15-33
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: LEFT">
	Office furniture and equipment
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: LEFT">
	Clinical and medical equipment
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	15
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: LEFT">
	Leasehold improvement
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="PADDING-LEFT: 2.85PT; TEXT-ALIGN: CENTER">
	The shorter of term of the lease or the useful life of the asset
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-WEIGHT: BOLD">
	NOTE 2:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-WEIGHT: BOLD">
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The Company's property and
	equipment are reviewed for impairment in accordance with ASC 360, &quot;Property, Plant, and Equipment,&quot; whenever events or
	changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held
	and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
	by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which
	the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the
	carrying amount or fair value less costs to sell. In 2015 and 2014, no impairment losses have been identified.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	g.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other long-term assets:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Other long-term
	assets mainly include long-term deposits for office lease and motor vehicles under operating leases, presented at their cost.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	h.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Research and development expenses:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Research
	and development expenses are expensed as incurred. Those expenses include payments to third party clinical consultants, expenses
	related to conducting clinical and pre-clinical trials, salaries and related personnel expenses, travel expenses and share based
	compensation expenses to research and development employees. During 2015, 2014 and 2013, no grants were received.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	i.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Severance pay:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company's
	liability for its Israeli employees regarding severance pay is pursuant to Section 14 of the Israeli severance pay law (&quot;Section
	14&quot;). All the Israeli employees are included under this section, and entitled only to monthly deposits, at a rate of 8.33%
	of their monthly salary, made in the employee's name with insurance companies. Payments in accordance with Section 14 release the
	Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time
	the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits
	under Section 14 are not reflected in the balance sheet as the severance pay risks have been irrevocably transferred to the severance
	funds.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Severance
	pay expense for the years ended December 31, 2015, 2014 and 2013, amounted to $ 130, $ 102 and $ 26, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-WEIGHT: BOLD">
	NOTE 2:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN; FONT-WEIGHT: BOLD">
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	j.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Employee benefit plan:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Since 2014,
	the Company&rsquo;s U.S. operations maintain a retirement plan (the &ldquo;U.S. Plan&rdquo;) that qualifies as a deferred salary
	arrangement under Section&nbsp;401(k) of the Internal Revenue Code. Participants in the U.S. Plan may elect to defer a portion
	of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. The Company matches 100% of each participant&rsquo;s
	contributions up to 3%. Contributions to the U.S. Plan are recorded during the year contributed as an expense in the consolidated
	statement of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Total employer
	401(k) contributions for the years ended December 31, 2015 and 2014 were $ 21 each year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	k.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Income taxes:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	accounts for income taxes in accordance with ASC 740, &quot;Income Taxes&quot; (&quot;ASC 740&quot;). This topic prescribes the
	use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between
	financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be
	in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets
	to the amount that is more likely than not to be realized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
	taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely
	than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any
	related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than
	50% (cumulative basis) likely to be realized upon ultimate settlement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	As of December
	31, 2015 and 2014 the Company has not recorded a liability for uncertain tax positions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	l.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Concentrations of credit risk:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Financial
	instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents
	and bank deposits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Cash and
	cash equivalents and short term bank deposits are invested in major banks in Israel. Generally, these deposits may be redeemed
	upon demand and therefore bear minimal risk
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging
	arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	m.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Fair value of financial instruments:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	has no financial instruments that are measured at fair value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The carrying
	amounts of cash and cash equivalents, short term bank deposits, accounts receivable and accounts payable, approximate their fair
	value due to the short-term maturities of such instruments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	n.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Basic and diluted net loss per share:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	Basic net loss per share is
	computed based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is computed
	based on the weighted average number of ordinary shares outstanding during each year plus dilutive potential equivalent ordinary
	shares considered outstanding during the year, in accordance with ASC 260, &quot;Earnings per Share.&quot;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	The total weighted average
	number of shares related to the outstanding options and warrants excluded from the calculations of diluted net loss per share,
	since they would have an anti-dilutive effect, was 1,755,766, 1,053,055 and 873,031 for the years ended December 31, 2015, 2014
	and 2013, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT">
	o.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Accounting for share-based compensation:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	accounts for share-based compensation in accordance with ASC 718, &quot;Compensation - Stock Compensation&quot; (&quot;ASC 718&quot;)
	that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment
	awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on
	the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite
	service periods in the Company's statements of operations based on the accelerated method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	selected the Black-Scholes-Merton (&quot;Black-Scholes&quot;) option-pricing model as the fair value method for of its share-options
	awards. The option-pricing model requires a number of assumptions as noted below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<I>
	Expected dividend yield
</I>
	- The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend
	payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Volatility
</I>
	-
</FONT>
	Since the Company's shares started trading in NASDAQ in May 2013, quoted prices of the Company's share are available for
	two and a half years only. Due to insufficient historical data for the Company, the expected volatility determination was based
	on a weighted average of the Company and similar companies' stock volatility.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 2:-
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<B>
	SIGNIFICANT ACCOUNTING POLICIES (Cont.)
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<I>
	Risk free interest rate
</I>
	- The risk free interest rate is based on the yield of U.S Treasury bonds with equivalent terms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-SIZE: 10PT">
<I>
	Expected
	term
</I>
</FONT>
	-
<FONT STYLE="FONT-SIZE: 10PT">
	ASC 718 provides the factors to consider when estimating the expected term of an
	option: An option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting
	employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that
	data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that
	circumstance, it may be appropriate to consider external data or the SEC staff's &quot;simplified&quot; method for the expected
	term. Accordingly, the Company used the &quot;simplified&quot; method, meaning the expected life can be set as the average of the
	vesting period for each vested tranche of options and the contractual term for those options.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The
	Company used the Black-Scholes option-pricing model to determine the fair value of grants made in 2015, 2014 and 2013. The following
	assumptions were applied in determining the compensation cost:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.25IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Risk-free interest rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.9-2.1
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.7-2.8
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	0.8-2.4
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Expected option term&nbsp;(years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.3-7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3-10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.3-10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Expected price volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	78-87
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	65-89
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69-88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Weighted average grant date fair value
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.67
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.76
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.9PT">
</TD>
<TD STYLE="WIDTH: 28.1PT; TEXT-ALIGN: LEFT">
	p.
</TD>
<TD>
	New accounting pronouncements:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	In August 2014, the Financial
	Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2014-15, Presentation of
	Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going
	Concern. ASU 2014-15 defines management&rsquo;s responsibility to assess an entity&rsquo;s ability to continue as a going concern
	and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The
	pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company
	is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company&rsquo;s financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 3:-
</TD>
<TD>
	PREPAID EXPENSES AND OTHER RECEIVABLES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 88%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.79IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Government authorities
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	116
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,296
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	311
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Restricted cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	161
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Other current assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	93
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,666
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	428
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
<B>
	NOTE 4:
</B>
</TD>
<TD>
<B>
	PROPERTY AND EQUIPMENT, NET
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 88%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.79IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Cost:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	Computers and electronic equipment
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	146
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	63
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	Office furniture and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	Clinical and medical equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.35PT">
	Leasehold improvement
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	93
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	39
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	157
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Accumulated depreciation:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	Computers and electronic equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	Office furniture and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 11.35PT">
	Clinical and medical equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 11.35PT">
	Leasehold improvement
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	42
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	111
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	60
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	Depreciated cost
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	227
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Depreciation
	expenses for the years ended December 31, 2015, 2014 and 2013, were $ 51, $&nbsp;31 and $&nbsp;9, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 5:-
</TD>
<TD>
	ACCRUED EXPENSES AND OTHER LIABILITIES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 88%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.79IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Employees and payroll accruals
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,277
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	308
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	888
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,697
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Government authorities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Other liability
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	71
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,295
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,070
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 6:-
</TD>
<TD>
	CONVERTIBLE NOTES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	During 2012
	and 2013, the Company issued convertible promissory notes to certain investors for a total amount of $&nbsp;715. The convertible
	notes bore an annual interest rate of 6%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In
	connection with the Company's Initial Public Offering (&quot;IPO&quot;), in May 2013, according to the terms of the
	convertible notes, in May 2013 the notes were automatically converted into 123,553 ordinary shares of the Company. Upon
	conversion of the convertible notes, the entire redemption amount was derecognized against additional paid in capital in the
	amount of $ 980. The financial expenses for the year ended December 31, 2013, amounted to $ 203.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 7:-
</TD>
<TD>
	INCOME TAXES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN">
</TD>
<TD STYLE="WIDTH: 0.39IN; TEXT-ALIGN: LEFT">
	a.
</TD>
<TD>
	Tax laws applicable to Alcobra Ltd. and the Subsidiary:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 84.45PT">
</TD>
<TD STYLE="WIDTH: 28.95PT; TEXT-ALIGN: LEFT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Alcobra Ltd. is taxed under the Israeli income tax
	law.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Taxable income
	of Israeli companies is subject to tax at the rate of 25% in 2013 and a rate of 26.5% in 2014 and in 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On January
	4, 2016, the Israeli Parliament's Plenum approved by a second and third reading the Bill for Amending the Income Tax Ordinance
	(No. 217) (Reduction of Corporate Tax Rate), 2015, which consists of the reduction of the corporate tax rate from 26.5% to 25%,
	starting January 1, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 102.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 84.45PT">
</TD>
<TD STYLE="WIDTH: 28.95PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Subsidiary is taxed under U.S. tax law. The federal tax rates applicable to the Company whose
	place of incorporation is within the United States. are corporate (progressive) tax at the rate of up to 35%, excluding state tax,
	which rates depend on the state in which the Subsidiary conducts its business.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN">
</TD>
<TD STYLE="WIDTH: 0.39IN; TEXT-ALIGN: LEFT">
	b.
</TD>
<TD>
	Net operating losses carry forward:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Alcobra
	Ltd. has accumulated losses for tax purposes in Israel as of December&nbsp;31, 2015 in the amount of approximately $&nbsp;48,000
	which may be carried forward and offset against taxable income in the future for an indefinite period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 7:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	INCOME TAXES (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN">
</TD>
<TD STYLE="WIDTH: 0.39IN; TEXT-ALIGN: LEFT">
	c.
</TD>
<TD>
	Deferred income taxes:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Deferred
	income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
	reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are
	as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating loss carry forward
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,791
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,595
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Reserves and allowances
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,688
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,073
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred tax assets before valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	17,479
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,668
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(17,479
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(12,668
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net deferred tax assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	All
	deferred taxes are domestic. Management currently believes that since the Company has a history of losses it is more likely than
	not that the deferred tax regarding the loss carry forward and other temporary differences will not be realized in the foreseeable
	future.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN">
</TD>
<TD STYLE="WIDTH: 0.39IN; TEXT-ALIGN: LEFT">
	d.
</TD>
<TD>
	No liability for uncertain tax positions was recorded
	as of December 31, 2015 and 2014.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 28.35PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The main reconciling item between the statutory tax rate of the Company and the effective tax rate
	is the recognition of valuation allowances in respect of deferred taxes due to the uncertainty of the realization of such deferred
	taxes.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN">
</TD>
<TD STYLE="WIDTH: 0.39IN; TEXT-ALIGN: LEFT">
	f.
</TD>
<TD>
	Net loss before taxes is comprised as follows:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Domestic (Israel)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	19,003
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	31,154
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	10,505
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	Foreign (U.S.)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	395
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,697
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	19,398
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	32,851
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	10,487
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.79IN">
</TD>
<TD STYLE="WIDTH: 0.39IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	g.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Taxes on income relate
	solely to the foreign Subsidiary.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 8:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	CONTINGENT LIABILITIES AND COMMITMENTS
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27.75PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	a.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Legal Proceedings:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On
	November 19, 2014, a class action lawsuit was filed against the Company and certain of its current and former officers and directors
	in the United States District Court for the Southern District of New York. The case was filed on behalf of a putative class of
	investors who purchased or acquired the Company's publicly traded securities between March 28, 2014 and November 14, 2014. The
	complaint asserted violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. The
	complaint alleged, among other things, that the Company's officers and directors made false or misleading statements relating to
	the results of the Phase III study for its MDX drug candidate. The complaint sought an unspecified amount of damages, as well as
	other forms of relief. On December 16, 2014, another class action lawsuit was filed against the Company and certain of its current
	and former officers and directors in the United States District Court for the Southern District of New York. This complaint is
	largely identical to the earlier complaint and purports to bring the same claims on behalf of the same putative class. On December
	23, 2014, the first plaintiff in the first action moved to voluntarily dismiss his case, which motion was granted on December 30,
	2014. On February 9, 2015, the court appointed a group of investors to act as lead plaintiff for the second action.&nbsp;On May
	20, 2015, the defendants moved to dismiss the complaint. The motion to dismiss has been fully briefed and oral argument occurred
	on September 22, 2015. At this preliminary stage the Company cannot assess the exposure under such complaint.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	b.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Lease commitments:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Facilities
	of the Company are rented under operating lease agreements, which expire on various dates, the latest of which is in 2018. The
	Company recognizes rent expense under such arrangements on a straight-line basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In
	June 2013 the Company entered into a new operating lease agreement for its vehicles until 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Aggregate
	minimum lease commitments, net of sub-lease proceeds in the amount of $ 22, under non-cancelable operating leases as of December
	31, 2015, were as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December 31,
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Minimum
<BR>
	&nbsp;Facilities
<BR>
	Lease
<BR>
	Payments
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5.65PT; TEXT-ALIGN: CENTER">
<B>
	Minimum
<BR>
	Vehicles
<BR>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5.65PT; TEXT-ALIGN: CENTER">
<B>
	Lease
<BR>
	Payments
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5.65PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5.65PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 5.65PT; TEXT-ALIGN: CENTER">
<B>
	Total
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	511
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	523
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	2017
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	396
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	2018
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	193
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	193
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,100
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,112
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: RIGHT; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: RIGHT; TEXT-INDENT: -28.35PT">
<B>
	&nbsp;ALCOBRA
	LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	U.S.
	dollars in thousands, except share data
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 8:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	CONTINGENT LIABILITIES AND COMMITMENTS (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Facilities
	rent expense, not including sublease income, was $ 498, $ 179 and $ 63 for the years ended December 31, 2015, 2014 and 2013, respectively.
	Sublease rental income for the year ended December 31, 2015 was $ 17.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	vehicle rent expenses for the years ended December 31, 2015, 2014 and 2013, amounted to $&nbsp;110, $&nbsp;67 and $ 51, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In
	August 2015, the Company moved its headquarters to new offices. The previous lease agreement for the headquarters office will be
	terminated in April 2017 and the Company is currently seeking for a sublease for the period until the end of the lease agreement.
	As of December 31, 2015 the Company recognized a loss of $ 71, net in respect with this onerous contract.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 74.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	c
<FONT STYLE="FONT-WEIGHT: NORMAL">
	.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Royalty bearing Government grants:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	The
	Company partially financed its research and development expenditures under programs sponsored by the Office of Chief Scientist
	(&quot;OCS&quot;) for the support of certain research and development activities conducted in Israel.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	In
	connection with the participation payments received from the OCS in previous years, the Company is committed to pay royalties
	at a rate of 3%-5% of sales of the developed product linked to U.S dollars, up to 100% of the amount of grants received (100%
	plus interest at LIBOR). The Company's total commitment for royalties payable with respect to future sales, based on OCS participations
	received or accrued, net of royalties paid or accrued, totaled approximately $&nbsp;119 as of December 31, 2015. In addition,
	the OCS may impose certain conditions on any arrangement under which it permits the Company to transfer technology or development
	out of Israel.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD>
	SHAREHOLDERS' EQUITY
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	a.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share capital:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The ordinary
	shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share
	in the distribution of dividends, if any declared by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	b.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Issuances of shares:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 81PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During May 2013, the Company completed an IPO and listed its ordinary shares and issued 3,125,000 ordinary shares
	in consideration of $ 21,920, net.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Following the
	IPO and according to the terms of the convertible notes, the notes were automatically converted into 123,553 ordinary shares of
	the Company. In addition, 120,255 warrants were exercised into 85,192 ordinary shares of the Company, using the cashless exercise
	method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 99PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
</B>
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	SHAREHOLDERS' EQUITY (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 81PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During October 2013, the Company completed a secondary public offering and issued 2,300,000 ordinary
	shares in consideration of $ 35,334, net.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 81PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During January 2015, the Company completed a public offering and issued 7,475,000 ordinary shares
	in consideration of $ 27,903, net.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 81PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	During November 2015, the Company completed a public offering and issued 6,379,197 ordinary shares
	in consideration of $ 38,556, net.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	c.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	2010 incentive option plan:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In February
	2010, the Company authorized through its 2010 incentive option plan (the &quot;2010 Plan&quot;) the grant of options to officers,
	directors, advisors, management and other key employees. The Company reserved for grants of options up to 2,118,531 of the Company's
	ordinary shares. The options granted have generally four year vesting terms and expire between five to ten years after the grant
	date. As of December&nbsp;31, 2015, 5,121 options were still available for future grants under the Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On March
	2, 2016 the Company increased its option pool for grants of options to 3,078,102. Please also refer to Note 12.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	A summary
	of the Company's options activity (for employees and directors) under the 2010 Plan is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="14" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year&nbsp;ended&nbsp;December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	average
<BR>
	exercise
<BR>
	price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	average
<BR>
	exercise
<BR>
	price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Outstanding at beginning of year
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,540,869
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7.30
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	805,300
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6.86
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	445,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,154,345
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11.29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.29
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Cancelled*
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(112,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23.85
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(372,345
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18.38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(45,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	10.39
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(46,431
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	10.07
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Outstanding at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,824,369
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5.83
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,540,869
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7.30
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Vested and expected to vest
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,824,369
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	5.83
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,540,869
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	7.30
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Options exercisable at the end of the year
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	843,661
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6.50
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	640,401
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	6.24
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD>
	SHAREHOLDERS' EQUITY (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT; TEXT-ALIGN: LEFT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	*
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	On March 31, 2015
	the Company granted to its Chief Executive Officer options to purchase 400,000 of the Company's ordinary shares, subject to the
	cancellation of 112,500 out-of-money options. The Company accounted for the cancellation of options, accompanied by the concurrent
	grant of options in accordance with ASC 718-20-35-8 and calculated the incremental compensation cost as the excess of the fair
	value of the replacement award over the fair value of the cancelled award at the cancellation date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, the
	aggregated intrinsic value of outstanding and exercisable options is $ 4,024 and $ 2,388, respectively. As of December 31, 2015,
	the unrecognized compensation cost is $ 1,940 to be recognized from 2016 through 2019, respectively
<FONT STYLE="COLOR: #1F497D">
	,
</FONT>
	excluding cost of $ 746 for options with vesting subject to certain performance conditions, which are not probable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The options
	outstanding as of December 31, 2015, have been separated into ranges of exercise price, as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Outstanding
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercisable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise price
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.85PT; TEXT-ALIGN: CENTER">
<B>
	Weighted
</B>
<BR>
<B>
	average
</B>
<BR>
<B>
	remaining
</B>
<BR>
<B>
	contractual
</B>
<BR>
<B>
	life
<BR>
	(years)
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	average
<BR>
	exercise price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.85PT; TEXT-ALIGN: CENTER">
<B>
	Weighted
</B>
<BR>
<B>
	average
</B>
<BR>
<B>
	remaining
</B>
<BR>
<B>
	contractual
</B>
<BR>
<B>
	life
<BR>
	(years)
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted
<BR>
	average
<BR>
	exercise price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 22%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0.33-3.29
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	916,305
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.30
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.19
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	461,421
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.64
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.10
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	5.63-8.00
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	666,494
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.38
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.74
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	192,543
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.06
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	12.99-18.49
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	199,071
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16.63
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	150,009
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.99
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16.60
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
	23.00-23.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	42,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.61
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	23.75
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	39,688
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.36
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	23.80
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2.5PT">
	0.33-23.48
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,824,369
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.11
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.83
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	843,661
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.77
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.50
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	d.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Options granted to consultants:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	granted options to certain service providers and accounted for these options in accordance with ASC 505-50, &quot;Equity-Based
	payment to non-employees&quot;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The outstanding
	options granted to the Company's consultants are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant&nbsp;date
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise&nbsp;
<BR>
	price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiration&nbsp;date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	February 28, 2010
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	8,805
</TD>
<TD NOWRAP STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2.184
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	February 28, 2020
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	February 17, 2011
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,804
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	0.0005
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2.85PT">
	February 17, 2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,609*
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	*) All options
	were fully vested on grant date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0IN">
	&nbsp;
<B>
	ALCOBRA
	LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 9:-
</TD>
<TD>
	SHAREHOLDERS' EQUITY (Cont.)
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 84.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	e.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Warrants granted to underwriters:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The outstanding
	options granted to the underwriters for the IPO are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant&nbsp;date
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number&nbsp;of
<BR>
	options
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise&nbsp;
<BR>
	price
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Expiration&nbsp;date
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	May 28, 2013
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	52,084
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	20
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	May 28, 2016
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 56.7PT">
</TD>
<TD STYLE="WIDTH: 27.75PT">
	f.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Share-based payment:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The share-based
	expense recognized in the consolidated financial statements for services received from employees and directors is shown in the
	following table:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 85.05PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 82%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 1.18IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year&nbsp;ended
<BR>
	December&nbsp;31,
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	768
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,773
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	430
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Pre-commercialization expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	308
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	616
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	General and administrative expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,289
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,700
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	1,110
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,365
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,089
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,540
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 113.4PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 10:-
</TD>
<TD>
	RELATED PARTY BALANCES AND TRANSACTIONS
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	Related
	parties' expenses:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.79IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Year
	ended
<BR>
	December 31,
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; PADDING-LEFT: 2.85PT">
	Amounts charged to:
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 2.85PT">
	General and administrative expense
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	332
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	268
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	On March
	1, 2008, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, as a contractor to render
	management, finance and operation services. The Company paid the consultant an amount of $ 7 per month. During May 2013, the monthly
	fee was increased to an amount of $ 12. The amendment was effective upon consummation of the IPO in May 2013. In June 2013, and
	in connection with the consummation of the IPO, the Company granted the consultant a bonus in the amount of $ 50.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 56.7PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In February
	2014, the general meeting of the Company's shareholders approved the grant of an annual bonus to the consultant, in the amount
	of $ 200. The agreement was terminated in May 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63.8PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63.8PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63.8PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 101; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 63.8PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.3PT; TEXT-ALIGN: RIGHT">
<B>
	ALCOBRA LTD. AND ITS SUBSIDIARY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	U.S. dollars in thousands, except share
	data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 11:-
</TD>
<TD>
	FINANCIAL EXPENSES (INCOME), NET
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-LEFT: 0.79IN">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="10" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.85PT; TEXT-ALIGN: CENTER">
<B>
	Year ended
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 2.85PT; TEXT-ALIGN: CENTER">
<B>
	December 31,
</B>
</P>
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD NOWRAP STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Financial expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Exchange rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Bank fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Interest on convertible notes
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	203
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	219
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Financial income:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Exchange rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	Interest income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	237
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	239
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	22
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 19.85PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -8.5PT; PADDING-LEFT: 11.35PT">
	Financial expenses (income), net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(300
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(227
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	197
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.79IN; TEXT-ALIGN: LEFT">
	NOTE 12:-
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	SUBSEQUENT EVENS
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -56.7PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 56.7PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	On
	March 2, 2016 the Company's board of directors resolved to increase the company's option pool to 3,078,102 options and to grant 959,571 options to employees and directors with an exercise price of $4.55 per share.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	- - -
	- - - - - - - - - - -
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-WEIGHT: NORMAL">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 102; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage103"></A>
<A NAME="V432397_EX4-3_HTM"></A>
<EFX_EXHIBIT_4>
<A NAME="FIS_EXHIBIT_4"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
<U>
	Exhibit 4.3
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 18PT">
<B>
	Alcobra
	Ltd.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 18PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	The 2010 Incentive Option Plan
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	1.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	PURPOSE OF THE PLAN
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The purpose of this 2010 Incentive
	Option Plan (the
<B>
	&ldquo;Plan&rdquo;
</B>
	) is to advance the interests of Alcobra Ltd. (the
<B>
	&ldquo;Company&rdquo;
</B>
	) and
	its shareholders by attracting and retaining the best available personnel for positions of substantial responsibility, providing
	additional incentive to employees, office holders and service providers and promoting a close identity of interests between those
	individuals and entities and the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	2.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	DEFINITIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 35.45PT">
	As used
	herein, the following definitions shall apply:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Administrator
</B>
	&quot; means the Board or the Committee, as shall administer the Plan,
	as set forth herein.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Articles
</B>
	&rdquo; mean the Company&rsquo;s Articles of Association, as amended from
	time to time.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Board
</B>
	&quot; means the Board of Directors of the Company.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Committee
</B>
	&quot; means the Company&rsquo;s compensation committee, or in the case there
	is no such committee, a committee appointed in order to administer the Plan, and until such committee is appointed, the Board.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Companies Law
</B>
	&rdquo; means the Israeli Companies Law 5759 - 1999.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Employee
</B>
	&quot; means: (I) any person, employed by the Company or employed by any Related
	Entity; and (II) any Office Holder (as such term is defined in the Companies Law), officer or Director of the Company or a Related
	Entity.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Exercise Price
</B>
	&rdquo; means the price that is to be paid in order to exercise an
	Option.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Group
</B>
	&rdquo; means the Company and the Related Entities taken together.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	IPO
</B>
	&rdquo; means an initial public offering of the Company's Shares.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Option
</B>
	&quot; means an option to purchase a Share according to the provisions of this
	Plan.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.11.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Option Grant
</B>
	&rdquo; means a single grant of Options to a certain Participant as determined
	by the Board or the Committee.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.12.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Option Grant Letter Agreement
</B>
	&quot; means the notice letter attached to this Plan
	as
<B>
<U>
	Exhibit A
</U>
</B>
	.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.13.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Participant
</B>
	&quot; means a person or entity that has been granted Options.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.14.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Related Entity
</B>
	&rdquo; means any parent or subsidiary of the Company. In addition,
	Related Entity shall include any business, corporation, partnership, limited liability company or other entity in which the Company,
	or the Company&rsquo;s parent or a subsidiary holds a substantial ownership and/or interest, directly or indirectly, and is determined
	by the Board to be a Related Entity.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.15.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Service Provider
</B>
	&rdquo; means a person or entity who is engaged by the Company or
	any Related Entity to render services (e.g., consulting services, advisory services, development services, marketing and sale services
	or any other services, including suppliers) to the Company or a Related Entity.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.16.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Share
</B>
	&quot; means the Company&rsquo;s Ordinary Share of NIS 0.01 par value, or that
	was issued following an exercise of an Option.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.17.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Total Option Amount
</B>
	&rdquo; means the amount of Options granted to a Participant in
	a single Option Grant.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	3.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	ADMINISTRATION OF THE PLAN
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	3.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Subject to the provisions of the Plan, any applicable law, the Articles and any other binding commitments
	taken by the Company, the Board or the Committee shall have the power and authority to administer the Plan. Such power and authority
	shall include, but not be limited to: (i) approval of Option Grants and the
<B>
</B>
	determination of the terms and provisions of
	respective Option Grants, including, the vesting schedules of the Options; the Exercise Price thereof; provisions concerning the
	time or times when and the extent to which Options may be exercised; the nature and duration of restrictions as to transferability;
	or any other special conditions relating to an Option Grant; (ii) the acceleration of any Participant&rsquo;s right to exercise
	Options, in whole or in part; (iii) the interpretation of the provisions of the Plan; (iv) altering, amending or rescinding any
	resolution or act previously taken by the Committee; and (v) the determination of any other matter which is necessary or desirable
	for, or incidental to, the administration of the Plan, as set forth in the Plan.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	3.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding the above, the Board shall have the power and authority to take any act the Committee
	is empowered and authorized to take, and to alter amend or rescind any act or resolution taken by the Committee.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	3.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Committee shall consist of such number of directors as may be appointed by the Board.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	3.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Board shall have the exclusive discretion and power to grant Options. Such power may be delegated
	by the Board to the Committee subject to the provisions of the Companies Law.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	3.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All Committee resolutions and decisions, including the interpretation and construction of any provision
	of the Plan, shall be final and conclusive unless otherwise determined by the Board.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	3.6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No member of the Board or of the Committee shall be held liable for any act or determination made
	in good faith with respect to the Plan or any Option Grant.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	SHARES RESERVED FOR THE PLAN
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	4.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Subject to adjustments, as set forth in Section 9 below, a total of 3,078,102 Ordinary
	Shares, of NIS 0.01 par value each, from the Company&rsquo;s authorized share capital shall be reserved and subject to the
	Plan (the &ldquo;
<B>
	Reserved Shares
</B>
	&rdquo;).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	4.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Until termination of the Plan the Company shall at all times reserve sufficient number of Ordinary
	Shares in its authorized share capital to cover for all Reserved Shares that were not issued.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	4.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Without derogating from Section 4.2 above:
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	4.3.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company need not reserve Shares with respect to Options that terminated, expired or were canceled
	for any reason prior to exercise thereof.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	4.3.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the case that there are certain Reserved Shares, which remain unissued and which are not subject
	to outstanding Options, then the Board may resolve that such Reserved Shares shall cease to be reserved.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	5.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	DESIGNATION OF PARTICIPANTS; OPTION GRANTS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Board may grant Option Grants to the following persons and entities:
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.1.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Employees.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.1.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Service Providers and their employees.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Unless determined otherwise by the Board or Committee, a Participant shall not be required to pay
	any consideration for an Option Grant.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	6.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	VESTING; EXERCISE PERIOD
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Unless determined otherwise by the Committee or Board, upon approval of the Option Grant or thereafter,
	Options underlying an Option Grant shall vest over four years, commencing on the vesting commencement date (the &quot;
<B>
	Vesting
	Commencement Date
</B>
	&quot;) as determined by the Committee.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The vesting schedule of each Option Grant shall be as determined by the Committee. However, unless
	determined otherwise by the Committee or Board, upon approval of the Option Grant or thereafter, the following shall apply:
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 106.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	25% of the
	Total Option Amount shall vest on the first anniversary of the Vesting Commencement Date, and additional 6.25% of the Total Option
	Amount shall vest on the last day of each three months period immediately after the first anniversary of the Vesting Commencement
	Date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 106.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In the case
	that as a consequence of the vesting schedule mentioned above a fraction of vested Option is created, then such fraction shall
	be rounded up or down, as determined by the Board.
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in this Plan, all Options shall terminate and not bestow
	any rights on their owner after ten years from the date the Options were granted. All Options that have not been exercised by such
	date shall expire immediately and the Participants shall not have any claim against the Company with respect thereto.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The period within which Options are exercisable shall be called the
<B>
	&ldquo;Exercise Period&rdquo;
</B>
	.
	Options which have not been exercised during the Exercise Period shall expire immediately, and will be automatically returned to
	the Options pool and may be re-allocated.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	7.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	TERMINATION OF EMPLOYMENT WITH THE GROUP
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In the event
	that the Participant is an Employee at the time of the Option Grant, whose employment with the Group was subsequently terminated,
	for whatever reason but subject to Section 7.6 (including but not limited to (i) dismissal of a Participant or (ii) a Participant&rsquo;s
	resignation, or (iii) death of a Participant or (iv) disability of a Participant), then the following provisions shall apply:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The date on which employment was terminated under applicable labor laws, or, in the case an Employee
	is not an employee under applicable labor laws the date in which such Employee ceases to be an Employee as defined in the Plan,
	shall be deemed the date in which such Employee&rsquo;s employment was terminated (
<B>
	&ldquo;Employment Termination Date&rdquo;
</B>
	).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On the Employment Termination Date all Options that are not vested shall immediately expire.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the event that the Participant's termination of employment is not due to the Participant's death
	(but does include termination due to Disability), then the Participant will be entitled to exercise all, or part of, the vested
	Options that have not expired, for a period of thirty (30) days after the Employment Termination Date. After such thirty days period,
	all unexercised Options will automatically expire.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 106.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	For purposes
	of this Section 7.3, &quot;Disability&quot; shall mean the inability in 100%, due to illness or injury, to engage in any gainful
	occupation for which the individual is suited by education, training or experience, which condition continues for at least six
	(6) months.
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding the above, in the event of termination of employment due to the Participant's death
	or Disability, the Participant (if applicable) or Participant's estate, or other person who acquired the right to exercise the
	Options by way of bequest or inheritance, may, but only within six (6) months after the date of such death or the Employment Termination
	Date (in the case of Disability), exercise all, or part of, the vested Options that have not expired. After such six (6) months
	period, all unexercised options shall automatically expire.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding Section 7.3 above, all Options granted to a certain Employee (whether vested or
	unvested) will immediately expire if the termination of the Participant&rsquo;s employment is due to Participant&rsquo;s breach
	of his/her employment agreement (whether written or oral) including without limitation, a breach of non compete obligations, or
	breach of his/her fiduciary duties towards the Company or a Related Entity as determined by the Committee or the Board, in their
	sole discretion, or in the case that competent court or other authority resolves that such employee is not entitled to discharge
	compensation.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	For the purposes of this Plan, the Committee or Board is authorized to determine if and when a
	Participant terminated his/her employment with the Company, and due to what reason, subject to the provisions of Israeli labor
	laws with respect to Israeli employees.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	7.7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Committee or the Board shall be entitled, prospectively and retroactively, to extend the periods
	in which Options (either vested or unvested) do not expire and remain exercisable after the Employment Termination Date.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 106.35PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	8.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	TERMINATION OF ENGAGEMENT WITH THE GROUP
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	In the event that a Participant
	is not an Employee, and the agreement of such Participant with the Group is terminated, then, unless otherwise specified in the
	Option Grant Letter Agreement, or otherwise determined by the Committee, on the date of such termination, all Options that have
	not vested by then shall expire and the vested options shall remain exercisable as specified in sections 7.3, 7.4 or 7.5, as the
	case may be, which shall apply
<I>
	mutatis mutandis
</I>
	to such Participant (where if such Participant has more than one agreement
	with the Group, then the foregoing shall apply to the Options underlying the terminated agreement or issued in connection therewith).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	9.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	ADJUSTMENTS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Merger, Sale of the Company or Sale of the Company&rsquo;s Assets.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In the event
	of a merger of the Company into another corporation, in a way that the Company shall no longer continue to exist as a legal entity
	subsequent to such merger, the sale of all, or substantially all of the Company&rsquo;s issued and outstanding shares to a third
	party or the sale of all, or substantially all of the assets of the Company (each of them, a &ldquo;
<B>
	Transaction
</B>
	&rdquo;),
	then the following provisions shall apply:
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.1.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Each outstanding Option shall be assumed by, or an equivalent option shall be substituted by the
	successor corporation or a parent or subsidiary of the successor corporation.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.1.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the event that the successor corporation does not agree to assume the Options or to substitute
	them with equivalent options, the Committee may in lieu of such assumption or substitution, provide for the Participant to have
	the right to exercise the Options as to all, or part of the Shares, including certain Shares as to which it would not otherwise
	be exercisable.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.1.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In addition to Section 9.1.2 above, and if Section 9.1.1 does not apply, the Committee may notify
	the Participants that all Options that are exercisable shall remain so for a period of no less then seven (7) days from the date
	of such notice, and that all Options will terminate upon the expiration of such period. In any case, the Committee may condition
	the termination of all said Options upon consummation of the Transaction.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Bonus Shares
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	In the event
	that the Company issues any of its shares as bonus shares to all its shareholders, on a pro rata basis, then the number of Shares
	received upon exercise of certain Options shall be increased to the number of Shares the Participant would have held after the
	issuance of the bonus shares had such Participant exercised such Options immediately before the issuance of the bonus shares.
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Reorganization; Separation
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	If the Company
	is separated, reorganized, or consolidated with another corporation (other than as part of a Transaction) while Options which were
	not yet exercised remain outstanding under this Plan, the Company shall use reasonable efforts to maintain the rights of each Participant
	through such separations, reorganizations or consolidations, or compensate the Participant for such event in lieu of the Options
	such Participant holds. The Committee, at its sole discretion, shall determine what steps shall be taken according to this section
	9.3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Changes in Capitalization
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	If the outstanding
	shares of the Company shall at anytime be changed or exchanged by declaration of a share split, reverse share split, combination
	or reclassification of Ordinary Shares, or any other increase or decrease in the number Company&rsquo;s Ordinary Shares effected
	without receipt of consideration by the Company from the shareholders, then the number, class and kind of Shares subject to this
	Plan or subject to any Options therefore granted, and the Exercise Prices of the Options, shall be appropriately and equitably
	adjusted so as to maintain the proportionate number of Shares without changing the aggregate Exercise Prices of the Options (except
	in case the Exercise Price is equal to the par value of the shares, in which case the Exercise Price will be increased respectively).
	However no adjustment shall be made by reason of the distribution of subscription rights on outstanding shares, or conversion of
	securities into shares of the Company.
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Other terms and conditions
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.5.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The allocation of each Option Grant hereunder is subject to the relevant Participant&rsquo;s agreement
	to sign any document he/she is required to sign pursuant to the provisions of this section 9. If a Participant refuses to sign
	any such documents, the Committee or Board may determine that the Options held by the Participant or by a trustee for such Participant&rsquo;s
	benefit shall immediately expire.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.5.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Such adjustments as mentioned in this Section 9 shall be made by the Committee, whose determination
	in such respect shall be final, binding and conclusive.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	9.5.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Anything herein to the contrary notwithstanding, if prior to an IPO, there is a bona fide offer
	to purchase all or substantially all of the issued and outstanding shares of the Company, or upon a reorganization separation or
	the like, all or substantially all of the shares of the Company are to be exchanged for securities of another company, then each
	Participant shall be obliged to sell or exchange (in accordance with the value of such Participant&rsquo;s Options and Shares pursuant
	to the terms of such transaction) as the case may be, any Shares such Participant purchases hereunder, in accordance with the instructions
	issued by the Board in connection with such transaction, which will be given according to a policy of the Board concerning all
	of the Participants under the Plan.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 141.75PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -70.85PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	10.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	ASSIGNABILITY AND SALE OF OPTIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	No Option
	shall be assignable, transferable, given as collateral, hypothecated pledged or encumbered and no right with respect to the Options
	shall be given to any third party whatsoever, and during the lifetime of each Participant, each and all of such Participant&rsquo;s
	rights to purchase Shares hereunder shall be exercisable only by such Participant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	11.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	TERM AND EXERCISE OF OPTIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Options shall be exercised by a Participant by giving written notice to the Company, in the form
	substantially attached hereto as
<B>
<U>
	Exhibit B
</U>
</B>
	or such other form(s) and method as may be determined by the Company from
	time to time (the &ldquo;
<B>
	Exercise Notice
</B>
	&rdquo;).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Exercise Price shall be payable upon the exercise of the Option in cash or by check, or other
	form satisfactory to the Committee.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Exercise Price will be paid in NIS, or if the Exercise Price is fixed in U.S. dollars, in U.S.
	dollars or in accordance with the representative rate of exchange of the U.S. dollar, last published by the Bank of Israel at the
	time of actual payment, or as provided for by the Company.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Each Participant will be entitled to exercise, upon signing the Exercise Notice and any additional
	documents as required by the Company, and paying the Exercise Price, all, or part of the Options that are vested at the Exercise
	Period.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Options shall not be deemed exercised unless: (I) the Company receives duly signed Exercise Notice
	including all relevant details; and (II) the Company receives the Exercise Price.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Options may be exercised only to purchase whole Shares, and in no case may a fraction of a
	Share be purchased. If any fractional Shares would be deliverable upon exercise, such fraction shall be rounded up or down, to
	the nearest whole number. Half of a Share will be rounded up.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Each Option granted under this Plan shall be exercisable during the Exercise Period. Subject to
	adjustments, as set forth in Section 9 above, the exercise of one Option shall entitle the Participant to hold one Share.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Without derogating from any restrictions mentioned hereinabove, the exercise of the Options is
	being subject to the following terms, restrictions and conditions as may be in effect on the time of the exercise of the Options
	is requested: (i) any applicable law or regulation; (ii) any order or limitation set by any stock exchange in which the Company&rsquo;s
	securities may be traded (e.g., blackout periods, and lock up after an IPO); and (iii) any limitation undertaken by the Company
	with respect of the shares of the Company, including limitations set forth by Company&rsquo;s underwriters. Such period of restriction
	of sale or exercise shall not be counted as part of the applicable exercise period.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	11.9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding the foregoing, starting as of the Employment Termination Date of a certain Participant
	and during the period that the vested Options are exercisable, the Company shall be entitled (subject to the provisions of applicable
	law) to purchase the vested Options held by such Participant by sending the Participant a purchase notice (the &quot;
<B>
	Purchase
	Notice
</B>
	&quot;). The purchase price of each Option shall be the Market Value of an Ordinary Share less the Exercise Price of
	the Option. The Market Value of an Ordinary Share shall be determined as follows: (i) in case the Company's shares are listed on
	a stock exchange, the Market Value shall be the average price of the Shares during 5 days prior to the Purchase Notice; or (ii)
	in case the Company's shares are not traded, the Market Value shall be the value determined in good faith unanimously by the Board
	and in the event the Board members are unable to reach&nbsp;an agreement with respect to the Market Value within 10 days of the
	Purchase Notice to the Participant, the Board will refer&nbsp;to an external expert. The Committee or the Board shall be entitled
	to establish further processes for the purchase of the Options as set forth above, provided, however, that if the Company receives
	the Participant&rsquo;s Exercise Notice prior to the receipt of the Purchase Notice from the Company, then the Company&rsquo;s
	right to purchase the said Options shall become null and void and the Participant may exercise the vested Options pursuant to their
	terms.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	12.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	RIGHTS AND OBLIGATIONS ATTACHED TO THE SHARES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No Participant shall have any of the rights or privileges of a shareholder of the Company with
	respect to any of the Shares, unless and until, following exercise, the registration of the Participant as holder of such Shares
	in the Company&rsquo;s register of members is duly completed.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The rights and obligations attached to the Shares will be as set forth in the Articles. The Shares
	may be subject to rights of first refusal, co-sale rights and other rights specified in the Articles.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Participant waives any of the following rights to the extent such rights are attached to the
	Shares: (i) pre-emptive rights in relation to issuance of new securities in the Company; (ii) rights of first refusal in relation
	with any sale of shares of the Company; (iii) co-sale rights in relation with any sale of shares of the Company.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Unless provided otherwise by the Committee, until an IPO, all voting rights, and rights to receive
	information from the Company with respect to the Shares shall be granted to the Board or as determined by the Board, in accordance
	with
<B>
<U>
	Exhibit C
</U>
</B>
	attached hereto.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Without derogating from any restrictions mentioned hereinabove, by accepting an Option Grant, each
	Participant agrees that the sale or disposal of Shares is subject to the following terms, restrictions and conditions as may be
	in effect on the time when such sale or disposal is requested: (i) any applicable law or regulation; (ii) any order or limitation
	set by any stock exchange in which the Company&rsquo;s securities may be traded (e.g., blackout periods, and lock up after an IPO);
	and (iii) any limitation undertaken by the Company with respect of the shares of the Company, including limitations set forth by
	Company&rsquo;s underwriters.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Until an IPO the Company shall have the authority to endorse upon the certificate or certificates
	representing the Shares such legends referring to the foregoing restrictions, and any other applicable restrictions, as it may
	deem appropriate (and which do not violate the Participant's rights according to this Agreement).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	By accepting an Option Grant, each Participant agrees that in the case of an IPO or after registering
	the Company&rsquo;s securities for trading, to sign any document and approve any resolution or restriction upon the Shares, or
	modify the terms of allocation of the Shares, if such Participants signature or approval or such restriction or modification were
	reasonably required, in the Committee&rsquo;s discretion, in order to facilitate the Company in meeting all the underwriters and
	stock exchange demands and all applicable securities and corporate laws and regulations.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Participant shall not sell, pledge, transfer or otherwise dispose of any Shares in transactions
	which violate, according to the Company&rsquo;s sole discretion, any applicable laws, rules and regulations, or the Articles.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	No transfer of Shares shall be effective if the Committee determines that the transferee is a competitor
	of the Company (either directly or indirectly).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	12.10.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to the contrary in this Section 12, as long as Shares are held by a trustee
	for the benefit of a Participant (if applicable) the Shares shall not be sold, pledged, transferred or otherwise disposed of, by
	the Participant until an IPO, or until such time or event as determined by the Committee, either individually or with respect to
	all Participants.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	13.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	TERM OF THE PLAN
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	This Plan shall be effective
	as of January 1, 2010, which is the day it was adopted by the Board and shall terminate when all the Options are exercised into
	Shares or expired in accordance with the provisions of this Plan or such other date as shall be determined by the Board, which
	date shall be no later than January 1, 2020.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	14.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	AMENDMENTS; TERMINATION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	14.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Board may, at any time and from time to time, amend, alter or terminate the Plan, provided,
	however, that the rights of the Participants shall not be adversely affected, unless such Participants agreed to such amendment,
	alteration or termination.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	14.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Plan may be terminated at any time by an action of the Board, but any such termination will
	not terminate any Options granted under this Plan, which are then outstanding, without the consent of the Participant that is holding
	such Options.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	15.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	BINDING EFFECT
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The provisions of the Plan
	shall be binding upon the heirs, executors, administrators, and successors of the Participants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	16.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	GOVERNMENT REGULATIONS AND OTHER RESTRICTIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	16.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	This Plan, the Option Grant Letter Agreements, the grant and exercise of Options hereunder, the
	obligation of the Company to issue the Shares, and any other act or obligation of the Company or any related individual or entity
	acting in connection with this Plan are all subject to the Articles, all applicable laws, rules, and regulations, whether of the
	State of Israel or of the United States or any other state having jurisdiction over the Company and any Participant.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	16.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	By accepting an Option Grant, each Participant agrees not to sell, pledge, transfer or otherwise
	dispose of any of the Shares such Participant may hold except in compliance with: (I) the United States Securities Act of 1933,
	as amended, and the rules and regulations thereunder if applicable; and (II) the Israeli Securities Law 5728 &ndash; 1968; and
	(III) any other applicable securities law, regulations or other rules set by any stock exchange in which the Company's securities
	may be traded; and to further agree that certificates evidencing any of such Shares shall bear appropriate legend to reflect such
	restrictions. The Company does not obligate itself to register any shares under the United States Securities Act of 1933, as amended
	or any other securities laws.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	17.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	TAX CONSEQUENCES, INDEMNIFICATION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	17.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Any tax consequences (pursuant to Israeli or any other applicable law that the relevant Participant
	is subject to), including tax consequences due to adjustments, made in accordance with Section 9 above, arising from the grant
	or exercise of any Option, the payment for Shares covered thereby, or any other event or act (of the Company or any Participant)
	relating to the Plan, shall be borne solely by each Participant.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	17.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company and/or the Board and/or the Committee and/or a trustee for the Plan shall not be required
	to release any Share certificates or transfer any Shares to a Participant until all required tax payments have been fully made.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	17.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company may withhold taxes according to the requirements under the applicable laws, rules,
	and regulations, including withholding taxes at source. In the case that applicable law requires so, the Company shall deduct taxes
	at source. Such deduction may be made from any proceeds attributed to the exercise of the Options and sale of Shares, or from any
	proceeds the Participant is entitled to receive from the Group or other proceeds such Participant owns and are held by the Group,
	including from Participant&rsquo;s salary or other proceeds he/she is entitled to receive from the Company or a Related Entity.
	It is explicitly stated herein that each Participant who is an Employee, by accepting an Option Grant agrees to the deduction from
	his/her salary of any amounts that in the Company&rsquo;s determination are required to be deducted under applicable law in connection
	with the Plan.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	In any such case, the Company shall be entitled
	to offset any amounts due to such Participant on account of such taxes.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	17.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the case that the Company, or any other person on its behalf is required to pay taxes, that
	under applicable law should have been paid by the Participant, then such Participant shall immediately either pay such tax, or,
	if such tax was already paid, reimburse the Company, or such other person for the total amount paid.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	17.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Neither the Company, nor any Related Entity nor anyone on their behalf, shall give, or be deemed
	to be giving any Participant, or a potential Participant, advice regarding tax consequences relating to the Plan and issuance of
	securities thereunder. Each Participant shall rely solely, while considering participation in the Plan, on the advice of such Participant&rsquo;s
	consultants.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	18.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	CONTINUANCE OF EMPLOYMENT OR ENGAGEMENT
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	Neither the Plan nor any Option
	Grant shall be construed to impose any obligation on any entity included in the Group to continue any Participant&rsquo;s employment
	with it (in the case that the Participant is an Employee) or to maintain any business engagement with such Participant. Nothing
	in the Plan or in any Option Grant shall confer upon any Participant any right to continue to be employed by the Group or to maintain
	any other business engagement with it, or restrict the right of any entity included in the Group to terminate such employment or
	business engagement at any time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	19.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	RULES PARTICULAR TO SPECIFIC COUNTRIES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	19.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything herein to the contrary, the terms and conditions of the Plan may be amended
	with respect to particular types of Participants as determined by the Board (for example, Israeli employees, employees that are
	subject to US taxation) by an addendum to the Plan (the &ldquo;
<B>
	Appendix
</B>
	&rdquo;).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	19.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company may adopt one or more Appendixes. Each Appendix shall be approved by the Board and
	as required or advisable under applicable law.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	19.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The terms of an Appendix shall govern only with respect to the types of Participants specified
	in such Appendix.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	19.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the case that the terms and conditions set forth in an Appendix conflict with any provisions
	of the Plan, the provisions of the Appendix shall govern with respect to Participants that are subject to such Appendix, provided,
	however, that such Appendix shall not be construed to grant the Participants rights not consistent with the terms of the Plan,
	unless specifically provided in such Appendix.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.05PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	20.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	NON-EXCLUSIVITY OF THE PLAN
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	20.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The adoption of the Plan by the Board shall not be construed as amending, modifying or rescinding
	any previously approved incentive arrangements or as creating any limitations on the power of the Board to adopt such other incentive
	arrangements as it may deem desirable, including, without limitation, the granting of Options other than under this Plan, and such
	arrangements may be either applicable generally or only in specific cases.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	20.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The grant of Options hereunder shall neither entitle the recipient thereof to participate, nor
	disqualify him from participating in, any other grant of Options pursuant to this Plan or any other option or stock plan of the
	Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.05PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	21.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	MULTIPLE AGREEMENTS; OTHER CORPORATE ACTIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	21.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The terms of each Option Grant may differ from other Options Grants granted under the Plan at the
	same time, or at any other time. The Board may also grant more than one Option Grant to a certain Participant during the term of
	this Plan, either in addition to, or in substitution for, one or more Option Grants previously granted to such Participant.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	21.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Under no circumstances shall the Plan be construed to grant any right to a Participant, or any
	other third party, to postpone, delay or affect any corporate action resolved by the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	22.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	GOVERNING LAW &amp; JURISDICTION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	This Plan shall be governed
	by, construed and enforced in accordance with the laws of the State of Israel, without giving effect to the principles of conflict
	of laws. Any dispute or claim shall be put to the Board&rsquo;s resolution. Subject to the above, the competent courts of Tel-Aviv,
	Israel shall have sole jurisdiction in any matter pertaining to this Plan, and any other issue related to it.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	23.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	NO WAIVER
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	The failure of the Company
	or any other party acting on its behalf or assisting it in implementing the Plan to enforce at any time any provisions of the Plan
	shall not be construed to constitute a waiver of such provision or of any other provision hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	24.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	NOTICES
</B>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	24.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Any notice, request, demand or other communication required or permitted under the Plan shall be
	in writing and shall be deemed to have been duly given, made and received only by personal delivery or if sent by certified mail,
	postage prepaid, return receipt requested, overnight delivery service, facsimile transmission (with confirmation of delivery),
	or confirmed e-mail to the address of the Company (if sent to the Company), or to the address of the Participant as such was provided
	by him in the Option Grant Letter Agreement, unless such address is changed by written notice received by the Company.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	24.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Except as otherwise set forth herein, any notice sent by mail shall be deemed to be given six days
	after deposit with the relevant post service; any notice sent by overnight delivery service shall be deemed given the first business
	day after deposited with the delivery service; and any notice sent by facsimile transmission or e-mail, shall be deemed given when
	transmitted if sent during normal business hours or if not, on the next business day; and any notice given by personal delivery
	shall be deemed given on the date of delivery.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	24.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the case a certain Participant changes his or her contact details, in a way that the contact
	details provided to the Company by him do not enable the Company to provide notices and other communications to such Participant,
	then such Participant shall be deemed to have waived his or her right to receive any notices, and the Committee shall have the
	right, in its sole discretion, to take any appropriate action under the circumstances.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	Appendixes
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	Appendix A: Terms of grant of options
	to Israeli employees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	Exhibits:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	Exhibit A: Option Grant Letter Agreement
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	Exhibit B: Form of Exercise Notice
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	Exhibit C: Proxy
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Appendix A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Terms of grant of Options
	to Israeli employees
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	1.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Purpose of the Appendix
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	1.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	This Appendix (the &ldquo;
<B>
	Appendix
</B>
	&rdquo;) is made as part of the Plan (as defined herein
	whereas all terms not otherwise defined herein shall have the meaning ascribed to them in the Plan) and pursuant to the provisions
	of Section 102 of the Income Tax Ordinance (as defined herein).
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	1.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	This Appendix governs grants of Options to Israeli Employees, either by a Trustee, or without a
	Trustee.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 70.9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	2.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Definitions
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 35.45PT">
	As used
	herein, the following definitions shall apply:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Capital Gain Method
</B>
	&rdquo; means choosing the alternative of capital gain method
	under Section 102.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Eligible Participant
</B>
	&rdquo; means any employee as such term is defined in Section
	102. Without derogating from the foregoing Eligible Participant shall include any employee or Office Holder (as such term is defined
	in the Companies Law) of the Company or any Subsidiary except for such persons that are deemed to be &lsquo;
<I>
	Ba&rsquo;al Shlita
</I>
	&rsquo;
	under Section 32 to the Income Tax Ordinance.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&quot;
<B>
	Deposit Date
</B>
	&quot; means the date in which options were deposited with the Trustee
	for the benefit of a certain Participant.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Income Tax Authorities
</B>
	&rdquo; mean the Israeli income tax authorities that are authorized
	to give approvals in relation with this Appendix and Option Grants to Eligible Participants.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.5.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Income Tax Ordinance
</B>
	&rdquo; means the Israeli Income Tax Ordinance (New Version)
	1961, as amended from time to time.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.6.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Labor Income Method
</B>
	&rdquo; means choosing the alternative of labor income method
	under Section 102.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.7.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Participant
</B>
	&rdquo; means any Eligible Participant who is granted with Options.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.8.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Plan
</B>
	&rdquo; means the 2010 Incentive Option Plan this Appendix is attached to.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	2.9.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&ldquo;
<B>
	Realization Event
</B>
	&rdquo; means, with respect to each Option Grant granted to a certain
	Participant, the earlier to occur of: (I) transfer of Securities from the Trustee to such Participant; or (II) the sale of Shares
	by the Trustee; or (III) one day before such Participant is no longer an Israeli resident (as provided for in Section 100A to the
	Income Tax Ordinance).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.10.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Release
	Term
</B>
	&rdquo; means: (i) in the case of Capital Gains Method, a period ending twenty four (24) months after the Deposit
	Date; (ii) In the case of Labor Income Method &lsquo;Release Term&rsquo; shall mean a period ending twelve (12) months after
	the Deposit Date.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.11.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Section
	102
</B>
	&rdquo; means Section 102 to the Income Tax Ordinance as amended from time to time, and / or as superseded and any
	rules regulations or instructions promulgated or enacted under such Section 102.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.12.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Securities
</B>
	&rdquo;
	mean Options subject to a certain Option Grant and Shares received subsequent exercise of such Options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.13.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Tax
	Method
</B>
	&rdquo; means either Capital Gains Method or Labor Income Method.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.14.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Trust
</B>
	&rdquo;
	means a trust, maintained under the Trust Agreement entered into between the Company and the Trustee for administration of
	grant of Options under Section 102.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.15.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Trust
	Agreement
</B>
	&rdquo; means the agreement between the Company and the Trustee as may be in effect from time to time specifying
	the duties and authorities of the Trustee.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.16.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Trust
	Assets
</B>
	&rdquo; mean all Securities and other assets held in Trust for the benefit of the Participants pursuant to this
	Appendix and the Trust Agreement
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 95PX">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47PX; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	2.17.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&ldquo;
<B>
	Trustee
</B>
	&rdquo;
	means ESOP Trust Company Ltd. (and any successor Trustee) who was, or shall be appointed by the Board of Directors of the
	Company and approved by the Income Tax Authorities to hold the Trust Assets.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="COLOR: BLACK">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	3.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Provisions of the Appendix shall govern
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The provisions
	of the Appendix shall supersede and govern in the case of any inconsistency or conflict arising between the provisions of the Appendix
	and the provisions of the Plan, provided, however, that this Appendix shall not be construed to grant Participant rights not consistent
	with the terms of the Plan, unless specifically provided herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Selection of Tax Method &ndash; Capital Gains Method
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	The Company
	chooses the Capital Gain Method (&lsquo;
<I>
	Maslul Revach Hon
</I>
	&rsquo;). This choice may be changed in the future, by a Board
	resolution, provided, however, that the change in selection is permissible under the provisions of Section 102.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT 0PT 28.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	5.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Holding of Securities by the Trustee
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All Securities shall be issued to the Trustee to be held in the Trust for the benefit of the relevant
	Participants. All certificates representing Securities issued to the Trustee under this Appendix shall be deposited with the Trustee,
	and shall be held by the Trustee until such time that such Options or Shares are released from the Trust as herein provided.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	After the Release Term is over, a Participant shall be entitled to instruct the Trustee to transfer
	the Shares held for such Participant&rsquo;s benefit to such Participant, provided, however, that the Trustee confirms that all
	applicable tax as set in Section 102 was actually paid and the Trustee holds a confirmation to that effect from Income Tax Authorities.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	5.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	In the case that the Company distributes dividends, than the amount of dividends with respect of
	Shares held in Trust shall be paid to the Participants that are the beneficial holders of such Shares, subject to deduction at
	source of the applicable tax.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -35.45PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	6.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Provisions governing this Appendix and Plan
<FONT STYLE="COLOR: #FF6600">
</FONT>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	Notwithstanding anything to
	the contrary in the Plan or elsewhere in this Appendix:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Plan shall have one, sole, Trustee.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Appendix shall be subject to one Tax Method, unless the provisions of Section 102 allow otherwise.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Participants shall not be entitled to cause a Realization Event to occur unless the Release
	Term is fulfilled.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	6.4.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All rights or benefits that are received subsequent to the grant or exercise the Options or the
	Shares underlying such Options (including and not limited to bonus shares) shall be deposited with the Trustee until the end of
	the Release Term, and all such rights and benefits shall be subject to the Tax Method selected by the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	7.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Effectiveness
	of the Appendix
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	This Appendix
	shall become effective, and Option Grants may be granted hereunder only after receipt the required approvals under Section 102
	from the Income Tax Authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	8.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Additional limitations
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	8.1.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company shall not issue Options to a Participant unless such Participant confirmed in writing
	that he/she is aware of the provisions of Section 102 and the applicable Tax Method, and such Participant agreed in writing to
	the terms of the Trust Agreement, and that he/she shall not cause a Realization Event to occur before the Release Term is over.
	The form for the above confirmation shall be determined by the Committee, and shall be attached to the Plan as
<U>
	Exhibit A
</U>
	.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	8.2.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	By accepting an Option Grant, each Participant agrees irrevocably to discharge the Trustee, the
	Company and any other office holder, employee or agent thereof from any liability with respect of any action or decision duly taken
	and
<I>
	bona fide
</I>
	executed in relation with the Plan, or relating to any Option Grant or Shares.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 70.9PT">
</TD>
<TD STYLE="WIDTH: 35.45PT">
	8.3.
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Trustee shall use the voting rights vested in any such shares issued upon the exercise of any
	Options granted under the Plan, in accordance with Exhibit C of the Plan.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	9.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Grant of Options not by a Trustee
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding
	the above, the Company shall be entitled to allocate Option Grants not according to the Tax Methods, but by direct grant to Participants,
	provided, however, that the requirements of Section 102 are met.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	ADDENDUM
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
</U>
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0.5IN 0PT 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Terms of Options granted
	to United States
</U>
</B>
<BR>
<B>
<U>
	Employees and Service Providers
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	10.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Purpose of the Addendum
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	This Addendum (also referred
	to as the &quot;
<B>
	Addendum
</B>
	&quot;) is part of the 2010 Incentive Option Plan of Alocbra Ltd. (the &quot;
<B>
	Plan
</B>
	&quot;).
	All terms not otherwise defined herein shall have the meaning ascribed to them in the Plan. This Addendum governs grants of Options
	to United States Employees and other Service Providers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 1IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<B>
	11.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Provisions of the Addendum
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	The provisions of the Addendum
	shall supersede and govern in the case of inconsistency between the provisions of the Addendum and the provisions of the Plan,
	provided, however, that this Addendum shall not be construed to grant to any Participant rights not consistent with the terms of
	the Plan, unless specifically provided herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 35.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.3PT">
<B>
	12.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-RIGHT: 35.45PT">
<B>
	Eligibility
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<BR>
	The individuals who shall be eligible to receive Option Grants under the Plan that are subject to the provisions of this Addendum
	shall be employees, directors and other individuals and entities who are United States citizens or who are resident aliens of the
	United States for United States federal tax purposes (collectively, &ldquo;
<B>
	U.S. Persons
</B>
	&rdquo;), and who render services
	to the management, operation or development of the Company or a Subsidiary and who have contributed or may be expected to contribute
	materially to the success of the Company or a Subsidiary. ISOs (as defined in Section 4 below) shall not be granted to any individual
	who is not an employee of a corporation for United States federal tax purposes. The term &ldquo;
<B>
	Subsidiary
</B>
	&rdquo; as used
	in this Addendum means a corporation or other business entity of which the Company owns, directly or indirectly through an unbroken
	chain of ownership, fifty percent or more of the total combined voting power of all classes of stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.3PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	13.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Terms and Conditions of Options
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Every Option
	granted to a U.S. Person shall be evidenced by a written stock option agreement (the &quot;
<B>
	Stock Option Agreement
</B>
	&quot;)
	in such form as the Committee shall approve from time to time, specifying the number of Shares that may be purchased pursuant to
	the Option, the time or times at which the Option shall become exercisable in whole or in part, whether the Option is intended
	to be an incentive stock option (&ldquo;
<B>
	ISO
</B>
	&rdquo;) or a nonqualified stock option (&ldquo;
<B>
	NSO
</B>
	&rdquo;) and such other
	terms and conditions as the Committee shall approve, and containing or incorporating by reference the following terms and conditions.
	The Plan and this Addendum shall be administered in such a manner as to permit those Options granted hereunder and specially designated
	as an ISO to qualify as incentive stock options as described in Section 422 of the Internal Revenue Code of 1986, as amended (the
	&ldquo;
<B>
	Code
</B>
	&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a)
</FONT>
<U>
	Duration
</U>
	. Each Option shall expire no later than ten (10) years from its grant date; provided, however, that no ISO granted
	to an Employee who owns (directly or under the attribution rules of Section 424(d) of the Code) stock possessing more than ten
	percent of the total combined voting power of all classes of stock of the Company or any Subsidiary shall expire later than five
	(5) years from its date of grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b)
</FONT>
<U>
	Exercise Price
</U>
	. The exercise price of each Option shall be as specified by the Committee in its discretion; provided, however,
	that the price shall be at least 100 percent of the Fair Market Value (as hereinafter defined) of the Shares on the date on which
	the Board grants the Option (or shareholders resolution to grant such options, if such resolution is required), which shall be
	considered the date of grant of the Option for purposes of fixing the price; and provided, further, that the price with respect
	to an ISO granted to an Employee who at the time of grant owns (directly or under the attribution rules of Section 424(d) of the
	Code) stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or of any Subsidiary
	shall be at least 110 percent of the Fair Market Value of the Shares on the date of grant of the ISO. For purposes of the Plan,
	except as may be otherwise explicitly provided in the Plan or in any Stock Option Agreement, the &ldquo;
<B>
	Fair Market Value
</B>
	&rdquo;
	of a Share at any particular date shall be determined according to the following rules: (i) if the Shares are not at the time listed
	or admitted to trading on a stock exchange, the Fair Market Value shall be the closing price of the Shares on the date in question
	in the over-the-counter market, as such price is reported in a publication of general circulation selected by the Board and regularly
	reporting the price of the Shares in such market; provided, however, that if the price of the Shares is not so reported, the Fair
	Market Value shall be determined in good faith by the Board, which may take into consideration (1) the price paid for the Shares
	in the most recent trade of a substantial number of shares known to the Board to have occurred at arm&rsquo;s length between willing
	and knowledgeable investors, (2) an appraisal by an independent party or (3) any other method of valuation undertaken in good faith
	by the Board, or some or all of the above as the Board shall in its discretion elect; or (ii) if the Shares are at the time listed
	or admitted to trading on any stock exchange, then the Fair Market Value shall be the last known closing price of the Shares when
	the relevant Option Grant is approved by the Company. Notwithstanding Subsection (ii) above, the Administrator may adopt any other
	method in order to determine the Fair Market Value of a Share, as long as use of such method will not give rise to adverse tax
	consequences under Internal Revenue Code Section 409A.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(c)
</FONT>
	&#9;
<U>
	Notice
	of ISO Stock Disposition
</U>
	. The Participant must notify the Company promptly in the event that he sells, transfers, exchanges
	or otherwise disposes of any Shares issued upon exercise of an ISO before the later of (i) the second anniversary of the date of
	grant of the ISO or (ii) the first anniversary of the date the shares were issued upon his exercise of the ISO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(d)
</FONT>
	&#9;
<U>
	Effect
	of Cessation of Employment or Service Relationship
</U>
	. The Committee shall determine in its discretion and specify in each Stock
	Option Agreement the effect, if any, of the termination of the Participant&rsquo;s employment with or performance of services for
	the Company or any Subsidiary on the exercisability of the Option.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(e)
</FONT>
	&#9;
<U>
	No
	Rights as Stockholder
</U>
	. A Participant shall have no rights as a stockholder with respect to any Shares covered by an Option
	until the date of issuance of a stock certificate to him for the Shares. No adjustment shall be made for dividends or other rights
	for which the record date is earlier than the date the stock certificate is issued, other than as required or permitted by the
	Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(f)
</FONT>
	&#9;
<U>
	Transferability
	of Options
</U>
	. Except as permitted by the Committee, and set forth in the terms of a Participant&rsquo;s Stock Option Agreement,
	an Option shall not be assignable or transferable by the Participant except by will or by the laws of descent and distribution.
	During the life of the Participant, an Option shall be exercisable only by him, by a conservator or guardian duly appointed for
	him by reason of his incapacity or by the person appointed by the Participant in a durable power of attorney acceptable to the
	Company&rsquo;s counsel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	14.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	R
</B>
</FONT>
<B>
	equirements
	of Law
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 34.9PT">
	(a)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	The Company shall not be required to transfer Shares or to sell or issue any Shares upon the exercise
	of any Option if the issuance of such Shares will result in a violation by the Participant or the Company of any provisions of
	any law, statute or regulation of any governmental authority. Specifically, in connection with the Securities Act of 1933, as amended
	from time to time (the &ldquo;
<B>
	Securities Act
</B>
	&rdquo;), upon the exercise of any Option, the Company will not be required
	to issue Shares unless the Committee has received evidence satisfactory to it to the effect that the holder of the Option will
	not transfer such shares except pursuant to a registration statement in effect under the Securities Act or unless an opinion of
	counsel satisfactory to the Company has been received by the Company to the effect that registration is not required. Any determination
	in this connection by the Committee shall be conclusive. The Company shall not be obligated to take any other affirmative action
	in order to cause the exercise of an Option to comply with any law or regulations of any governmental authority, including, without
	limitation, the Securities Act or applicable state securities laws.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 34.9PT">
	(b)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	All other provisions of this Addendum and the Plan notwithstanding, this Addendum and the Plan
	shall be administered and construed so as to avoid any person who receives an Option Grant incurring any adverse tax consequences
	under Internal Revenue Code Section 409A. The Administrator shall suspend the application of any provisions of the Plan which could,
	in its sole determination, result in an adverse tax consequence to any person under Internal Revenue Code Section 409A.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<FONT STYLE="FONT-SIZE: 10PT">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	-
</FONT>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	15.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Forfeiture for Dishonesty or Termination for Cause
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Notwithstanding
	any provision of the Plan to the contrary, if the Committee determines, after full consideration of the facts, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a)
</FONT>
	the Participant has been engaged in fraud, embezzlement, theft or commission of a felony in the course of his or her employment
	by or involvement with the Company, a Subsidiary or a parent corporation as defined in Section 424 of the Code or any direct or
	indirect subsidiary of such parent (an &ldquo;
<B>
	Affiliate
</B>
	&rdquo;) or has made unauthorized disclosure of trade secrets or
	other proprietary information of the Company, a Subsidiary, an Affiliate or of a third party who has entrusted such information
	to the Company, a Subsidiary or an Affiliate; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b)
</FONT>
	the Participant has violated the terms of any employment, noncompetition, nonsolicitation or proprietary information agreement
	to which he is a party; or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(c)
</FONT>
	the Participant&rsquo;s employment or involvement with the Company, a Subsidiary or an Affiliate was terminated for &ldquo;cause,&rdquo;
	as defined in any employment agreement with the Participant, if applicable, or if there is no such agreement, as determined by
	the Committee, which may determine that &ldquo;cause&rdquo; includes among other matters the willful failure or refusal of the
	Participant to perform and carry out his or her assigned duties and responsibilities diligently and in a manner satisfactory to
	the Committee;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	then the Participant&rsquo;s
	right to exercise an Option shall terminate as of the date of such act (in the case of (a) or (b)) or such termination (in the
	case of (c)), the Participant shall forfeit all unexercised Options and shall be required to sell to the Company or, in the case
	the Company is not allowed to repurchase its own shares, to a third party approved by the Company, all or any part of the Shares
	acquired by the Participant prior to such event, at a price equal to the lesser of their Fair Market Value or the amount paid to
	the Company upon such transfer or exercise. If a Participant whose behavior the Company asserts falls within the provisions of
	(a), (b) or (c) above has exercised or attempts to exercise an Option prior to consideration of the application of this Section
	6 or prior to a decision of the Committee, the Company shall not be required to recognize such exercise until the Committee has
	made its decision and, in the event any exercise shall have taken place, it shall be of no force and effect (and shall be void
<U>
	ab
</U>
<U>
	initio
</U>
	) if the Committee makes an adverse determination, provided, however, that if the Committee finds in favor
	of the Participant then the Participant will be deemed to have exercised the Option retroactively as of the date he or she originally
	gave notice of his or her attempt to exercise or actual exercise, as the case may be. The decision of the Committee as to the cause
	of a Participant&rsquo;s discharge and the damage done to the Company shall be final, binding and conclusive. No decision of the
	Committee, however, shall affect in any manner the finality of the discharge of such Participant by the Company. For purposes of
	this Section 6, reference to the Company shall include any Subsidiary or Affiliate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 35.45PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	16.
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Tax Withholding
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 35.45PT; TEXT-ALIGN: JUSTIFY">
	To the extent required by law,
	the Company may withhold or cause to be withheld income and other taxes with respect to any income recognized by a Participant
	by reason of the exercise of an Option, and as a condition to the receipt of any Option the Participant shall agree that if the
	amount payable to him by the Company and any Subsidiary in the ordinary course is insufficient to pay such taxes, then he shall
	upon the request of the Company pay to the Company an amount sufficient to satisfy its tax.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_4>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage125"></A>
<A NAME="V432397_EX12-1_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12"></A>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
<U>
	Exhibit 12.1
</U>
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	CERTIFICATION PURSUANT TO EXCHANGE
	ACT RULE 13a-14(a) or 15d-14(a)
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	I, Dr. Yaron Daniely, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	1. I have reviewed this annual report on
	Form 20&ndash;F of Alcobra Ltd.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2. Based on my knowledge, this annual report
	does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
	in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
	report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3. Based on my knowledge, the financial
	statements, and other financial information included in this annual report, fairly present in all material respects the financial
	condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	4. The Company&rsquo;s other certifying
	officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
	13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
	and 15d-15(f)) for the Company and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	a) Designed such disclosure controls
	and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
	information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities,
	particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	b) Designed such internal control
	over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
	reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
	purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	c) Evaluated the effectiveness
	of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
	of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	d) Disclosed in this report any
	change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report
	that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial
	reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5. The Company&rsquo;s other certifying
	officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s
	auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	a) All significant deficiencies
	and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
	adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	b) Any fraud, whether or not material,
	that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial
	reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Date: March 4, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 20%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
	Dr. Yaron Daniely
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 30%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Yaron Daniely
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Executive Officer
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage126"></A>
<A NAME="V432397_EX12-2_HTM"></A>
<EFX_EXHIBIT_12>
<A NAME="FIS_EXHIBIT_12_2"></A>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<B>
<U>
	Exhibit 12.2
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO EXCHANGE ACT
	RULE 13a-14(a) or 15d-14(a)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	I, Dr. Tomer Berkovitz, certify that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	1. I have reviewed this annual report on
	Form 20&ndash;F of Alcobra Ltd.;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2. Based on my knowledge, this annual report
	does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
	in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
	report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3. Based on my knowledge, the financial
	statements, and other financial information included in this annual report, fairly present in all material respects the financial
	condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	4. The Company&rsquo;s other certifying
	officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
	13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
	and 15d-15(f)) for the Company and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	a) Designed such disclosure controls
	and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
	information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities,
	particularly during the period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	b) Designed such internal control
	over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
	reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
	purposes in accordance with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	c) Evaluated the effectiveness
	of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
	of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	d) Disclosed in this report any
	change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report
	that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial
	reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5. The Company&rsquo;s other certifying
	officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s
	auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	a) All significant deficiencies
	and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
	adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	b) Any fraud, whether or not material,
	that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial
	reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 21PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Date: March 4, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 20%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Dr. Tomer
	Berkovitz
</FONT>
</TD>
<TD NOWRAP STYLE="WIDTH: 30%">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Dr. Tomer Berkovitz
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial
	Officer and Chief Operating Officer
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_12>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage127"></A>
<A NAME="V432397_EX13-1_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13"></A>
<P STYLE="MARGIN: 0">
<B>
<U>
	Exhibit 13.1
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	18 U.S.C.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Section
	1350
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the filing of the Annual
	Report on Form 20-F for the period ended December 31, 2015 (the &ldquo;Report&rdquo;) by Alcobra Ltd. (the &quot;Company&quot;),
	the undersigned, as Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant
	to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the
	requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the
	Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	/s/ Dr. Yaron Daniely
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dr. Yaron Daniely
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chief Executive Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 4, 2016
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_13>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage128"></A>
<A NAME="V432397_EX13-2_HTM"></A>
<EFX_EXHIBIT_13>
<A NAME="FIS_EXHIBIT_13_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Exhibit 13.2
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	18 U.S.C.
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Section
	1350
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	In connection with the filing of the Annual
	Report on Form 20-F for the period ended December 31, 2015 (the &ldquo;Report&rdquo;) by Alcobra Ltd. (the &quot;Company&quot;),
	the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant
	to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the
	requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the
	Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 50%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	/s/ Dr. Tomer Berkovitz
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dr. Tomer Berkovitz
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Chief Financial Officer and Chief Operating Officer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 4, 2016
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_13>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage129"></A>
<A NAME="V432397_EX15-1_HTM"></A>
<EFX_EXHIBIT_15>
<A NAME="FIS_EXHIBIT_15"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
<U>
	Exhibit 15.1
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
<U>
	Consent of Independent Registered
	Public Accounting Firm
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We consent to the incorporation by reference
	in the Registration Statement on Form F-3 (Registration No. 333-197411) and Registration Statements on Form S-8 (Registration No.
	333-194875 and Registration No. 333-202394) of Alcobra Ltd. of our report dated March 4, 2016 with respect to the consolidated
	financial statements of Alcobra Ltd. and its subsidiary for the year ended December 31, 2015 included in this Annual Report on
	Form 20-F for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 66%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	/s/
	Kost, Forer, Gabbay &amp; Kasierer
</U>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Tel Aviv, Israel
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	KOST, FORER, GABBAY &amp; KASIERER
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March 4, 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;A Member of EY Global
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_15>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
